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ABSTRACT 
Background: Childhood asthma is less common in rural compared to urban settings. This could 
be linked to possible asthma under-diagnosis in rural children. Furthermore, asthma presents 
with multiple phenotypes and degrees of severity; and may have varied associations with indoor 
microbial exposures.     
Objectives: i) to investigate if rural children experience more asthma under-diagnosis compared 
to urban children; ii) to investigate the relationship between endotoxin and beta-(1→3)-D-glucan 
(BDG) with atopic asthma and exercise-induced bronchospasm (EIB); and iii) to examine the 
associations between endotoxin and BDG with asthma severity.  
Methods: In 2015, following a 2013 cross-sectional study, we approached those who gave 
consent for further testing and repeated the survey and completed clinical assessments. The 2015 
study included 335 schoolchildren (aged 7–17 years) in Saskatchewan, Canada. Play and 
mattress area settled dust sample collection was also completed. Asthma was identified based on 
survey responses and then based on a validated asthma algorithm. Children with confirmed 
asthma using the asthma algorithm (n = 116) formed the study population for the second (asthma 
phenotypes) and third (asthma severity) objectives. We evaluated asthma phenotypes based on 
skin prick testing and exercise challenge testing and asthma severity based on standard 
guidelines. Endotoxin and BDG were measured from dust samples using limulus amoebocyte 
lysate assay.  
Results: The study population was comprised of 73.4% (large urban, LU), 13.7% (small urban, 
SU) and 12.8% (rural, R). The proportions of participants with survey-based vs. algorithm-based 
asthma classification were: 28.5% vs. 33.3% (LU), 34.8% vs. 41.3% (SU), and 20.9% vs. 34.9% 
(R). Among the algorithm-based asthma cases, 71.1% were atopic, 22.4% had EIB, 75.9% had 
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mild asthma, and 24.1% had moderate/severe asthma. Play area endotoxin was inversely 
associated with atopic asthma while mattress endotoxin was positively associated with EIB. 
Furthermore, mattress endotoxin was positively associated with moderate/severe asthma and 
decreased lung function while play area BDG was inversely association with moderate/severe 
asthma.  
Conclusion: The study revealed evidence of asthma under-diagnosis in rural children. 
Furthermore, the study provided evidence of varied associations between indoor microbial 
exposures and asthma phenotypes as well as asthma severity. 
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CHAPTER 1 
INTRODUCTION 
1.1 General introduction  
Asthma is less common in rural compared to urban children,1 prompting the conclusion that rural 
living may protect against the development of childhood asthma. While the protective effect of 
rural living for childhood asthma may be true, there is other evidence of increased frequency of 
asthma symptoms in rural compared to urban children2–4 suggesting that the often reported lower 
prevalence of asthma in rural children may be due, in part, to asthma under-diagnosis in children 
living in rural settings. 
The indoor environment is an important factor in the management and risk of childhood 
asthma. The relationships between indoor microbial exposures and childhood asthma have been 
shown to be inconsistent with protective as well as risk effects reported.5 The reported opposing 
associations could be linked to the different presentations of asthma in children with the disease; 
as asthma is a multifactorial condition with multiple presenting phenotypes and differing degrees 
of severity.6 To guide asthma management, characterization of asthma phenotype and severity is 
necessary and understanding its relationship with indoor microbial exposures could identify 
biological agents that aggravate asthma among children. Making use of this knowledge may 
eventually aid attempts to reduce asthma morbidity.  
Despite the general understanding that there is geographic variation in asthma prevalence 
and severity, urban-rural asthma diagnostic patterns as well as the relationships between indoor 
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microbial exposures and asthma phenotypes and severity have not been well studied. This gap is 
the focus of my dissertation. 
1.2 Background 
Asthma is a chronic inflammatory disease of the airways characterized by airflow obstruction 
and symptoms such as wheeze, cough, shortness of breath, and chest tightness.7 It is one of the 
most common chronic diseases among children,8,9 and a leading cause of medical expenses.10–12 
More than 13% of children had been diagnosed with asthma in Canada13,14 and the average direct 
cost from asthma exacerbations in 2013 was estimated to be around $883.48 per patient per 
year.15 Knowledge of the etiology of asthma is currently less clear as asthma is a multifactorial 
disease with multiple presenting phenotypes and varied degree of severity.16,17 While asthma can 
affect individuals of all ages, it is more common in children.18  
It is generally believed that childhood asthma is less common in rural compared to urban 
settings.1,19,20 In a nationwide prospective cohort study investigating asthma incidence among 
children in Canada, rural children had lower prevalence of asthma compared to their urban 
counterparts.21 Similar urban-rural variations have also been reported in cross-sectional studies in 
Saskatchewan2 and Manitoba,22 Canada with childhood asthma (defined as doctor-diagnosed 
asthma) reported to be significantly higher in urban compared to rural children. 
Some of these studies of urban-rural childhood asthma prevalence are of particular 
interest because in addition to demonstrating evidence of lower asthma prevalence in the rural 
areas,19,20 they have also shown that children living in rural areas, and possibly farming 
environment, are less often atopic and have less allergic diseases than non-rural, non-farm 
children. This was demonstrated in a Canada-wide longitudinal study [the National Longitudinal 
Survey of Children and Youth (NLSCY)] involving 13,524 asthma-free children, aged 0–11 
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years old.23 Participants were drawn from the original cycle conducted in 1994/1995 (Cycle 1) 
and followed for two years to the second cycle in 1996/1997 (Cycle 2). Children were 
categorized into three groups based on their locations; rural farming, rural non-farming, and non-
rural children. Cumulative incidence of asthma (defined as physician-diagnosed asthma) for the 
two year follow-up period was 2.3% for rural farming, 5.3% for rural non-farming, and 5.7% for 
non-rural children.  The Cycle 8 of the NLSCY study was completed in (2008/2009) among 
10,941 of the participants who were followed up over a 14 year period. Similar to the results 
obtained in Cycle 2, the cumulative incidence of asthma was 10.2% rural farming, 13.1% for 
rural non-farming, and 16.5% for non-rural children;21 further suggesting that farm and/or rural 
environments is protective of asthma.   
There have been several potential explanations for the observed differences in asthma 
prevalence based on location of dwelling. One of these explanations has been that exposure to 
multiple environmental microbial agents protects against the development of asthma and 
atopy.24,25 Recent renditions of the microbial exposure hypothesis suggest that inflammation 
associated with the development of allergic diseases such as asthma is often driven by an 
imbalance between T-helper type 1 [TH1 (anti-inflammatory)] cells and TH2 (pro-inflammatory) 
cells depending on the influence of environmental exposures and allergens on these cells.25 That 
is, decreased microbial exposures early in life results in insufficient production of TH1 cells, 
which in turn, results in persistent production of TH2 cells. The decreased microbial exposure 
helps to skew the immune response away from TH1 toward TH2 or suppress the TH1cytokine 
producing cells and thus, increases the tendency to develop asthma later in life.25  
Prenatal exposures in rural and farm environments have further reinforced the protective 
effects of microbial exposures on allergic diseases through production of certain cytokines. Of 
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note is TH1 cell-associated cytokines such as interleukin-12 (IL-12) and interferon-gamma (IFN-
γ), which have been found to be significantly higher in cord blood cells of farm compared to 
non-farm infants whereas the TH2 cell-associated cytokines such as IL-5, and IL-10 (which are 
allergic inflammatory cytokines) were unaffected.25,26 This evidence demonstrates that 
stimulating TH1 cells during pregnancy and in early childhood might suppress TH2 immune 
responses and associated allergic diseases. Furthermore, the lower levels of TH2 cytokine 
secretion that have been observed in children from farming families further supports the 
protective role of rural and farm exposures.27 
While environmental exposures may explain some of the urban-rural asthma prevalence 
differences, there may be other factors that also help explain the differences. Compared to urban 
children, rural children may have reduced or limited access to healthcare services for asthma 
symptoms reporting, diagnosis, and management. These barriers to healthcare services may lead 
to failure to properly diagnose asthma and subsequently lead to lower asthma prevalence in the 
rural areas. For example, in a nationwide cross-sectional study in Canada, asthma prevalence was 
observed to be significantly lower in rural compared to urban-metro children whereas there was 
no statistically significant difference in asthma symptoms or hospitalization due to wheeze in the 
past 12 months across location of dwelling (urban-metro, non-metro-adjacent, and rural 
locations).28 The evidence suggests that differences in diagnosing patterns could be another 
potential explanatory factor for the previously observed lower prevalence of asthma in rural 
children. Therefore, research focusing on specific rural conditions, such as consequences of lack 
of access, patient reporting differences, and differences in asthma diagnostic patterns, rather than 
simply rural residential status may further our understanding on the asthma-protective dogma 
associated with rural living.  
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Although there is no “gold standard” for assessing childhood asthma diagnosis, clinical 
symptom history in combination with airway obstruction as measured by pulmonary function 
testing remains the recommended standard protocol.29,30 Due to accessibility difficulties, it is 
possible that rural and farm children with underlying symptoms of asthma may have limited 
access to pulmonary specialists leading to under-diagnosis of asthma and potential biases in the 
estimation of urban-rural asthma outcomes and differences in management strategies for 
asthma.31 These barriers to accessing pulmonary specialists may particularly contribute to asthma 
diagnostic disparities suffered among asymptomatic rural children whose asthma conditions may 
only manifest in the presence of triggers.   
Irrespective of location of dwelling, the indoor environment is considered an important 
factor in the management and risk of childhood asthma. Children are exposed to a complex 
variety of microbial agents in the indoor environment, mostly derived from fungal or bacterial 
origin.32,33 However, an exposure that has received attention in recent years, partly because of its 
potential roles in the development or exacerbation of asthma, is endotoxin which is used as a 
surrogate for gram-negative bacterial exposure in house dust.32,34 Mold derived components such 
as beta-(1→3)-D-glucan is another exposure that has received attention and is used as surrogate 
for indoor fungal exposure.32–35 While indoor microbial exposures, particularly endotoxin, have 
been observed to reduce the risk of childhood asthma in both rural farming and rural non-
farming children,34 the evidence is inconsistent as some studies have reported increased risk36,37 
or no association.38,39  This could be linked to different presentation characteristics of asthma in 
children with the disease. Thus, characterization of asthma phenotypes is important when 
investigating asthma in relation to microbial exposures. Also, while endotoxin34,40,41 and beta-
(1→3)-D-glucan35,42,43 exposures may be thought to prevent asthma development, these 
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exposures may worsen asthma conditions and increase severity of the disease in children with 
asthma since endotoxin44,45 and beta-(1→3)-D-glucan46,47 are also pro-inflammatory in nature. 
1.3 Purpose of the study 
The purpose of this dissertation is to examine: 1) differences in asthma diagnostic patterns 
between rural and urban children and to see if rural children are likely to experience more asthma 
under-diagnosis compared to urban children; 2) the relationship between asthma phenotypes and 
endotoxin and beta-(1→3)-D-glucan levels in house dust; and 3) associations between asthma 
severity, as measured by recommended guidelines, and endotoxin and beta-(1→3)-D-glucan 
exposures in house dust.  
1.4 Organization of the dissertation 
A manuscript-style approach was used for this dissertation. The objectives were investigated 
through three separate manuscripts. Manuscript I: The aim of the study reported in Manuscript I 
was to identify if the previously reported lower prevalence of asthma found with rural children 
was related to asthma under-diagnosis in rural children. For Manuscripts II and III, only children 
identified as positive for asthma from the study conducted in Manuscript I were considered as 
the study population. This selection allows for a strong asthma definition for the study 
population. Manuscript II describes the findings regarding asthma phenotypes as assessed by 
atopic status and bronchial hyperresponsivesness (BHR) and their associations with indoor 
endotoxin and beta-(1→3)-D-glucan exposures. Manuscript III reports a similar approach used in 
Manuscript II assessing the role of domestic endotoxin and beta-(1→3)-D-glucan exposure 
levels for asthma phenotypes but in this study asthma severity is examined using categories 
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determined according to the National Asthma Education and Prevention Program (NAEPP) 
guidelines17 as well as the relationship with lung function. 
 Chapter 2 details the relevant literature describing asthma in general, operational 
definitions, asthma phenotypes and severity, urban-rural asthma differences in asthma morbidity 
and reported associated risk factors. Chapter 3 describes the study populations and the research 
methodology in general. Chapters 4, 5, and 6 present Manuscript I, II, and III, respectively. 
Chapter 7 reports the conclusions from the dissertation based on the three manuscripts and brings 
the three manuscripts together for discussion. Finally, the recommendations resulting from the 
study and future research directions are presented in Chapter 8.   
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CHAPTER 2 
LITERATURE REVIEW 
2.1 General scope of literature review 
The overall aim of this study was to investigate urban-rural asthma diagnostic patterns and the 
relationship between indoor microbial exposures and asthma phenotypes and severity in children 
with asthma. This chapter describes the disease, asthma, its pathophysiology and natural history 
as well as the operational definitions of asthma that are commonly used in epidemiological 
studies.  Asthma phenotypes, and severity as well as asthma prevalence (international and local) 
are also described.  The urban versus rural asthma phenomenon was also reviewed to show 
geographical variation in asthma prevalence and morbidity. Literature providing explanations to 
the observed urban-rural difference in childhood asthma and the associated risk factors are 
presented. Finally, characteristics of studies that have investigated associations between 
microbial exposures and childhood asthma and asthma-related symptoms are also provided.  
2.2 Methods 
The literature review for this study was conducted using information from multiple sources 
including peer-reviewed journal articles, textbooks, review articles, consensus guidelines, 
conference attendance, and internet resources. Updated searches were completed in June and 
July 2017 and the literature review was updated as appropriate. Searches were completed using 
PubMed, Embase, Google Scholar, Science Direct, Web of Science and the University of 
Saskatchewan Library search engines to identify studies that evaluated rural and farming 
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environment and asthma. The search was broadened to include asthma severity, phenotypes and 
diagnostic patterns. Search terms included combinations of key words such as: “rural”, “urban”, 
“farming or agriculture” “endotoxin” “asthma”, “severity” “phenotypes”, “diagnostic patterns”, 
“lung function”, “FEV1”, “FVC”, “asthma risk factors”, “burden of asthma”, “asthma care and 
management”, “access to care”, “environment”, “children”, among others as well as 
combinations of these. Bibliographies of all relevant articles were also screened to find other 
appropriate articles based on their appearance in the previously read scientific articles. Selected 
articles were mostly peer-reviewed articles but technical reports, executive summaries and 
proceedings were also considered if they contained important information. Selected articles were 
evaluated based on the following criteria: 1) studies written in the English Language, 2) studies 
that include data and information pertinent to any of the research objectives, 3) studies that were 
published after 1990. Most of the selected publications used a cohort or cross sectional study 
design, and originated from different countries.   
2.3 Pathophysiology and pathogenesis of asthma, and its natural history  
This section describes asthma, the processes that lead to asthma manifestations, its 
complications, and its natural history. The understanding of these processes is important in 
establishing the rationale for investigating specific risk factors and to help identify a suitable 
study population.   
2.3.1 Pathophysiology and pathogenesis of asthma 
Asthma is a multifactorial disease of the bronchial airway that typically presents with a high-
pitched whistling sound (wheezing), which is heard during breathing in individuals suffering 
from the disease.1 The word “asthma” comes from a Greek word meaning “panting” or 
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“gasping” and was first described by the Ancient Greek physician Hippocrates.2 From the 
ancient times to the present day, asthma has puzzled and confused physicians with symptoms of 
asthma sharing similarities or overlapping with other respiratory and allergic reaction symptoms 
such as bronchiolitis and croup.1 According to the Global Strategy for Asthma Management and 
Prevention, three main features define asthma: chronic inflammation, bronchial 
hyperresponsiveness (BHR), and airway obstruction.3 These terms form the basis of the 
pathological, physiological and clinical features of asthma and defined asthma as a common 
chronic inflammatory disorder of the airways characterized by variable and recurring symptoms, 
airflow obstruction, and BHR.3 The interaction of these three features of asthma determines the 
clinical manifestations of the disease.   
The concept of asthma pathophysiology and pathogenesis has been described and 
continues to evolve since asthma is a complex, multifactorial disease with multiple presenting 
phenotypes.4 However, irrespective of the phenotypic patterns of asthma, airway inflammation 
has remained the predominant feature underlying the pathophysiology of asthma.5 The resultant 
effect of the inflammation on the airway structure and function leads to the development of 
asthma (Figure 2–1); which often manifests as symptoms of recurrent episodes of wheezing, 
shortness of breath, chest tightness, and coughing.  
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Figure 2–1: Pathophysiology of asthma [Used with permission (Appendix 1) from the National 
Heart, Lung, and Blood Institute; National Institutes of Health, U.S. Department of Health and 
Human Services. Link: https://www.nhlbi.nih.gov/health/health-topics/topics/asthma/]. 
(A) Location of the lungs and airways within the body; (B) Cross-section of airway of a person 
without asthma: the muscles around the airway are relaxed and open and there is no swelling 
inside the airway; (C) Cross-section of airway of a person with asthma: the inside of the airways 
is swollen, filled with mucus, and the muscles around the airways narrowed or tightened.     
The airway inflammatory process in the pathophysiology of asthma is a complex 
multicellular process. In a susceptible individual, inhalation of allergens and/or other irritants 
initiate the release of mast cells, eosinophils, and TH2 lymphocytes triggering a cascade of 
inflammation and systemic inflammatory responses such as acute bronchoconstriction.6 The 
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airway responds to inhaled allergen through the TH2 response pathway with the release of TH2-
associated cytokines or key mediators such as IL-4, IL-5, and IL-13 as well as the antibody IgE 
which are more specific to and regulate many aspects of allergic inflammation.7  
The early inflammatory response to allergen is mast cell proliferation, promoted by IL-
13, which induces rapid release of mediators such as histamine, leukotrienes, and 
prostaglandins.8 These mediators are responsible for the contraction of smooth muscle cells and 
mucous secretion which result in severe airway obstruction in patients with asthma.9 While the 
allergen activation through the TH2-dependent pathway and IgE receptors is likely the most 
common occurrence in the pathophysiology of asthma, sensitized mast cells may also be 
activated by osmotic stimuli to induce bronchoconstriction which is usually seen in the case of 
exercise-induced bronchospasm (EIB)10 The mast cell mediators are also responsible for the late 
phase cellular responses characterized by influx of inflammatory cells, eosinophils, and 
neutrophils which are associated with swelling of the bronchial wall and increased airway 
hyperresponsiveness (AHR).11 
Maturation of eosinophils is stimulated by IL-512 with eosinophils identified as the major 
contributing cells implicated in allergic asthma as well as airway dysfunction.13 These cells 
contain inflammatory mediators which induce airway epithelial cell damage, AHR, and airway 
remodeling that are constantly seen in patient with allergic asthma14 with the exception of 
patients with severe asthma who may demonstrate a combination of eosinophilic and 
neutrophilic inflammation or, in some cases, neutrophilic inflammation alone.14,15 As such, 
“eosinophilic asthma” is currently used to characterize a subclass of asthma phenotype with high 
influx of eosinophils in the bronchial airways.16,17 The use of anti-IL-5 monoclonal antibody in 
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patients with asthma has demonstrated greater efficacy in reducing eosinophils in the airway18 
further confirming the role of eosinophils in the pathophysiology of asthma.  
Contrary to eosinophils, the pathological role of neutrophils remains uncertain but 
neutrophils have been found to be the dominant inflammatory leucocyte in the airways and 
sputum of person with severe asthma19 and have been found to be associated with severe airway 
obstruction in patients with asthma.20 
In addition to inflammation and AHR, persistence of chronic inflammation through 
increased production of IL-13 may also induce epithelial damage, leading to airway remodeling 
in individuals with asthma.5 Airway remodeling is believed to occur due to aberration in the 
process of injury-repair mechanism which leads to reconstruction of the epithelial wall of the 
airways.21 The resultant effect of thickening of the basement membrane is another morphological 
hallmark of asthma and is found to be common in patients with atopic compared to non-atopic 
asthma.22  
While the understanding of the pathophysiology of asthma continues to evolve, 
confidence in the fundamental role of TH2 cytokines and pattern of inflammation exists. The TH2 
cytokines have been found to be significantly elevated in the bronchoalveolar lavage (BAL) of 
individuals with asthma leading to suggestion that asthma is a TH2-cell-dependent, IgE-mediated 
allergic disease.23  
2.3.2 Natural history of asthma and wheeze 
The natural course of manifestation of symptoms of asthma over time, either by remission, 
relapse or increasing severity, is commonly referred to as the natural history of the disease.24 
From the available longitudinal studies, it appears that the manifestations of asthma and wheezy 
disorders have temporal patterns; varying considerably over time in the course of life. Studies 
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have shown that children who experienced asthma symptoms (e.g. wheeze) early in life may 
have different experience of the condition later in life:4,25 In some cases the condition may either 
completely resolve (often known as remission), temporally resolve and recur again (known as 
relapse), or persist into adolescence and adulthood (known as persistent).24 Each of these 
categories has differing risk factors, albeit with some degree of overlap between categories. 
Based on the above life course patterns of asthma, longitudinal studies investigating the 
natural history of asthma and wheeze have identified several phenotypes depending on the onset 
of wheeze and asthma. One of these studies is the 1980 to 1984 population-based Tucson 
Children’s respiratory birth cohort study from Arizona, USA.4 Participants for this study were 
826 children who had complete follow-up data at both three and six years of age from the 
original 1,246 newborns between 1980 and 1984. Depending on their history of wheezing, 
children were observed to fall into one of four clinically distinct wheezing categories (or three 
temporal patterns): never wheeze (51.5%); transient wheezing [(19.9%) defined as children who 
had ≥1 lower respiratory tract illness (LRTI) with wheezing during the first 3 years but no 
wheeze at 6 years of age]; late-onset wheezing [(15%) defined as children with no episodes of 
wheeze before the first 3 years of life but had wheeze at the age of 6 years]; and persistent 
wheezing [(13.7%) defined as children who had wheezing before the first 3 years of life and 
continued to wheeze at 6 years of age]. The study also observed that compared to never wheeze 
children, persistent wheezing children were more likely to have allergic sensitization, maternal 
smoking, and mothers with history of asthma during the first year of life, whereas transient 
wheezing children were more likely to have mothers who smoked but not mothers with history 
of asthma. In two other cohort studies, one from each of Canada26 and the United Kingdom,27 
similar results were observed where majority of children were likely to wheeze early in life 
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(preschool age) and outgrow the conditions by school age, although those with persistent 
wheezing were more likely to develop asthma at school age.  
While the majority of infants with wheeze are transient wheezers and may outgrow the 
conditions by school age, other evidence from the Tucson study suggests that after infancy, both 
transient wheezing and persistent wheezing may continue to experience a significant decrease in 
lung function into adolescence signaling negative respiratory outcome and predisposition to 
asthma later in life.25 In this study nested within the Tucson study, children were further 
monitored from age 6 to 16 years.25 The results showed that both late-onset and persistent 
wheezers were more likely to continue to wheeze from age 8 to 16 years compared with never 
wheezing [RRs = 3.12; 95%CI: 2.5–3.9 (late-onset wheezing), and 3.8; 95%CI: 3.1–4.7 
(persistent wheezing)]. The diminished lung function which was originally observed in both 
transient early wheezing and persistent wheezing at age 6 years in the Martinez et al study4 
persisted at age 11 and 16 years with these groups of children experiencing significantly lower 
lung function compared with never wheezing.25 Additionally, persistent wheezers continued to 
be more atopic at ages 11 and 16 years as earlier observed when they were at age 6 years.4  
Cumulatively, these studies revealed a number of temporal patterns of asthma-related 
symptoms from preschool age to adulthood and suggest different pathogenesis for wheezing and 
asthma among children. The general consensus from the studies is that, although asthma may 
begin at any time in life, most asthma-related symptoms (e.g wheeze) are experienced in the first 
few years of life, mostly at infancy and may be associated with allergic sensitization while 
wheezing conditions after preschool age are more likely to be non-atopic.4   
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2.4 Asthma diagnosis 
Accurate asthma diagnosis is the first step towards effective treatment and management of the 
disease. However, asthma presents with a variety of features with different phenotypic 
expressions. As such, establishing diagnosis in children may be difficult as there is currently no 
“gold standard”. In addition, different guidelines suggest slightly different criteria that should be 
applied. 
The Global Initiative for Asthma (GINA),28 National Heart, Lung, and Blood Institute 
(NHLBI),29 European Respiratory/American Thoracic Societies (ERS/ATS),30 and the Canadian 
Thoracic Society (CTS)31 guidelines specifically addressed the challenges of diagnosing asthma 
in children and described key features for assessing the possibility of asthma in this particular 
age group, most notably, the assessment of symptoms history. The features are not exclusive to 
asthma alone, but those that increase the probability of asthma. According to these guidelines, 
features include symptoms such as wheeze, shortness of breath, chest tightness and cough, 
particularly if these symptoms occur: 1) at night or early in the morning; 2) when exposed to 
cold air or common allergens; and 3) when engaged in vigorous exercise. Other features such as 
sensitization to common environmental allergens, and the presence of sputum eosinophils may 
also be used to assist in asthma diagnosis.31 While the presence of a combination of these 
multiple key symptoms may increase the probability of asthma, objective lung function 
assessment as determined by spirometry is also recommended to improve diagnostic accuracy.31 
This section provides a background of methods commonly used to identify the presence of 
asthma for epidemiological studies.  
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2.4.1 Methods used to evaluate the presence of asthma in epidemiological studies 
Two methods are generally used to aid diagnosis of asthma in epidemiological studies: 
questionnaire report of symptoms and assessment of lung function.  
2.4.1.1 Questionnaire report of symptom history 
A physician diagnosis of asthma in children should be based on a comprehensive and careful 
review of current and past clinical symptoms (such as wheeze or cough), frequency and duration 
of symptoms, timing of symptoms (day or night), family and personal history of atopy, as well as 
response to previous treatments.  While family and personal history of allergic disease are strong 
risk factors for predicting asthma and should be taken into consideration in arriving at a 
diagnosis for asthma,32 most diagnoses of asthma using symptoms is based on a history of 
recurrent wheeze and/or cough,33 especially if these symptoms improved in children following 
the use of asthma medications.  
In epidemiological studies, questionnaires incorporating asthma-related symptoms such 
as wheeze, cough, chest tightness or shortness of breath are the most frequently and widely used 
tools in studies investigating the prevalence, incidence, and severity of asthma.34 The 
questionnaire developed for the International Study on Asthma and Allergies in Childhood 
(ISAAC) study team for the prevalence of respiratory symptoms and asthma in children ages 6–7 
and 13–14 years has been the most widely and commonly used tool worldwide.35 The ISAAC 
questionnaire is comprised of four “core” questions for assessing asthma and asthma symptoms 
(Ever wheeze: history of wheezing ever; Current wheeze: wheezing in the last 12 months; 
wheezing upon exertion/vigorous exercise, and dry cough at night), three questions on the 
severity of symptoms (number of wheezing episodes or attacks in a year, wheezing at night and 
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difficulty in completing sentences due to wheezing), and one question on the physician diagnosis 
of asthma.  
Several validation studies have reported good agreement between questionnaire report of 
physician-diagnosed asthma and clinical assessment of asthma in children.34,36–38 In a study 
among 2,845 children in Melbourne, Australia, the ISAAC questionnaire demonstrated high 
sensitivity (85%) and specificity (81%) when compared with physician diagnosis of asthma.37 In 
Sweden, a study among 6,295 children (aged 1–6 years) validated three of the core ISAAC 
questions against clinically diagnosed asthma and found high validity (Ever asthma: sensitivity = 
76.9%, specificity = 97.5%; Ever wheeze: sensitivity = 84.5%, specificity = 77.4%; Current 
wheeze: sensitivity = 86.3%, specificity = 84.1%).39 Similarly, in Norway, the ISAAC 
questionnaire report of ever asthma had a sensitivity of 96% and specificity of 87% among 729 
children (aged 7–14 years) when compared with physician assessment of asthma.40 Also, in 
Finland, current wheeze in the past 12 months showed high agreement when validated against 
clinical assessment of current asthma (sensitivity = 78% and specificity = 97%) among 1,633 
children (7–12 years).34 In the same study, ever asthma had a sensitivity of 88% and specificity 
of 97%.  A study conducted in Canada also found high sensitivity (83.6%) and specificity 
(93.6%) for parental report of childhood asthma when validated against diagnosis of asthma 
using health claim data.36 Therefore, based on the good agreement and validity between 
questionnaire responses and clinical assessment of asthma across populations as noted above, 
questionnaire report of asthma and asthma symptoms remains a powerful tool for identifying 
those with asthma and assessing asthma prevalence in epidemiological studies, especially where 
cost and practical limitations of working with large populations are present.  
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2.4.1.2 Spirometry  
Measurement of lung function is made possible with the use of spirometry conducted by blowing 
into a spirometer which measures how quickly full lungs can be emptied of inhaled air and the 
total volume of air exhaled in the process.41 The obtained lung function variables such as forced 
expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, peak 
expiratory flow rate (PEFR), and forced expiratory flow between 25% and 75% of FVC 
(FEF25%–75%) provide objective assessment of the degree of severity of airway obstruction and 
help to confirm the diagnosis of asthma.28,29 The most important variables from the spirometry 
measurements are the FVC (the volume of air expired as forcefully as possible following full 
inspiration) and FEV1 (volume of air expired in one second of an FVC manoeuvre) as they are 
more repeatable.42 While FEV1/FVC ratio and FEF25%–75% are also important variables, they are 
dependent on the validity of expiratory effort measured by the FEV1 and FVC.
42  
Guidelines for performing and interpreting pulmonary function to aid asthma diagnosis 
have been published by the ATS, CTS, and ERS.41–43 Spirometry results can be expressed as 
absolute values and as a percentage of predicted values.42 The predicted values (also known as 
the reference values) are obtained from a comparable population of healthy and asymptomatic 
subjects matched for age, gender, height, and, on occasion, ethnicity. The FEV1, expressed as a 
percent of predicted values, is used to grade the degree of severity of the abnormality in airflow 
obstruction (e.g. FEV1 >80% = mild, 60% – 80% = moderate, and <60% = severe).29 However, 
FEV1 is generally an insensitive measure for asthma diagnosis as this has been shown to be 
normal in approximately 90% of children with asthma, regardless of level of severity, especially 
if the asthma condition is stable and well managed.44–46  
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Peak flow measurement assessed as peak expiratory flow (PEF) is also used to assist in 
the diagnosis of asthma. However, the sensitivity of PEF in assessing the presence of asthma in 
children is limited (sensitivity = 50% and specificity = 72%) compared to FEV1 (sensitivity = 
45% and specificity = 95%).47 In addition, PEF requires serial assessment of lung function over a 
period of time (days or weeks) where a change in PEF value of >12% and >200 mL 
demonstrates variability in lung function and may be useful in establishing asthma diagnosis.48       
Pulmonary function assessments are useful steps in asthma diagnosis but they are often 
effort dependent with some degree of insensitivity,48 especially in individuals with stable asthma. 
In addition, while spirometry may be useful to assess symptomatic asthma, they may not be 
useful to assess subjects with intermittent or non-symptomatic asthma.49 Further diagnostic tests 
are needed to establish a diagnosis of asthma in such individuals. One method to improve the 
diagnosis of asthma is to induce bronchoconstriction to access the degree of BHR.  
2.4.1.3 Bronchial hyperresponsiveness (BHR) testing  
In many asymptomatic children with relatively mild, controlled or stable asthma, FEV1/FVC can 
be normal.43 Such children are further screened through bronchial provocation testing to assess 
AHR. In most cases, a challenge test with inhaled methacholine [methacholine challenge test 
(MCT)] is used but an exercise challenge test (ECT) can also provide similar information. The 
response is assessed with spirometry. The spirometry variable mostly used for BHR testing is 
FEV1 because it is repeatable and the exhalation time can be shortened to 2 seconds to assess 
BHR at other stages of the spirometry procedure compared to standard 6 seconds used at 
baseline.43   
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BHR tests such as ECT stimulates the release of histamine from mast cell and other 
inflammatory cytokines to induce inflammation, swelling of airway tissues, and subsequent 
narrowing of the airway.50 The acute airway narrowing resulting from ECT with a fall of 10%–
15% in baseline predicted FEV1 values in response to vigorous exercise (ECT) is indicative of 
possible asthma51 and is referred to as exercise-induced bronchospasm (EIB).52  
Several epidemiological studies have validated the use of MCT53,54 or ECT55–57 as 
methods to identify children with asthma. All of these studies demonstrated moderate sensitivity 
and high specificity [MCT: sensitivity (49%–50%)53,54 and specificity (84%–99%);53,54 ECT: 
sensitivity (27%–57%)55–57 and specificity (90%–95%)55–57]. In a study among 8–11 years 
children to demonstrate whether ECT is a suitable measure for BHR, Haby et al55 showed ECT 
had low sensitivity (27%) but high specificity (95%) when validated against physician-diagnosed 
asthma. Another study in Australia among 393 children (aged 13–15 years) demonstrated 
sensitivity of 57% and specificity of 90% for ECT.57 Similar validity results have been observed 
for MCT in New Zealand (sensitivity = 50% and specificity = 84%).54  
These results suggest that BHR, especially ECT, has a limited sensitivity but is highly 
specific in establishing asthma diagnosis.  
2.5 Assessment of asthma severity  
Asthma severity can be measured using a combination of clinical symptoms, and lung function 
variables.58 While spirometry, as a “standard method”, may assist in diagnosing asthma, the use 
of spirometry and clinical symptoms, separately, to diagnose asthma has been reported to result 
in significant under-classification of asthma severity in children59 and therefore, should be used 
together to assess severity. Based on this, an asthma severity classification has been created by 
the National Asthma Education and Prevention Program (NAEPP) which recommends that, in 
  
28 
 
children older than five years, the initial determination of asthma severity be based on a 
combination of current daytime and nighttime symptoms as well as on objective evaluation of 
lung function by spirometry or peak expiratory flow (FEV1 or PEF).
58 This scheme classifies 
asthma into four levels at diagnosis: mild intermittent asthma, mild persistent asthma, moderate 
persistent asthma, and severe persistent asthma (Table 2–1). 
Table 2–1: Criteria for classification of asthma severity according to the NAEPP guidelines58 
Severity categories Daytime 
symptoms 
Nighttime symptoms FEV1 or PEF 
(% of Predicted Normal) 
Mild intermittent asthma ≤2 days/week ≤2 nights/month ≥80 
Mild persistent asthma >2  days/week 3–4 night/month ≥80 
Moderate persistent asthma Daily ≥5 nights/month >60 – 80 
Severe persistent asthma Continuously Frequent ≤60 
The effectiveness and the accuracy of the NAEPP guideline for classifying asthma 
severity have been assessed. In a cohort study from the USA: The National Cooperative Inner-
City Asthma Study (Cohort 1) and the Inner-City Asthma (Cohort 2), Stout et al examined 640 
children (aged 8–11 years) with asthma (Cohort 1: n = 257 children and Cohort 2: n = 383 
children) to determine whether addition of lung function testing to clinical history contained in 
the NAEPP guidelines significantly changes asthma severity classification.60 Results from the 
study showed that a combination of clinical symptoms and spirometry results could improve the 
accuracy of asthma severity classification. Specifically, when daytime or nighttime symptoms 
alone were used to classify children into severity categories, 47.9% and 38.6% of children were 
classified to have mild intermittent asthma while 33.5% and 42.6% were classified to have 
moderate or severe persistent asthma in Cohort 1 and Cohort 2 respectively. However, the 
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addition of spirometry variables (either FEV1 or PEF) to clinical symptoms reclassified 22.8% 
and 27.7% of children originally classified as intermittent asthma into moderate or severe asthma 
in Cohort 1 and Cohort 2, respectively. Similarly, 31.2% and 33.3% of children with symptoms 
consistent with mild persistent asthma were reclassified as having moderate or severe asthma in 
Cohort 1 and Cohort 2, respectively.60  
The above results demonstrated that symptoms history alone is likely to underestimate 
asthma severity and further confirmed the clinical application of the NAEPP guidelines in 
asthma severity assessments. However, one of the fundamental components of asthma guidelines 
has been the actual assessment of disease severity to guide treatment recommendations and 
management of asthma conditions.61 As such, the NAEPP asthma severity guidelines were meant 
to be used to categorize asthma severity in patients not already receiving treatment or therapy.62 
However, this is not often the case, as the guidelines have also been used to assess severity in 
patients already on treatment.63 For this reason, asthma severity guidelines were updated. 
According to the first updates of the GINA guidelines,28 it is important to recognize that asthma 
severity not only involves frequency of symptoms and the underlying lung function impairments 
but also based on frequency of medication use and response to treatment. This is the additional 
definition requirement to the clinical features already proposed by the NAEPP guidelines for 
assessing asthma severity58 and was subsequently endorsed by the ATS/ERS Task Force.63 The 
medication use and response to treatment criteria have also been incorporated into the CTS 
guidelines31 for asthma control. 
Both the NAEPP and GINA guidelines have been validated against physician assessment 
of asthma severity with GINA showing better agreement compared to NAEPP guidelines.62 This 
could be as a result of the inclusion of medication use in the GINA compared to NAEPP 
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guidelines. However, GINA guidelines also raised another concern in that it may be assessing 
asthma control as opposed to asthma severity because the criteria included medication use and 
response to treatment therapy. It is possible that physicians may label patients with severe 
asthma condition as less severe asthma, especially if their asthma conditions are well controlled 
under intensive medication regimen.62 Furthermore, not all patients with asthma or asthma-
related symptoms have access to effective medications and respiratory specialists, especially if 
they live in settings with limited access to healthcare services.61 They may not have received a 
diagnosis of their asthma conditions or been prescribed appropriate medications for treatment. 
Therefore, to help disease management and allow for appropriate epidemiological assessments of 
asthma severity in a population, it is necessary that disease severity be determined in the absence 
of treatment therapy, especially if patients are currently untreated.61 Based on these reasons, the 
NAEPP guidelines is currently being used as a simple tool in epidemiological studies to assess 
asthma severity and to identifying people at risk of severe exacerbation.61,62 This will allow for 
initial asthma management plans which could be supplemented with step-by-step treatment 
procedures for effective asthma control.61,64 
2.6 Asthma phenotypes  
The NAEPP/GINA guidelines for asthma severity suggest that if an individual with asthma 
meets any one criterion for a specific severity category, the subject is assigned to that category 
despite potential disease heterogeneity within each category.58 The major assumption with these 
schemes is that all subjects within a specific asthma severity category share similar disease 
characteristics. However, asthma is a heterogeneous disease with multiple phenotypes.4,65 
Patients with asthma differ with respect to factors that triggered attacks, the clinical 
presentation,66,67 and patterns of inflammatory responses.65  
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The early classification of asthma phenotypes described two distinct phenotypes: allergic 
(atopic) and non-allergic (non-atopic) asthma, based on positive skin test to common allergens or 
the presence of specific IgE antibodies against common allergens.68,69 Although allergic 
sensitization remains the basis of atopic asthma phenotype, not all children with asthma are 
atopic and most children with atopy do not develop asthma.68 The prevalence of atopy among 
children with asthma appears to be mainly determined by the general prevalence of atopy in the 
population.70 While atopic status remains the most commonly used parameter for classifying 
asthma phenotypes, the recognition of other phenotypes based on triggers (e.g. infection71,72 and 
exercise,65,73), clinical or physiological expression (e.g severity-defined,74,75 treatment 
resistant,76,77 and age at onset4,78), and type of inflammation (e.g eosiniphilic and 
neutrophilic23,78) has demonstrated that the development and manifestation of the disease is 
beyond allergic sensitization alone. The recognition of these differences in asthma presentation 
has led to its description as a heterogeneous disorder.79  
EIB is also currently being recognized as another asthma phenotype and has been found 
to be useful for identifying children at risk of asthma.51 A large proportion of patients with 
asthma demonstrated BHR following ECT. This can also occur in individuals without a known 
asthma diagnosis.80 For this reason, there are current debates on the use of ECT as a unique 
entity asthma phenotype.80 However, the resulting AHR or bronchoconstriction induced by ECT 
is considered a marker of asthma or showed evidence that exercise may trigger asthma and 
should be regarded as a pathological process that leads to symptom expression and clinical 
evidence of asthma in children.10,80,81 
Classifying asthma into unique phenotype categories is difficult because of overlaps 
between phenotype groups. However, epidemiological methods (statistical methods) and 
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symptom-based methods (clinical methods) have been used to classify the disease into unique 
clusters within a population of asthma patients.82 Using cluster analyses which attempt to 
eliminate bias in categorizing asthma phenotypes by avoiding definition of the asthma conditions 
(i.e. placement of patients into asthma severity categories) before analysis, three large studies 
performed in Europe83–85 and one in the United States86 identified distinct phenotype clusters 
based on age of onset of asthma and duration, allergic status, sex, clinical symptoms, medication 
use, healthcare utilization, lung function, airway inflammation and other clinical characteristics 
that varied between the studies. Despite differences in study designs, variables that were 
analyzed, and studied populations from these studies, no asthma phenotype class achieves all the 
requirements for a distinct or discrete phenotype. There were clear overlaps in phenotypes 
identified.   
2.7 Asthma prevalence 
2.7.1 Global asthma prevalence 
In 1998, after the completion of the ISAAC Phase I (1993–1997), global asthma prevalence for 
children was reported to be 11.2%.87 From 2000–2003, Phase III of the project was repeated to 
assess changes over time. While there were some differences in results across centers (some with 
increased prevalence and some with decreased prevalence) , the time trend analysis showed that, 
overall, the percentage of children and adolescents reported to have asthma increased 
significantly with global asthma prevalence increasing from 11.2% to 13.5%; which indicates an 
annual increase of 0.28% overall.87 Currently, the prevalence of asthma-related symptoms 
(particularly wheeze) has reached 20% or more in some developed parts of the world, including 
Canada.88 Using combined data from the ISAAC Phase I and the European Community 
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Respiratory Health Survey (ECRHS) for children (6–7 years and13–14 years) Masoli et al 
estimated that prevalence of “clinical asthma” defined by current wheezing (self-reported 
wheezing in the past 12 months) increases globally by 50% every decade while BHR plus 
current wheezing is around 40%–60%.89 Based on this figure, the study projected that in addition 
to the currently estimated 300 million people (both children and adults) who suffer from asthma 
worldwide; there may be an additional 100 million more cases in 2025 as countries become more 
urbanized.89 This is evidenced from the observed decreases in international differences in asthma 
prevalence. In the ISAAC Phase I study, asthma was reported to be more common in high-
income and industrialized countries but much lower in low-income and developing countries.90 
In Phase III, however, it became clearer that a high prevalence of asthma symptoms is not 
restricted to the high-income countries alone. The majority of countries that originally had low 
asthma prevalence in Phase I reported increases in asthma prevalence in Phase III.87 This 
suggests that while the overall global prevalence of asthma continues to increase, the global 
prevalence disparities are at the same time decreasing, possibly reflecting greater awareness of 
asthma, improved diagnostic practices, and increased environmental exposure or a combination 
of these factors.  
2.7.2 Childhood asthma prevalence in Canada 
Over 3 million people (including children and adults) are already diagnosed with asthma in 
Canada.91 Using data from the NLSCY study, changes in asthma prevalence among children 
aged 0–11 years were examined from 1994/1995 through 2000/2001.92 Reports from the study 
showed that in the mid-1990s, 11% of Canadian children were diagnosed with asthma. However, 
over a period of five years (by 2000/2001), the prevalence had risen to more than 13.4%, an 
increase of nearly 70,000 cases over the five year period, at a rate of 14,000 cases per year.92 
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Also, among 2–7 year olds, the prevalence of asthma increased between 1994/1995 (11.5%) and 
2000/2001 (13.2%) but later decreased between 2006/2007 (11.5%) and 2008/2009 (9.8%).93 
Using a broader age category (0–19 years), Statistics Canada reported that asthma prevalence 
among Canadian children and adolescents increased steadily from 2.3% to 12.2% between 1978 
and 1996 and later stabilized in the late 1990s and early 2000s (15.5% in 1998, 15.6% in 2000, 
16% in 2003).94 While this report and another study95 suggested that asthma prevalence 
stabilized in the later years of 1990s, the overall trends in asthma prevalence have been 
increasing in different provinces in Canada. For examples, in the province of Ontario, which has 
one third of Canada’s population (nearly 13 million), a population-based cohort study suggested 
that age- and sex-standardized asthma prevalence increased from 8.5% to 13.3% between 1996 
and 2005,96 In British Columbia (BC) and Prince Edward Island (PEI), the proportions of doctor-
diagnosed asthma also increased from 7.1% to 8.3% between 2002 and 2007 in BC,97 and from 
7.4% to 10.1% between 2002 and 2008 in PEI.98 The recent overall asthma prevalence from the 
NLSCY over a 14-year period from Cycle 1 (1994/1995) to Cycle 8 (2008/2009) is 15.9% with 
highest prevalence (18%) in the Atlantic provinces (Nova Scotia, New Brunswick, and Prince 
Edward Island), followed by Quebec (17%), Prairie provinces (Alberta, Manitoba, and 
Saskatchewan; 15.6%), Ontario (15.2%), and British Columbia (14.9%).99 This suggests 
increasing asthma prevalence among children in Canada.   
2.7.3 Childhood asthma prevalence in Saskatchewan  
The prevalence of asthma has also been shown to follow increasing trends over time in the 
province of Saskatchewan although there has been some indication of stabilization as well.95 
Using physician billing data from the Medical Claim Insurance Branch (MCIB) database, the 
prevalence of asthma among school-age children (5–14 years) in Saskatchewan was reported to 
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increase from 2.6% in 1981 to 4.4% in 1990.100 This is consistent with the results of the national 
asthma trends as reported by the Statistics Canada where asthma prevalence among children <20 
years in Canada also increased from 3.2% in 1984 to 11.5% in 1994.94 Similarly, using the 
Saskatchewan Health databases, asthma prevalence among children (aged 5–14 years) in 
Saskatchewan also increased between 1991 and 1995 (increasing from approximately 5.3% to 
6.2%, respectively). Thereafter, it either decreased or stabilized between 1996 and 1998 (6.1% in 
1996, 6.0% in 1997, and 5.9% in 1998).95 After the stabilization period, asthma prevalence 
among children in Saskatchewan has continued to rise. Among adolescents aged ≥12 years, the 
asthma prevalence increased from 7.7% in 1997101 to 8.1% in 2003102 in two separate reports 
from the Statistics Canada databases. 
According to the Saskatchewan Ministry of Health reports, the overall asthma prevalence 
among children and adolescents in Saskatchewan has increased by three to four folds since 2002 
to 2011.103 Among children (age 5–9 years old) current asthma prevalence was reported to be 
16% while among adolescents (10–14 years old) the prevalence is approximately 21%.103 In 
addition, the report also showed that among children, asthma appeared to be more prevalent in 
males compared to females in both age groups (18.9% vs. 13% and 24.1% vs. 16.7%, 
respectively). Recent report from the NLSCY study, also shows that the overall cumulative 
incidence of asthma over a 14-year period from Cycle 1 (1994/1995) to Cycle 8 (2008/2009) in 
children (0–11 years) in the Prairies which comprised of Alberta, Manitoba and Saskatchewan is 
15.6%.99 
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2.8 Place of residence and asthma prevalence and severity 
The importance of “place” to health status has become increasingly evident as places where 
people live and work can have enormous impact on their health. This is also the case with 
childhood asthma.  
2.8.1 The urban versus rural asthma phenomenon 
The prevalence of asthma among children appears to differ depending on places of residence.104 
Data from the ISAAC Phases I and III studies suggest that the prevalence of asthma and asthma-
related symptoms are higher among children and adolescents living in urban compared to 
children in rural settings.105 Within Canada, regional variation in asthma and asthma-related 
symptoms have also been reported. In a nationwide cross-sectional survey of schoolchildren 
(aged 11–15 years) participating in the Health Behaviour in School-aged Children study, asthma 
prevalence was reported to be higher in urban metro areas compared to rural regions (17.6% vs. 
14.8%) with adolescents from rural areas having a lower risk of current asthma compared with 
participants from large metro regions (OR = 0.76; 95%CI: 0.61–0.95).106 Similarly, in two 
separate surveys among 3,564 children (7 year-old) in Manitoba, Canada; Korzyskyj and Becker 
also observed prevalence of both atopic asthma and asthma to be higher in children living in 
urban center compared to children living in southern and northern parts of rural Manitoba (atopic 
asthma: 9% in urban, 5% in southern rural, and 4% in northern rural;107 asthma: 14% in urban, 
10% in southern rural, and 8% in northern rural108). 
Several other studies from different countries have also investigated urban-rural 
differences in childhood asthma. While results may varies and inconsistent across these studies 
with some showing higher asthma prevalence in rural areas, urban locations tend to have higher 
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proportion of children with asthma.109 Characteristics of the various studies that have compared 
urban-rural differences in childhood asthma and asthma morbidity are presented in Table 2–2. 
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Table 2–2: Characteristics and results of studies investigating asthma prevalence and asthma-related symptoms in urban and rural 
populations among school-age children 
First 
AuthorReference# 
(Year published) 
Location(s) 
Study design Study 
population 
(Sample size) 
 
Operational definition 
of asthma used in 
study 
Urban vs. rural asthma findings Other related findings or 
strength of the association 
Lawson JA110 
(2017) 
Canada 
Cross-
sectional 
5–14 years 
(3509) 
1) Reported lifetime 
physician-diagnosed 
asthma 
2) Current asthma: 
Ever asthma plus 
positive response to 
wheeze, asthma 
episodes, breathing 
medication, or 
healthcare utilization 
for asthma in the past 
12 months 
Prevalence of both ever asthma 
(15.1% vs. 20.7%) and current 
asthma (10.9% vs. 14.9%) were 
significantly lower in rural 
compared to urban children. 
The prevalence of ever wheeze 
(27.4% vs. 27.2%) and current 
wheeze (13.1% vs. 14.0%) were 
similar and not statistically 
different between rural and 
urban children 
The risk of >3 wheezing 
episodes in the past 12 
months was higher among 
rural children with asthma 
(aOR = 2.93; 95%CI: 
1.26–6.86) compared to 
urban children despite 
lower prevalence in the 
rural children 
Brozek G111 
(2016) 
Belarus 
Poland 
 Ukraine 
Multicenter 
cross-
sectional 
7–13 years 
(n = 12548) 
1) Reported 
physician-diagnosed 
asthma 
2) Current wheeze: 
Wheezing in the past 
12 months 
Asthma prevalence was lower in 
rural compared to urban children 
in the three countries involved: 
Belarus: (1.4% vs. 1.5%) 
Poland: (3.5% vs. 4.1%) 
Ukraine: (1.4% vs. 2.1%). 
Similar results were observed for 
current wheeze: 
Belarus: (10.7% vs. 10%) 
Poland: (4.8% vs. 5.2%) 
Ukraine: (11.5% vs. 13%). 
Results were not statistically 
significant within country 
Further analysis of ratio of 
wheeze symptoms (current 
wheeze) to report of 
diagnosed asthma showed 
evidence of asthma under-
diagnosis among rural 
children in all three 
countries [Rural vs. Urban: 
10.9:1 vs. 8.1:1 (Belarus); 
17.3:1 vs. 7.3:1 (Ukraine); 
and 2.4:1 vs. 1.9:1 
(Poland)] 
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Zhu W112 
(2015) 
China 
Cross-
sectional 
≤14 years 
(n = 20722) 
1) Reported lifetime 
physician-diagnosed 
asthma  
2) On-the-spot 
physician 
confirmation of 
asthma following 
positive responses to 
any or a combination 
of asthma-related 
symptoms  
 Prevalence of asthma was 1.3% 
for rural and 3.7% for urban. 
On-the-spot diagnosis of asthma 
was 48.7% for rural and 73.9% 
for urban.  
Also, 28.9% of physician 
confirmed asthma (28.9% of 
48.7%) were rural children 
originally incorrectly diagnosed 
with bronchitis compared to 
12.9% of urban children (12.9% 
of 73.9%). 
The overall asthma 
prevalence based on 
screening questionnaire 
and on-the-spot physician 
examination was 2.83%.  
Due to the apparent 
asthma misdiagnosis in 
rural children, only 35.6% 
of rural children with 
confirmed asthma received 
prescription drug for 
asthma management 
compared to 56.5% of 
urban children 
Vlaski E113 
(2014) 
Macedonia 
Cross-
sectional 
12–16 years 
(n = 5507) 
Reported lifetime  
physician-diagnosed 
asthma 
Prevalence of asthma was lower 
in rural compared to urban 
children (1.2% vs. 1.9%; 
p=0.26).  
Prevalence of current wheeze 
was lower in rural compared to 
urban children (4.9% vs. 7.2%; 
p=0.03) 
After adjusting for 
potential confounders, 
rural dwelling remained 
protective for current 
wheeze (OR = 0.74) and 
asthma (OR = 0.97) but 
not significant. 
Lawson JA114  
(2014) 
Canada 
Prospective 
cohort 
12–18 years 
(n = 956) 
Reported lifetime 
physician-diagnosed 
asthma 
Over a 12-year follow-up period 
of 21,274,890 person-years, the 
incidence of asthma was lower 
among rural compared to urban 
adolescents (6.4 vs. 10.7 cases 
per 1000 person-years).  
Overall incidence of 
asthma over the follow-up 
period was 10.2 cases per 
1000 person-years and was 
higher in females 
compared to male 
adolescents (13.2 vs. 6.6 
per 1000 person-years 
Kausel L115 
(2013) 
Chile 
Cross-
sectional 
13–14 years 
(n = 3363) 
Reported current 
asthma symptoms 
(Had wheezing or 
A significant dose-response 
effect was observed along an 
urban-rural gradient for current 
Both rural and semiurban 
location were inversely 
associated with current 
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whistling in the chest 
in the past 12 months) 
asthma with lowest prevalence 
observed in rural (6%) compared 
to semiurban (10.1%) and urban 
(16%) children. 
asthma (ORs = 0.4 and 
0.6, respectively) but the 
association was only 
significant for rural 
location 
Guner SN116 
(2011) 
Turkey 
Cross-
sectional 
6–18 years 
(n = 607) 
Reported lifetime 
physician-diagnosed 
asthma 
No statistical difference in the 
prevalence of asthma was 
observed between urban and 
rural location of residence 
(10.5% vs. 7.1%; p=0.16) 
Urban-rural asthma 
prevalence difference was 
also not significant among 
children with family 
history of atopy (31.4% vs. 
25.7%; p=0.71)  
Kolokotroni O117 
(2011) 
Cyprus 
Cross-
sectional at 
two point 
intervals 
(1999–2000 
and 2007–
2008) 
7–8 years 
(n = 4944 for 
1999–2000 
survey and n 
= 2216 for 
2007–2008 
survey) 
Reported lifetime 
asthma (Has your 
child ever had 
asthma?) 
Current wheeze 
(wheezing in the past 
12 months) 
This study assessed temporal 
changes in the prevalence of 
asthma in urban and rural areas 
between two intervals. In the 
first interval (2000), prevalence 
of both asthma and current 
wheeze were significantly lower 
in rural compared to urban areas 
(asthma: 9.7% vs. 11.9%; 
current wheeze: 5.4% vs. 7.5%, 
respectively). This was reversed 
in the second interval (2008) 
with the prevalence of both 
asthma and current wheeze 
higher in rural compared to 
urban areas (asthma: 18.4% vs. 
17.1%; current wheeze: 9.7% vs. 
8.4%, respectively). 
Between 2000 and 2008, 
the prevalence of current 
wheeze was almost 
significantly doubled in 
rural areas (5.4% vs. 9.7% 
with OR = 1.81). No 
apparent significant 
change was observed for 
urban areas (7.5% vs. 
8.4% with OR = 1.08); 
suggesting that recent 
increases in the prevalence 
of asthma and asthma-
related symptoms may 
appear to be more 
pronounced in rural 
Cyprus children  
Lawson JA106 
(2011) 
Canada 
Cross-
sectional 
11–15 years 
(n = 4726) 
Reported lifetime 
physician-diagnosed 
asthma (Has a doctor 
A significant dose response of 
lessening risk of asthma across 
an urban-rural gradient. 
Lower risk of asthma was 
associated with rural 
locations (OR = 0.81). 
However, prevalence of 
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ever said you have 
asthma?) 
Asthma prevalence was lowest 
in rural regions (14.8%), 
followed by non-metro adjacent 
(15.6%) and metro areas 
(17.7%) 
current wheeze was similar 
and non-significant across 
the three locations. 
Valet RS118 
(2011) 
USA 
Prospective 
cohort 
Children 
followed up 
from birth 
until the age 
of 5.5 years 
(n = 117080) 
Validated algorithm 
that required an ICD-9 
asthma diagnosis code 
493 
This study recruited children 
across an urban-rural gradient: 
urban, semiurban, and rural 
locations. Using the ICD-9 
asthma code, the prevalence of 
asthma was 13% in rural, 12% in 
semiurban, and 11% in urban 
children from the ages of 4–5.5 
years (p<0.001).  
Overall asthma prevalence was 
11.8% 
 
Rural and semiurban 
children had greater 
number (mean) of 
outpatient visits for any 
reason (15.7 and 14.6; 
respectively) compared to 
urban children (11.0).  
Urban compared to rural 
children with asthma had 
greater use of prescribed 
asthma medications (2.0 
vs. 1.0) 
Pesek RD119 
(2010) 
USA 
Cross-
sectional 
4–17 years 
(n = 6376) 
Physician provider 
diagnosis of asthma 
based on validated 
asthma algorithm 
No apparent difference in 
provider-diagnosed asthma 
between urban and rural children 
(20% vs. 19%) but rural 
compared to urban children were 
more likely to be identified as 
“at-risk” (having asthma-related 
symptoms without provider-
diagnosed asthma) for asthma 
(27.8% vs. 24.6%).   
Among children identified 
as “at-risk-for-asthma”, 
rural compared to urban 
children were also more 
likely to be classified as 
having moderate to severe 
persistent asthma (45.9% 
vs. 34.5%) 
Ma Y120 
(2009) 
China 
 
Cross-
sectional 
13–14 years 
(n = 7077) 
Reported lifetime 
physician-diagnosed 
asthma 
Prevalence of asthma was 
significantly lower in rural 
compared to urban area (1.1% 
vs. 6.3%).   
Prevalence of current 
wheeze was also 
significantly lower in rural 
compared to urban area 
(1.0% vs. 7.2%). The 
strength of the associations 
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were very strong both for 
asthma (OR = 6.1) and 
current wheeze (OR = 7.5)  
Solé D121 
(2007) 
Brazil 
Cross-
sectional 
13–14 years 
old from two 
cities: 
Caruaru (n = 
3026) and 
Santa Maria 
(n = 6123) 
Wheeze symptom in 
the last 12 months 
Prevalence of asthma was 
significantly lower in rural 
adolescents from Caruaru 
compared to their urban 
counterparts (12.5% vs. 18.6%). 
No urban-rural differences were 
observed in Santa Maria (16.7% 
vs. 15.3%) 
Rural living was 
significantly associated 
with asthma among 
Caruaru adolescents after 
adjusting for potential 
confounders (OR = 1.60) 
Kozyrskyj A107 
(2006) 
Canada 
Cross-
sectional 
0–7-years 
(n = 3564) 
Atopic asthma Children from both northern and 
southern rural areas compared to 
urban children had significantly 
lower prevalence of atopic 
asthma (4% and 5%, 
respectively vs. 9%) 
Children with family 
history of allergy (atopic) 
were more likely to 
develop atopic asthma 
(OR = 1.87) 
El-Sharif N122 
(2002) 
Palestine 
Cross-
sectional 
6–12 years 
(n = 3623) 
Reported lifetime 
physician-diagnosed 
asthma 
Asthma prevalence was 
significantly higher in children 
from urban refugee camps 
compared to children from rural 
villages (15.6% vs. 8.1%). 
Similar results were observed for 
urban-rural prevalence of 
wheezing in past 12 months 
(12.6% vs.  8.2%; respectively).  
Prevalence odds ratio 
(POR) for urban vs. rural 
asthma was 1.48.  
Severity of wheezing 
attacks (≥12 attack of 
wheezing in the past 12 
months) was significantly 
higher in urban compared 
to rural children (POR = 
2.67). 
 
 43 
 
While many of the studies in Table 2–2 showed lower prevalence of asthma in rural 
compared to urban children, symptoms suggestive of asthma were often higher in rural compared 
to urban children. This can be seen from three specific studies. 
The cross-sectional study from Saskatchewan, Canada, showed that rural children had 
significantly reduced risk of current asthma compared to their urban counterparts (OR = 0.58; 
95%CI: 0.42–0.99).110 However, the prevalence of ever wheeze (27.4% vs. 27.2%) and current 
wheeze (13.1% vs. 14.0%) were similar and not statistically different between rural and urban 
children.110 Also, among those with asthma, 24.8% of rural compared to 12.3% of urban had 
severe asthma symptoms (>3 episodes of wheeze in the past 12 months).110  
A second study by Valet et al from Tennessee, USA118 further showed evidence of 
asthma under-treatment in rural compared to urban children with urban children having greater 
proportion of one or more prescription fillings for asthma medication (35% vs. 31%; p<0.001) 
despite rural children having greater asthma morbidity.  
A third study by Pesek et al from Arkansas, USA119 also showed that asthma morbidity 
(measured by frequency of asthma symptoms, and medication use) was significantly higher in 
the rural compared to urban children, even though the use of healthcare services appeared to be 
similar between the two groups (19% vs. 20%). Furthermore, a higher proportion of children in 
the rural group were classified as being “at-risk-for-asthma” compared to urban children (27.8% 
vs. 24.6%). “At-risk-for-asthma” children in this study was defined as children who had 
symptoms and frequency of medication use consistent with asthma diagnosis but had never been 
diagnosed of their asthma conditions either by a physician or other healthcare professional 
workers.  
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Findings from these studies not only suggest higher asthma-related symptoms and 
morbidity in rural children but also show evidence that rural children may be under-diagnosed 
for asthma, thus contributing to the lower asthma prevalence estimates observed in the rural 
settings.   
Multiple factors may be used to explain the urban-rural asthma patterns described in 
Table 2–2. This may include environmental factors (particularly farm exposure in the rural 
areas), lower or lack of hospital report of symptoms consistent with asthma in rural children, 
limited access to healthcare facilities among others.  
2.9 Farm environment exposure as potential explanation for urban-rural asthma 
phenomenon 
One distinct factor between rural and urban areas which has been observed to have an 
association with asthma is exposure to a farming environment among the majority of rural 
populations. Exposure to farming environment may protect against allergic diseases in childhood 
such that children who grow up on farms are often less atopic, have less allergic disease, and 
often have less asthma compared to non-farm children.123 Although, the specific factors of the 
farming environments that may be responsible for the protection of allergic diseases among farm 
children are still not clear, it appears that high microbial exposure either through contact with 
farm animals (through animal feeding and cleaning of animal pens)124,125 or consumption of 
unpasteurized farm milk125,126 are possible explanations (Figure 2–1).  
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Figure 2–1: Farm exposures and the development of childhood allergic diseases127 (used with 
permission from Nature Publishing Group. Permission License: Appendix 2). 
The mechanisms of the protective effects of farming exposure and childhood asthma are 
still not well defined, but are likely to be associated with the developing immune system and 
exposures around the time of birth.127,128 As depicted in Figure 2–1, pregnancy and early life 
stages appear to represent the most important biological window of opportunity for shaping the 
immune responses in farm-exposed children. Specifically, contact with farm animals and/or 
consumption of unpasteurized farm milk results in increased microbial exposure of women 
engaging in farming activities during pregnancy. This programs the exposed child’s immune 
responses at birth by enhancing regulatory cell (Treg) and interferon (IFN)-γ to induce 
polarization of TH dependent cells. Further exposure of child to animals and/or consumption of 
unpasteurized farm milk in early childhood activates the innate immune pathways through 
expression of Toll-like receptors [specific for microbial products (TLRs)] and CD-14 that 
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upregulates and promotes TH1 cell-dependent cells has the potential to suppress the development 
of TH2 dependent allergic diseases including asthma at school age.
129  
2.10 Beyond urban-rural environmental exposure differences: urban-rural asthma 
diagnostic patterns 
Environmental exposures have mostly been implicated for the urban-rural asthma prevalence 
differences.123 While childhood asthma may be disproportionately common in urban compared to 
rural children,109,130 asthma may be under-diagnosed in rural children with recent studies 
showing similar or increased asthma-related symptoms in rural compared to urban 
children.110,118,119 Furthermore, many children in rural settings who reported absence of 
physician-diagnosed asthma upon screening by a questionnaire have been observed to have 
asthma when examined by a physician.131 This is not surprising as rural children who might 
otherwise be eligible for asthma care must also have the means to travel to the location of care 
before they can access healthcare services. Since triggers of asthma exacerbation, as well as 
healthcare access issues are common in rural communities, urban-rural differences in diagnosing 
patterns or access to healthcare services for symptoms reporting could also contribute to the 
observed asthma prevalence difference between rural and urban communities.   
There is evidence that rural children could be less likely to become diagnosed with asthma, even 
when they experience symptoms suggestive of asthma132,133 as  supported by a study that 
investigated childhood asthma prevalence among 6–14 years old children in two rural Iowa 
counties in the USA.131 Chrischilles et al reported that, overall, 13.8% of children in the two 
rural counties (Keokuk and Louisa) of Iowa reported frequent symptoms of asthma. Of these 
children, less than half (41.6%) reported ever been given a positive diagnosis of asthma by a 
physician. Similarly, of the 4.9% that reported severe asthma symptoms (defined as wheezing 
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limiting child’s speech to only 1 or 2 words between breaths or if the child had any visits to the 
emergency department or hospitalizations because of asthma, bronchospasm, or wheezing in the 
past 12 months), only 67.5% had received asthma diagnosis by a physician.  A recent cross-
sectional study in Saskatchewan, Canada, also showed lower asthma prevalence in rural (15.1%) 
compared to urban (20.7%) children but similar prevalence of ever wheeze (27.4% vs. 27.2%) 
and current wheeze (13.1% vs. 14.0%) between settings.110  
Data from these studies showed that asthma in rural and farming children may be under-
diagnosed and may explain some of the observed differences in asthma prevalence. A focus on 
urban-rural asthma diagnostic pattern as a potential explanation for urban-rural asthma 
prevalence differences is thus warranted.    
2.11 Risk factors for asthma   
In addition to place of residence as a risk factor for asthma, several studies have implicated a 
number of other risk factors in the development of childhood asthma. Reports from these other 
studies suggest that asthma appears to be a multifactorial disease where a number of 
personal/host factors (e.g. sex, gender, family history of allergic diseases) and environmental 
exposures (e.g. air pollution, dampness, mold, tobacco smoke exposure, microbial exposures, 
allergen exposure etc) play significant roles in its etiology. Many of these risk factors may also 
be distributed differently across rural and urban populations such that the geographical variation 
in the prevalence of asthma and asthma-related symptoms may be closely related to the 
differential distribution of these factors. As such, it is important to consider these other factors 
while investigating childhood asthma along an urban-rural gradient.  
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2.11.1 Personal or host risk factors for asthma 
2.11.1.1 Gender and age  
As mentioned earlier in the discussion of the natural history of asthma, the vast majority of 
asthma starts in early childhood in which children with asthma experienced their first episodes 
before the age of 6 years.134 During this stage of life, both incidence and prevalence of asthma 
are higher in males than in females. This trend continues until around puberty and reverses in 
adolescence, with higher prevalence of asthma occurring in females.135,136 The mechanisms 
underlying the gender shift in asthma prevalence are unclear but an increase in asthma incidence 
coupled with a decrease in remission of asthma in females compared with males during 
adolescence have been suggested as some of the possible explanations.137 
The Tracking Adolescents’ Individual Lives Survey (TRAILS) study in the Netherlands 
assessed the associations of puberty stages and transition through puberty with the prevalence, 
incidence and remission of asthma in 2,230 subjects followed from birth until 24 years of age.137 
Three survey data were collected on the presence of asthma at mean age. 11.1, 13.6, and 16.3 
years. Results showed prevalence of asthma to be similar in boys and girls at mean age of 11.1 
years (7.7% vs. 7.4%) and 13.6 years (6.0% vs. 5.8%). However, at a mean age of 16.3 years, the 
prevalence of asthma was significantly higher in females compared to males (6.2% vs. 4.3%). In 
addition, incidence of asthma was observed to be higher (2.8% vs. 1.4%) and remission was 
lower (2.1% vs. 3.4%) in female compared with male subjects at mean age of 16.3 years; 
suggesting that the observed shift in the prevalence of asthma was most likely related to both 
increased incidence and decreased remission of asthma in female subjects compared with males 
during puberty-adolescent transition stage. Similarly, a population-based study in Saskatchewan, 
Canada also revealed sex switchover in asthma predominance where asthma prevalence was 
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significantly greater in males compared to females for preschool age (0–4 years: OR = 1.57; 
95%CI: 1.54–1.60) and school-going children (5–14 years: OR = 1.39; OR = 1.36–1.40).95 
However, at age 15–34 years, a sex switchover from male to female predominance was observed 
with lower prevalence of asthma in males compared to females (OR = 0.90; 95%CI = 0.89–
0.90).  
2.11.1.2 Family history of asthma and allergy 
Children with a family history of asthma are more likely to develop asthma themselves. In an 
international systematic review of 33 studies, Burke et al observed that family history of asthma 
was consistently identified as a strong predictor of asthma when one or more first-degree 
relatives has asthma, with most ORs ranging between 2 and 4.138 Similarly, in another study, 
London et al demonstrated that having parents or siblings with history of asthma and allergy 
increases the risk of developing different asthma phenotypes with a prevalence ratio (PR) of 12.1 
for early-onset persistent, 7.51 for early-onset transient, and 5.38 for late-onset asthma.139 This 
familial aggregation of asthma disease suggests that a positive family history might be used to 
identify children at risk of developing asthma.  
2.11.1.3 Obesity 
Associations between obesity and asthma have been observed in adults and adolescents140–142 as 
well as school-age children.143 A study by Gilliland et al in Southern California followed up 
3,792 children for 5 years (1993–1998) and found overweight and obesity to be associated with 
increased risk of incident asthma with a RR of 1.5 (95%CI: 1.14–2.03) for overweight and 1.60 
(95%CI: 1.08–2.36) for obese children.143 Similarly, a study in Germany found prevalence of 
doctor-diagnosed asthma to be 2.5% for normal weight, 5.8% for overweight and 10.3% for 
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obese children.144 In Canada, Sharma et al also found obesity to be associated with airway 
hyperresponsiveness (OR = 1.37, 95%CI: 1.02–1.82).145  
Obesity may be particularly important for severe asthma as studies have reported that 
asthma in obese individuals tend be more severe and more difficult to control.146,147 A recent 
systematic review of asthma and obesity showed that apart from increasing the severity of 
asthma, overweight and obesity was associated with poorer asthma control and poorer response 
to therapy when compared with normal weight individuals.148 
2.11.1.4 Race/ethnicity and Socio-economic status 
Several studies have linked ethnicity as another possible risk factor for asthma. The prevalence, 
morbidity, and severity of asthma are believed to be higher in children who belong to certain 
ethnicity or group. In a National Health Survey study in the USA, being black was significantly 
associated with the likelihood of having current asthma among children <18 years of age (RR = 
1.47, 95%CI: 1.35–1.60) and ED visit for asthma in past 12 months (RR = 3.11, 95%CI: 2.72–
3.56).149 In another study among 0–19 years children, black children compared to white were 
likely to have severe asthma symptoms measured as frequency of ED visit (OR = 2.34, 95%CI: 
1.99–2.77).150  
Poor socio-economic status (SES) among the black population has further led to 
suggestion that the relationship between race and childhood asthma could be confounded by SES 
resulting in significant asthma burden in the less privileged group. This was confirmed in a 
cross-sectional study among 14,244 children (aged <18 years) in the USA where black children 
were at higher risk of asthma compared to white children (OR = 1.20, 95%CI: 1.03–1.40)151 but 
when the analysis was stratified by income status, only black children in which family income 
were less than half of federal poverty level showed increased risk for asthma (OR = 1.99, 
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95%CI: 1.09–3.64). This result suggests that while certain ethnic groups may be 
disproportionately affected by asthma, understanding how the disparities in childhood asthma 
occurred may play an important role in accurately assessing the risk of asthma among children.  
In Canada, study investigating the role of race/ethnicity in childhood asthma compared 
Aboriginal and non-Aboriginal children. The NLSCY study showed the prevalence of asthma to 
be lower in Aboriginal (5.7%) compare to non-Aboriginal children (10%).152 In the First Nations 
Regional Health Survey involving 238 First Nation communities from 10 Canadian provinces, 
the prevalence of asthma was reported to be 14.6% among 0–11 years children living on 
reserves.153 The population studied were drawn from the national population of children self-
identified as Aboriginal154 
2.11.2 Environmental risk factors for asthma and asthma severity 
Asthma can be triggered or exacerbated by exposure to many environmental factors.155,156   
2.11.2.1 Pet exposures 
The associations between pet exposures and asthma are inconsistent. Some studies suggest pet 
ownership is protective for asthma155,156 while others demonstrate a risk factor for asthma.157 A 
combined analysis of 11 European birth cohort studies found no association between keeping a 
pet early in life and asthma in school-age children.158 Similarly, a systematic review of 17 and 13 
birth cohort studies of cat and dog exposures, respectively, found that cat and dog exposures 
during infancy had no effect on the development of asthma or wheezing symptoms.159  In 
addition, dog exposure during infancy was found to protect children from developing 
sensitization against aeroallergens.159 In a large cross-sectional study from 35 centers in 16 
different countries, Roost et al found that early cat exposure was positively associated with 
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allergic sensitization to cat and wheezing.160 The difficulties in establishing consistent 
associations between pet ownership and respiratory disease may be as a result of potential 
selection bias or failure to assess interaction effects. A meta-analysis of data from 12 European 
birth cohort studies on asthma and allergy showed that family history of allergy to cat or dog 
significantly reduced the odds of owning both animals (OR = 0.91; 95%CI: 0.85–0.99 for cat and 
OR = 0.90; 95%CI: 0.86–0.94 for dog). In addition, high parental education level had even more 
pronounced effects on cat (OR = 0.84; 95%CI: 0.71–0.98) and dog ownership (OR = 0.61; 
95%CI: 0.54–0.70).161  
While pet exposures may show inconsistent results for asthma development, they are 
strong risk factors for asthma severity in sensitized children with asthma. A cohort study among 
4–12 years old children examined the relationship of common household allergens from cats and 
dogs and asthma severity (quantified using the GINA guidelines of both frequency of symptoms 
and medication use) in atopic and non-atopic children with asthma.162 After adjusting for 
potential confounders, children living in homes with detectable levels of dog allergen and who 
were tested positive to dog allergen were two to nearly three times as likely to suffer from severe 
asthma (OR = 2.52; 95%CI: 1.24–5.08). Similar results were observed for children living in 
homes with detectable levels of cat allergen and who were also sensitized to cat allergens (OR = 
2.18; 95%CI: 1.09–4.35).  
2.11.2.2 Environmental tobacco smoke (ETS) exposure 
Studies have reported an association between ETS and childhood asthma. In one of these studies 
investigating maternal smoking during pregnancy and asthma, the risk of developing asthma 
during the first 7 years of life was 25% higher in children whose mother smoked less than 10 
cigarette per day during pregnancy and 36% higher in children whose mother smoked more than 
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10 cigarettes per day compared to non-smokers.163 The risk of developing asthma has been found 
to be even stronger if the grandmother of a child had smoked during the mother’s own fetal 
period.164 A case-control study nested within the Children’s Health Study in Southern California 
showed utero exposure to maternal smoking to be associated with increased risk of asthma in 
children during the first 5 years of life and persistent asthma thereafter (OR: 1.5, 1.0–2.3 for 
both).164 The risk was particularly increased if the grandmother of a child had also smoked 
during the child mother’s fetal development period (OR = 2.1, 95%CI: 1.4–3.2).164  
In a meta-analysis of longitudinal studies, the incidence of asthma or wheezing was 
related to maternal smoking with a stronger effect in the first 5–7 years of life (OR = 1.31, 
95%CI: 1.22–1.41) and during the school years (OR = 1.13, 95%CI: 1.04–1.22).165 Similarly, in 
a cross-sectional study of children and adolescents aged 6–7 years and 13–14 years respectively, 
tobacco smoke exposure was positively associated with wheeze, current asthma, exercise-
induced asthma and severe asthma, particularly if mother or both parents smoke.166 
In addition to being a risk factor for the development of asthma, ETS can also exacerbate 
asthma conditions in children with the disease. This can exacerbate asthma conditions in children 
who already have the disease leading to more severe symptoms, decreased lung function, more 
asthma-related doctor visits, and a poorer response to asthma therapy.165,167 Using objective 
measures and biomarkers of ETS exposure, a study among children aged 4–16 years with 
physician-diagnosed asthma correlated smoke exposure as indicated by serum cotinine levels 
with pulmonary function test and clinical outcomes and observed that children with high serum 
cotinine levels (>0.63 mg/mL) were more likely to have frequent asthma exacerbations (aOR = 
2.7; 95%CI: 1.1–6.5).168  
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The risk of asthma following exposure to maternal smoking during pregnancy may be a 
result of the adverse influence on the development of fetal respiratory system, as suggested by 
findings of a relation between maternal smoking in pregnancy and lung function impairment in 
newborns,169,170 which may be increased when combined with postnatal maternal smoke 
exposure.163 
2.11.2.3 Biological exposures 
Biological exposures include a wide variety of biological agents commonly found in indoor 
environments such as allergens (e.g. house dust mite, cockroach, and mouse), bacteria (e.g. 
endotoxin), and fungi (e.g. mold); and have been recognized to have associations with 
respiratory disorders.171 Common household allergens that have been identified as risk factors 
for asthma and asthma severity include dust mite, mold, cockroaches, and animal dander 
allergens (from pets, mice, rats).162 While the specific roles of allergens in the development and 
exacerbation of asthma are currently not fully understood, indoor microbial agents (endotoxin 
and beta-(1→3)-D-glucan) are also independent risk and protective factors for asthma and 
asthma-like symptoms in children as detailed below:  
2.11.2.3.1 Endotoxin and its association with asthma and asthma severity 
Endotoxin is a lipopolysaccharide (LPS) which makes up a major component of the outer 
membrane of gram-negative bacteria172 and has the capacity to induce the production of TH1 
cells such as IFN-γ and IL-12 which are anti-inflammatory cytokines.172 The first observational 
study to report that environmental exposure to endotoxin protects against allergic sensitization 
was documented in the USA in 2000.173 In this study, 61 asthma-prone infants (aged 6–24 
months) with at least three physician-diagnosed episodes of wheezing were recruited and 
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concentrations of house dust endotoxin and allergens were examined in the infants’ homes. The 
results of the study demonstrated that the homes of allergen-sensitive infants contained 
significantly lower concentration of endotoxin [measured in endotoxin units (EU) per mL] 
compared to homes of non-sensitive infants (468 vs. 1,035 EU/mL; p=0.01). In addition, a high 
level of house dust endotoxin concentrations was also associated with increased production of 
IFN-γ-producing TH cells (CD14 T cells; r = 0.59; p=0.01) which are capable of inducing TH1 
immune responses173 prompting the general believe that endotoxin exposure early in life is 
potentially protective against allergic diseases, including asthma. 
Since the Gerada et al study in the USA, there have been some inconsistencies. Some 
studies have reported that endotoxin may modulate or protect against asthma development174,175 
while others have shown evidence of increased risk,176,177 and no association;178,179 making 
endotoxin a subject of continuous research. For example, Braun-Fahrlander et al180 reported that 
exposure to endotoxin levels in mattress dust were inversely associated with atopic asthma (OR 
= 0.48; 95%CI: 0.28–0.81) and atopic sensitization (OR = 0.76; 95%CI: 0.58–0.98) among 
schoolchildren (aged 6–13 years) in Germany, Austria, and Switzerland. Contrary to this report, 
Thorne et al demonstrated that exposure to high endotoxin concentration levels from bedroom 
floor (OR = 1.57; 95%CI: 0.76–3.22), mattress (OR = 1.88; 95%CI: 0.90–3.93), and family room 
floor (OR = 1.98; 95%CI: 0.99–3.94) increased the risk of physician-diagnosed asthma.177 
Similarly, in a case-control study among schoolchildren (aged 6–18 years) in Saskatchewan 
Canada, mattress endotoxin concentration (OR = 0.44; 95%CI: 0.20–0.98) and load (OR = 0.38; 
95%CI: 0.20–0.75) were inversely associated with being a case with a greater effect in children 
≤12 years and without a personal history of allergic disease.181 These results mirrored the 
protective effects observed in a two European birth cohort studies: The German LISA (Lifestyle 
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Related Factors on Immune System and the Development of Allergies in Childhood), and the 
GINI (German Infant Nutritional Intervention) where endotoxin from children’s mattresses’ 
dusts was also found to be associated with a lower risk of physician-diagnosed asthma among 6 
years old children (OR = 0.55; 95%CI: 0.31–0.97).182 A summary of studies investigating 
associations between endotoxin and childhood asthma is presented in Table 2–3. 
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Table 2–3: Characteristics and results of studies investigating the association between endotoxin and presence of asthma and asthma-
related symptoms among school-age children 
First author 
(Year published) 
Location(s) 
Study 
design 
Study 
population 
(Sample size) 
Method of dust sample 
collection and levels of 
endotoxin exposure 
Operational definition of 
outcomes 
Findings and strength of 
association 
Tischer C183 
(2015) 
Germany 
Spain 
The Netherlands 
 
Birth cohort  Children 
followed from 
birth to 10 years 
of age 
(n = 1429) 
Method of dust sample 
collection: Vacuum. 
Dust samples were 
collected at 2–3 months 
of age 
Living room GM beta-
endotoxin levels: 
Concentration (EU/mg): 
11.76 
Load (EU/m2): 1.16 
Physician-diagnosed 
asthma at age 10 years:  
Defined as report of 
doctor-diagnosed asthma 
ever within the 10 year 
period. 
Current asthma at age 6 
years and at age 10 years 
Defined as meeting ≥2 of 
3 conditions: 1) doctor-
diagnosed asthma ever, 
2) wheezing in the past 
12 months, 3) asthma 
medication use in the 
past 12 months 
Higher endotoxin 
concentrations were 
significantly and positively 
associated with current 
asthma at 6 years of age 
(OR = 1.96) in the 
Germany cohort while 
higher endotoxin load was 
inversely associated with 
doctor-diagnosed ever 
asthma in the Spain cohort 
(OR = 0.39).  
Kavonen AM184 
(2012) 
Austria 
Finland 
France 
Germany 
Switzerland 
Prospective 
cohort study 
Birth cohort of 
rural children 
followed from 
birth to 2 years 
of age 
(n = 1133) 
Method of dust sample 
collection: Vacuum  
Living room floor GM 
endotoxin levels (overall 
mean from the 5 
locations): 
Load (EU/m2): 17,007 
(rug), 2.582 (smooth 
floor) 
Mother’s mattress GM 
endotoxin level (overall 
mean from the 5 
locations): 
Asthma: ≥1 parental 
report of doctor-
diagnosed asthma and/or 
doctor-diagnosed 
asthmatic bronchitis >1 
during follow-up period. 
Wheezing: Parental 
report of wheeze 
symptoms at any time-
points between 2 and 24 
months of age 
Living room floor 
endotoxin load was 
inversely and significantly 
associated with incidence 
of asthma (OR = 0.71) and 
wheeze (OR = 0.72) 
during the first 2 years of 
life. Similar protective 
effect was seen for 
mattress endotoxin load 
and incidence of asthma 
(OR = 0.79). There was 
effect modification by 
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Load (EU/m2): 1,637  farming status. When the 
data was stratified by 
farming status, the 
significant protective 
effects of mattress 
endotoxin was only seen in 
non-farmers’ children 
(ORs = 0.68 for asthma 
and 0.71 for wheezing 
apart from cold) 
Lawson JA181 
(2012) 
Canada 
Case-
control 
6–18 years 
(n = 310) 
Method of dust sample 
collection: Vacuumed 
Play area GM levels: 
Concentration (EU/mg): 
Cases (51.8), Controls 
(40.8) 
Load (EU/m2): Cases 
(868.2, Controls (817.3) 
Mattress GM levels: 
Concentration (EU/mg): 
Cases (19.6), Controls 
(21.1) 
Load (EU/m2): Cases 
(240.5), Controls (376.2) 
Asthma cases: Report of 
doctor-diagnosed asthma 
or wheeze in the past 
year  
 
Play area endotoxin 
concentration (OR = 1.64) 
and load (OR = 1.10) 
increased the risk of being 
a case but not statistically 
significant. 
Mattress endotoxin 
concentration (OR = 0.44) 
and load (OR = 0.38) were 
significantly inversely 
associated with being a 
case only in children who 
were ≤12 years. 
Also, among children 
without a personal history 
of allergy, there were 
statistically significant 
inverse associations 
between mattress 
endotoxin concentration 
(OR = 0.20) and load (OR 
= 0.22) in children ≤12 
years 
  
 
 
5
9
 
Lawson JA176 
2011 
Canada 
Cross-
sectional 
6–18 years 
(n = 98) 
Method of dust sample 
collection: Vacuum 
Play area GM level 
Concentration (EU/mg): 
No wheeze (45.0), 
wheeze (83.2) 
Load (EU/m2): No 
wheeze (790.0), wheeze 
(1257.5) 
Mattress GM levels: 
Concentration (EU/mg): 
No wheeze (18.9), 
wheeze (19.7) 
Load (EU/m2): No 
wheeze (282.5), wheeze 
(272.1) 
Report of wheeze in the 
previous 12 months 
There was an increased 
likelihood of self-reported 
wheeze with higher 
endotoxin level. Play area 
endotoxin concentration 
was associated with 
increased risk of wheeze 
(OR = 4.41) with a 
borderline significance 
(p=0.08).  
Tischer C182 
(2011) 
Germany 
The Netherlands 
Multicenter 
birth cohort 
study 
Children 
followed up 
from birth to age 
6 years 
(n = 696) 
Method of dust sample 
collection: Vacuum 
Levels of endotoxin in 
the two locations were: 
Germany 
Play area median levels: 
Concentration (EU/g): 
19,400 
Load (EU/m2): 3,749 
Mattress median levels: 
Concentration (EU/g): 
12,222 
Load (EU/m2): 3,053 
The Netherlands 
Play area median levels: 
Concentration (EU/g): 
18,196 
Definitions of asthma 
outcome differed in the 
two locations 
Asthma 
Germany: Physician-
diagnosed asthma in the 
last 6 months between 
the 5th and 6th year of 
life.  
The Netherlands: Ever 
diagnosed asthma plus 
child had asthma past 12 
months 
Definition of wheeze 
outcome was similar and 
defined as wheeze or 
In the German study, 
mattress endotoxin 
concentration (OR = 0.55) 
and load (OR = 0.46) were 
significantly associated 
with reduced risk of 
physician-diagnosed 
asthma. Similar 
associations were observed 
for wheezing but this was 
not statistically significant. 
There were trends towards 
increased risk of asthma 
and wheeze in the 
Netherland study OR 
ranging from 1.11 to 1.51 
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Load (EU/m2): 2,299 
Mattress median levels: 
Concentration (EU/g): 
10,608 
Load (EU/m2): 2,356 
whistling in the chest 
past 12 months 
but the associations were 
not statistically significant.  
Rosenbaum PF185 
(2010) 
USA 
Cohort 
study 
Infants at risk 
for asthma (due 
to maternal 
history of 
asthma) 
followed from 
birth until 1 year 
of age 
(n = 103) 
Method of dust sample 
collection: Vacuum  
Play area GM endotoxin 
levels: 
Concentration (EU/mg): 
76.1 
 
Wheeze in the first year 
of life defined as 
healthcare provider 
diagnosis of wheeze. 
Clinical assessments of 
wheeze was undertaken 
at 3, 6, 9 and 12 months 
of age 
High endotoxin levels 
(≥100 EU/mg) were 
significantly associated 
with increased risk of 
wheeze in the first year of 
life (Unadjusted OR = 
2.62). Similar association 
trend was observed when 
endotoxin was used as 
continuous variable. OR = 
1.13 for each 20 EU/mg 
increase. 
Iossifova186 
(2009) 
USA 
Prospective 
Cohort 
Children 
followed up 
from birth to age 
3 years 
 (n = 483) 
Method of dust sample 
collection: Vacuum  
Living room endotoxin 
concentration 
interquartile end point: 
38.90–165.0 EU/g 
Children classified as 
having high future 
asthma risk based on a 
validated Asthma 
Predictive Index (API) 
index score. 
Positive API if they 
reported recurrent 
wheezing at age 3 years 
and met at least 1 of 3 
major criteria (parental 
history of asthma, 
allergic sensitization to 
≥1 aeroallergens, and 
eczema) or 2 of 3 minor 
criteria (wheezing 
When expressed as 
continuous or categorical 
variables in quartiles) 
endotoxin exposure was 
associated with a slight 
increased risk of wheezing 
in children with atopy at 
the age of 3 years (OR = 
1.37). Similar association 
was observed for API at 
age 3 years (OR = 1.37). 
These associations were 
not statistically significant.  
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without a cold, 
physician-diagnosed 
allergic rhinitis, and 
allergic sensitization to 
milk or egg) 
Gehring U178 
(2008) 
ISAAC Multi-centre 
study 
Albania  
Italy 
NewZealand 
Sweden 
United Kingdom 
Cross-
sectional 
9–12 years 
(n = 840) 
Method of dust sample 
collection: Vacuum. 
Living room floor GM 
endotoxin levels: 
Concentration (EU/g): 
Lowest to highest = 6,532 
(Sweden) – 35,581 (Italy) 
Load (EU/m2): Lowest to 
highest = 684 (Italy) – 
3602 (Sweden)  
Asthma ever: Report of 
ever had asthma 
Current wheeze: 
Wheezing or whistling in 
the chest past 12 months 
In a combined analysis 
across all countries, high 
living room floor 
endotoxin load levels were 
significantly associated 
with reduced risk of 
asthma ever (OR = 0.29) 
and current wheeze (OR = 
0.77) 
Rennie DC187 
(2008) 
Case-
control 
6–13 years 
(n = 197 
including 89 
cases matched to 
107 healthy 
controls based 
on age and sex) 
Method of dust sample 
collection: Vacuum. 
Play area GM endotoxin 
levels: 
Concentration (EU/mg): 
17.31 
Load (EU/m2): 6,536 
Mattress GM endotoxin 
levels: 
Concentration (EU/mg): 
8.82 
Load (EU/m2): 2,498.63 
Asthma case: Report of 
physician-diagnosed 
asthma and/or wheeze 
without a cold in the past 
12 months 
Control: No asthma or 
wheeze 
Mattress endotoxin (OR = 
0.90) and play area (OR = 
0.92) endotoxin 
concentration were not 
significantly associated 
with being a case.  
Campo P188 
(2006) 
USA 
Birth cohort Children 
followed up 
from birth to 1st 
year of life  
(n = 532) 
Method of dust 
collection: Vacuum 
Play area GM endotoxin 
levels: 
Concentration (EU/mg): 
77.8 if pets present in 
Asthma: Parental report 
of physician-asthma 
Recurrent wheezing: ≥2 
wheezing episodes in the 
past 12 months 
High play endotoxin 
exposures (≥10 EU/mg) 
were significantly 
associated with reduced 
risk of recurrent wheezing 
(OR = 0.4) and any 
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home and 58.7 if no pets 
present in home 
 
Any wheezing: ≥1 
wheezing episodes in the 
past 12 months. 
Allergic wheezing: ≥2 
wheezing episodes in the 
past 12 months and a 
positive SPT response to 
at least 1 of 15 
aeroallergens tested 
wheeze (OR = 0.3) only in 
the presence of two or 
more dogs in the home. 
This suggests an 
interaction between 
endotoxin exposure and 
pet ownership in the 
relationship between 
endotoxin exposure and 
childhood asthma.  
Douwes J189 
(2006) 
The Netherlands 
Birth 
Cohort  
Children of 
atopic mothers 
followed up 
from birth to 4th 
year of life 
 (n = 696) 
Method of dust sample 
collection: Vacuum 
Play area (living room 
floor) median endotoxin 
load (EU/m2): 217 
(smooth floor), 9,503 
(carpet floor), 27,481 
(rug floor) 
Mattress median 
endotoxin load (EU/m2): 
856 
Asthma: Report of 
physician-diagnosed 
asthma at any time in the 
past 4 years (Ever 
asthma) 
Wheeze symptoms: ≥1 
episodes in the first 3 
years 
Mattress levels of 
endotoxin was not 
statistically associated 
with asthma and wheeze. 
However, play area 
endotoxin levels were 
inversely and significantly 
associated with doctor-
diagnosed asthma (OR = 
0.40) at four years of age 
suggesting microbial 
endotoxin exposure in 
early life might protect 
against asthma. 
El-Sharif N190 
(2006) 
Palestine 
Case-
control 
6–12 years 
(n = 375). 
However, n=132 
(66 cases and 66 
controls were 
randomly 
selected for dust 
sampling and 
matched 1:1 for 
Method of dust sample 
collection: Vacuum 
Median play area floor 
endotoxin level: 
Concentration (EU/mg): 
48.51 
Median mattress 
endotoxin concentration 
(EU/mg): 25.722 
Cases: Report of wheeze 
past 12 months 
Controls: No report of 
ever wheeze and no 
physician-diagnosed 
asthma 
High living room 
endotoxin concentration 
was significantly 
associated with reduced 
risk of being a case among 
sensitized cases compared 
to non-sensitized controls 
(ORs = 0.04). 
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school location, 
class, and sex) 
Endotoxin exposure were 
categorized into tertiles: 
1st tertile (Low): <16.02 
EU/mg 
2nd tertile (Medium): 
16.021–41.754 EU/mg 
3rd tertile (High): >41.754 
EU/mg 
Similarly, medium levels 
of mattress endotoxin 
concentration was 
associated with lower odds 
of being a case among 
non-sensitized cases 
compared to non-
sensitized controls (OR = 
0.13)  
Gillespie J191 
(2006) 
New Zealand 
 
Birth cohort  Children 
followed up 
from birth to 15 
months of age 
 (n = 881) 
Method of dust sample 
collection: Vacuum 
Mattress floor GM 
endotoxin level: 
Concentration (EU/g): 
9,244. 
Endotoxin levels were 
categorized in quartiles 
Wheeze: Report of 
wheezing or whistling in 
the chest at any time 
during the 15 months 
monitoring period (Ever 
wheeze) 
Exposure to higher level of 
endotoxin concentration 
(within the 4th quartile) at 
3rd month of age was 
positively and significantly 
associated with wheezing 
at 15 months of age (OR = 
1.54). The association was 
particularly stronger and 
remained significant in 
children with parental 
history of allergic disease 
(OR = 1.67) 
Horick N192 
(2006) 
USA 
Prospective 
Cohort 
Children 
followed up 
from birth to 6–
8 months of age 
(n = 4044) 
Method of dust sample 
collection: Vacuum and 
airborne dust sampling at 
2–3 months of age; 
Airborne sampling at 6–8 
months of age  
Mean play area endotoxin 
levels: 
Vacuumed dust 
endotoxin: Concentration 
(EU/mg): 93.1 
Wheezing: Any 
wheezing episodes 
corresponding to one or 
more wheezing events in 
the first year of life. 
Uncorrected estimate: 
Represent the relative 
increase in risk of 
wheeze associated with 
an increase over the 
After adjusting for 
potential confounders, the 
model corrected for 
measurement error showed 
a significant larger effect 
of endotoxin exposure. 
The uncorrected RR of 
1.45 increased to RR of 
5.56 after correction for 
measurement error, 
suggesting that correction 
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Airborne endotoxin: 
Concentration (EU/m3): 
0.81. 
Both airborne and dust 
endotoxin levels were 
measured to correct for 
measurement errors by 
accounting for t error 
induced by using house 
dust endotoxin exposure 
as a surrogate measure 
for airborne endotoxin 
interquartile range in dust 
endotoxin exposure 
Corrected estimate: 
Represent relative risk 
(RR) for an interquartile 
range increase in 
airborne endotoxin 
exposure. 
 
for measurement error has 
a large impact on the point 
estimate of the effect of 
increased endotoxin 
exposure and respiratory 
diseases. 
Perszanowski MS179 
(2006) 
USA 
Prospective 
Cohort 
Children 
followed up 
from birth to 3 
years of age 
 (n = 301) 
Method of dust sample 
collection: Vacuum 
Bedroom floor GM 
endotoxin level: 
Concentration (EU/mg): 
75.9 
Load (EU/m2): 3,892 
Wheezing: Parental 
report of wheezing 
during at least one of 12, 
24, and/or 36 months of 
life at which interview 
was conducted. 
Higher endotoxin exposure 
was significantly 
associated with increased 
risk of wheezing at 2 years 
of age (OR = 1.34) with 
the association stronger in 
children with maternal 
history of asthma. 
However, when wheeze 
was considered as a 
longitudinal variable, 
endotoxin concentration 
was not associated with 
the presence of wheeze 
over time 
Tavarnier GOG193 
(2005) 
United Kingdom 
Case-
control  
4–17 years 
(n = 200 
including 90 
matched pairs of 
asthmatic and 
healthy controls 
Method of dust sample 
collection: Vacuum 
Play area median 
endotoxin levels: 
Concentration (EU/mg): 
36.11 
Report of physician-
diagnosed asthma.  
The study suggests 
endotoxin as a risk factor 
for asthma. Play area 
endotoxin concentration 
was significantly 
associated with increased 
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based on age, 
sex, and sibship) 
Mattress median 
endotoxin level; 
Concentration (EU/mg): 
10.99 
risk of asthma (OR = 
1.88). The association was 
not seen for mattress 
endotoxin concentration. 
Thorne PS177 
(2005) 
USA 
Cross-
sectional 
Nationwide 
sample 
comprising of 
adults and 
children 
(n = 2456) 
Method of dust sample 
collection: Vacuumed 
Play area geometric mean 
(GM) levels: 
Concentration (EU/mg): 
63.9 
Load (EU/m2): 17,600 
Mattress levels GM 
Concentration (EU/mg): 
18.7 
Load (EU/m2): 4,160 
Asthma: Physician-
diagnosed asthma, 
Asthma symptoms: Any 
asthma-related symptoms 
(e.g. cough) past years 
Wheeze:  
i) Current wheeze: 
Wheeze past 12 months 
ii) Ever wheeze: Report 
of wheeze ever 
 
High level of mattress 
endotoxin (>19.6 EU/mg) 
increased the risk of 
current wheeze (OR = 
2.05) and ever wheeze 
(OR = 2.01).  
High level of play area 
endotoxin (>33.9 EU/mg) 
also increased the risk of 
asthma (OR = 1.98), 
medication use (OR = 
2.11), and ever wheeze 
(1.35), p>0.05. 
After stratification by age 
(<18 years vs. ≥18 years), 
the significant associations 
were only seen in adults 
and absent in children. 
Braun-Fahrländer 
C180 
(2002) 
Austria 
Germany 
Switzerland 
Multicenter 
cross-
sectional 
6–13 years 
(n = 812) 
Method of dust sample 
collection: Vacuum. 
Dust samples was 
collected from mattress 
of children rural locations 
stratified by farming 
households and non-
farming households. 
GM endotoxin levels: 
Concentration (EU/mg): 
Farming households 
Atopic asthma: Report of 
physician-diagnosed 
asthma plus positive test 
for specific IgE ≥3.5 kU 
per liter otherwise, they 
are considered non-
atopic asthma. 
Atopic wheeze: Report of 
wheeze or whistling in 
the chest during the 
previous 12 months plus 
Mattress endotoxin loads 
was significantly 
associated with reduced 
risk of atopic asthma (OR 
= 0.48) and atopic wheeze 
(OR = 0.62) but not non-
atopic asthma (OR = 1.13) 
and non-atopic wheeze 
(OR = 1.14) in the total 
population. The study 
further showed that 
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(37.8), non-farming 
households (22.8) 
Load (EU/m2): Farming 
households (29,897), 
non-farming households 
(14,456)  
 
positive test for specific 
IgE ≥3.5 kU per liter 
otherwise, they are 
considered non-atopic 
wheeze 
exposure to farming 
environment during the 
first year of life and 
current endotoxin 
exposure significantly 
reduced the risk of atopic 
asthma (ORs = 0.42 and 
0.52; respectively) but not 
non-atopic asthma. 
Gerada JE173 
(2000) 
USA 
Cross-
sectional  
9–24 months 
(n = 61) 
Method of dust sample 
collection: Vacuum. 
Dust samples was 
collected from living 
room floor, kitchen floor, 
and participant’s mattress 
and in a single vacuum 
bag. 
GM level: 
Concentration: 912 
EU/mL.  
Range: 104 EU/mL–
10000 EU/mL. 
Allergen sensitization: 
Skin prick testing to 
common indoor inhalant 
allergens and food 
allergens. 
Sensitized infants had 
significantly lower 
concentrations of 
endotoxin in their homes 
compared to non-
sensitized infants (GM = 
468 vs. 1035 EU/mL, 
respectively; p=0.01). 
Furthermore, increased 
endotoxin concentration 
correlated with increased 
production of IFN-γ CD4 
T cells (r = 0.59; p=0.01). 
 67 
 
Individuals exposed to endotoxin may also demonstrate acute pulmonary responses that 
may indicate symptoms of asthma severity. In a case-control study among children in Humboldt, 
Saskatchewan, exposure to higher levels of endotoxin, particularly, mattress endotoxin, were 
significantly associated with a lower lung function (FEV1), especially in female children with 
asthma or wheeze (beta = –0.25, p<0.01).176 Similarly, endotoxin load in the play areas of 
children with asthma or wheeze was significantly associated with greater variability in the 
diurnal peak expiratory flow (DV-PEF) (OR = 2.42; 95%CI: 1.03–5.67).194 Another study 
among 148 schoolchildren (aged 7–11 years) in the Netherlands also showed association 
between house dust endotoxin exposure and greater PEF variability.195 However, after adjusting 
for beta-(1→3)-D-glucan exposure in the indoor environment, the association was lost 
suggesting that the acute inflammatory effects of indoor endotoxin exposure may be equally 
related to other microbial biomarkers in the indoor environments. A summary of studies 
investigating associations between endotoxin and lung function as well as asthma severity 
indicators is presented in Table 2–4. 
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Table 2–4: Characteristics and results of studies investigating the association between endotoxin and asthma severity indicators and 
lung function among children and adults 
First author 
(Year published) 
Location(s) 
Study design Study 
population 
(Sample size) 
Method of dust sample 
collection and levels of 
endotoxin exposure 
Operational definition of 
outcomes  
Findings and strength of 
association 
McSharry C196 
(2015) 
Scotland 
Cross-
sectional 
16–60 years 
(n = 55) 
 All 
participants 
have asthma) 
Method of dust sample 
collection: Vacuum. 
Median living room floor 
endotoxin levels: 
Concentration (EU/g): 10.4 
Median bedroom room floor 
endotoxin levels: 
Concentration (EU/g): 10.0 
Primary outcome: Lung 
function assessed with 
FEV1 before the use of a 
bronchodilator 
Living room endotoxin 
concentration levels were 
correlated with decreased 
FEV1 but was marginally 
significant (p=0.063). 
Lawson JA176 
(2011) 
Canada 
Case-control 6–18 years 
(n = 309) 
Method of dust sample 
collection: Vacuum 
Median endotoxin levels: 
Play area load (EU/m2): 
1011.3 
Mattress load (EU/m2): 
402.5 
Lung function measures: 
FEV1, FVC, FEV1/FVC, 
and FEF25%–75%  
Higher mattress endotoxin 
load was associated with 
lower FEV1 (beta = - 
0.25) only in female 
cases.  
There was a significant 
interaction between 
outcome, mattress 
endotoxin and gender. 
Among female cases, 
higher mattress endotoxin 
exposure was associated 
with lower FEV1 while 
the association was 
similar for between male 
and female controls.  
Lawson JA194 
(2011) 
Canada 
Cross-
sectional 
6–18 years 
(n = 98) 
Method of dust sample 
collection: Vacuum 
Play area GM level: 
Clinical measures of 
diurnal variation 
(morning and evening) 
in Peak Expiratory Flow 
There was a greater DV-
PEF associated with 
higher endotoxin levels 
during a two week 
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Concentration (EU/mg): 
Low DV-PEF (44.14), High 
DV-PEF (60.0) 
Load (EU/m2): Low DV-
PEF (705.3), High DV-PEF 
(1090.8) 
Mattress GM levels: 
Concentration (EU/mg): 
Low DV-PEF (15.7), High 
DV-PEF (23.2) 
Load (EU/m2): Low DV-
PEF (248.4), High DV-PEF 
(315.9) 
variability (DV-PEF) 
over a two week 
monitoring period. 
DV-PEF was 
categorized as high DV-
PEF and low DV-PEF. 
monitoring period. Play 
area endotoxin load was 
significantly associated 
with high DV-PEF (OR = 
2.42). Similar trend was 
seen for play area 
endotoxin concentration 
but was not significant 
(2.54).  
Rennie DC187 
(2008) 
Case-control 6–13 years 
(n = 197 
including 89 
cases matched 
to 107 healthy 
controls based 
on age and 
sex) 
Method of dust sample 
collection: Vacuum. 
Play area GM endotoxin 
levels: 
Concentration (EU/mg): 
17.31 
Load (EU/m2): 6,536 
Mattress GM endotoxin 
levels: 
Concentration (EU/mg): 8.82 
Load (EU/m2): 2,498.63 
Report of physician-
diagnosed asthma and/or 
wheeze without a cold in 
the past 12 months. 
Severity indicator: >3 
days of being kept at 
home for chest illness 
Mattress endotoxin 
concentration was 
significantly associated 
with being kept at home 
for chest illness for more 
than 3 days in the past 12 
months (β = 1.05). The 
association was not 
observed in non-atopic 
cases, atopic controls or 
non-atopic controls. 
Iossifova YY197 
(2007) 
USA 
Cohort study Children 
followed up 
from birth to 
age 2 years 
 (n = 574) 
Method of dust sample 
collection: Vacuum 
Play area  endotoxin range; 
Concentration (EU/mg): 6.0–
800.0. 
Exposure assessed in 
quartiles: (1st: 6.0–38.8; 2nd: 
38.9–78.8; 3rd: 78.9–165.0; 
4th: 165.1–800.0) 
Recurrent wheeze: ≥2 
wheezing episodes in the 
past 12 months 
Recurrent wheezing 
combined with allergen 
sensitization: Recurrent 
wheezing plus positive 
test (≥3mm) to at least 
There were no significant 
association between 
endotoxin exposures and 
studied outcomes 
although there was a 
positive trend towards 
increased risk of recurrent 
wheeze with allergen 
sensitization (OR = 1.60) 
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one of 15 common 
allergens  
Rabinovitch N198 
(2005) 
USA 
Two interval 
particulate-
exposure 
monitoring 
design 
 
6–13 year 
(n = 24: 
Interval 1 n = 
10; Interval 2 
n = 14). 
All subjects 
were children 
with asthma 
attending 
school 
specifically for 
asthma 
children 
Method of dust sample 
collection: Personal 
exposure monitoring of dust 
samples with personal 
exposure monitor calibrated 
at flow rate of 2 L/min. 
Interval 1: 10 consecutive 
days of personal exposure 
monitoring and indoor 
monitoring for PM2.5 
Interval 2: 2 consecutive 
days completed 3 times of 
personal exposure 
monitoring and indoor 
monitoring from PM10  
Median personal PM2.5  
endotoxin level (Interval 1): 
Concentration (EU/m3): 0.08 
Median personal PM10  
endotoxin level (Interval 2): 
Concentration (EU/m3): 0.37 
All children had asthma. 
Primary outcome: FEV1. 
Morning FEV1 
performed immediately 
after 24-hr personal 
monitoring period and 
evening FEV1 performed 
9–12 hrs after 
monitoring interval. 
Asthma severity score: 
Based on the 5-point (0–
4) severity of asthma 
symptoms. 0 = No 
symptoms; 4 = 
Symptoms severe 
enough to prevent play 
or sleep. 
asthma symptoms scores 
Higher level personal 
endotoxin exposure at 
interval 2 was 
significantly associated 
with decreased FEV1 (-
316 mL per EU/m3). 
Similar trend was 
observed for interval 1 but 
not statistically significant 
(p=0.15). This 
associations were not seen 
with indoor endotoxin 
concentration (p=0.80). 
In addition, during 
interval 2, personal 
endotoxin exposure was 
significantly associated 
with increased risk of 
reporting asthma 
symptoms severe enough 
to prevent sleep (OR = 
2.04, p=0.04) 
Thorne PS177 
(2005) 
USA 
Cross-
sectional 
Nationwide 
sample 
comprising of 
adults and 
children 
(n = 2456) 
Method of dust sample 
collection: Vacuumed 
Play area geometric mean 
(GM) levels: 
Concentration (EU/mg): 63.9 
Load (EU/m2): 17,600 
Mattress levels GM 
Concentration (EU/mg): 18.7 
Load 4,160 
Medication use: Current 
asthma medication use 
Unadjusted analysis 
showed significantly 
elevated odds ratios 
between high bedroom 
floor endotoxin 
concentration (>16.6 
EU/mg) and current 
asthma medication use 
(OR = 2.42). Similar 
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results was observed for 
mattress endotoxin 
concentration (OR = 
1.72). After adjustment, 
the ORs were still 
elevated (2.28 for 
bedroom floor endotoxin 
and 1.83 for mattress 
endotoxin) but not 
significant. 
Douwes J195 
(2000) 
The Netherlands 
Cross-
sectional 
7–11 years 
(n = 148) 
Method of dust sample 
collection: Vacuum 
Play area GM levels: 
Concentration (EU/g): 
Asthmatics (11,588), Non-
symptomatic (10,915), 
Symptomatic (12,642) 
Load (EU/m2):  Asthmatics 
(2,493), Non-symptomatic 
(2,082), Symptomatic 
(2,443) 
Mattress GM levels: 
Concentration (EU/g): 
Asthmatics (3,983), Non-
symptomatic (4,772), 
Symptomatic (5,696) 
Load (EU/m2):  Asthmatics 
(1,202), Non-symptomatic 
(1,820), Symptomatic 
(2,082) 
PEF variability (morning 
and evening) over a 16 
week monitoring period. 
Asthma symptoms: 
Report of respiratory 
symptoms such as recent 
wheeze, shortness of 
breath, or dry cough, 
and/or doctor-diagnosed 
asthma ever. 
Atopic: Positive test (≥3 
mm wheal diameter) to 
at least one allergen 
from a panel of six 
common allergens. 
In unadjusted analysis, 
levels of play area 
endotoxin load was 
associated with PEF-
variability over the 16 
week monitoring period 
(OR = 1.43). The 
association was 
significant particularly in 
atopic children with 
asthma symptoms (OR = 
1.66) However, the 
significant association 
was lost after adjusting for 
potential confounders. No 
association was found for 
mattress endotoxin levels 
both in the univariate and 
adjusted models. 
Rizzo MC199 
(1997) 
Brazil 
Case-control 6–16 years Method of dust sample 
collection: Vacuum 
Cases: Physician-
diagnosed asthma 
Study demonstrate that 
endotoxin exposure 
exacerbates asthma 
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(n = 20 
including 10 
controls) 
Monthly samples (from 
February 1993 to February 
1994) were taken from 
bedroom floor and from 
mattress.  
Levels of endotoxin: Not 
provided as a single unit but 
highest levels were observed 
in the summer months (Dec-
Feb) and lowest levels were 
observed in April and Aug.  
Controls: No personal 
history of allergic 
disease and no 
respiratory symptoms. 
Symptoms severity score 
among cases were 
established based on 
guidelines: “0” = none 
and ‘5” = severe enough 
to incapacitate 
symptoms in children 
with asthma. There was a 
positive correlation 
between endotoxin 
exposure and clinical 
asthma severity scores (r 
= 0.63, p<0.05). The 
association appeared to be 
similar all year round. 
Michel O200 
(1991) 
Belgium 
Cross-
sectional 
19–61 years 
(n = 28) 
Method of dust sample 
collection: Vacuum. 
Samples from mattress and 
bedroom floor were pooled 
as a single lot. 
Median LPS levels: 
Concentration (ng/ml): 5.6.  
Exposure was assessed as 
categorical (Low: ≤5.6 
ng/ml; and High >5.6 ng/ml) 
 
 
Asthma: Defined as 
recommended by ATS. 
That is, presence of 
clinical picture, 
associated with either an 
increase of ≥20% in 
FEV1 post 
bronchodilator or ≥20% 
decrease in FEV1 
following histamine 
inhalation dose of <480 
µg. In addition all 
subjects with asthma 
present with Dpt allergy 
(based on clinical 
history, RAST and SPT) 
or non-allergic asthma 
with perennial clinical 
presentation. Patients 
also had ≥4 visits to the 
clinic in the past 1 year. 
FEV1/FVC was 
significantly lower in 
subjects with high LPS 
exposure compared to low 
LPS exposure (67.0% vs. 
84.5%).  
Similarly, compared with 
patients exposed to low 
LPS concentration, high 
LPS group showed 
significantly 
bronchodilator (8.0 vs 
4.0), increased oral 
corticosteroid intake (13.5 
vs. 0 and treatment score 
(44.3 vs. 14.0) 
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Primary outcome: Lung 
function determined 
with FEV1 and 
FEV1/FVC 
Michel O201 
(1989) 
Belgium 
Case-control 
laboratory 
inhalation and 
responsiveness 
study 
23–62 years 
(n = 14 
including 6 
healthy 
controls) 
Method of dust sample 
collection: N/A 
Subjects were challenged 
with saline (as placebo) on 
day 1 and LPS (as treatment) 
on day 8. 
 
 
Asthma cases (n = 8): 
Subjects with complains 
of dyspnea and/or 
wheezing and 
demonstrated airway 
obstruction after 
histamine challenge 
Controls (n = 6): No 
allergic antecedents, no 
family history of atopy 
and not taking 
medication  
In control subjects, there 
was no significant change 
in FEV1 following 
challenge with 20 µg of 
LPS after comparison 
with placebo. However, 
among those with asthma, 
there was a significant 
reduction in FEV1 
following inhalation of 20 
µg of LPS compared with 
placebo group. The 
decrease in FEV1 was 
observed within 15 min 
after LPS inhalation and 
lasted for at least 5 hours. 
The mean decrease in 
FEV1 during the 5 hours 
after LPS inhalation was 
6.7%.   
 74 
 
2.11.2.3.2 Beta glucan and its association with asthma and asthma severity 
The association between beta-(1→3)-D-glucan and respiratory health is currently less well 
investigated than that with endotoxin. In a German birth cohort study,182 exposure to beta-
(1→3)-D-glucan from children’s mattresses was associated with a lower risk of asthma (OR = 
0.76; 95%CI: 0.40–1.45) and wheeze (OR = 0.78; 95%CI: 2.35–11.54). In a case-control study 
among 422 children that participated in the population-based Study of Asthma, Genes and 
Environment (SAGE) birth cohort in Manitoba, Canada, Maheswaran et al observed that 
children who were exposed to high level of beta-(1→3)-D-glucan in home dust at age 7–10 years 
developed persistent atopic asthma at age 11–14 years (OR = 1.79; 95%CI: 1.14–2.81).202 The 
results of the study further showed that, in children without asthma, exposure at age 7–10 years 
increased the risk of BHR at adolescence (OR = 1.74; 95%CI: 1.05–2.89). A summary of studies 
investigating associations between beta-(1→3)-D-glucan and childhood asthma and asthma 
symptoms is presented in Table 2–5. 
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Table 2–5: Characteristics and results of studies investigating the association between beta-(1→3)-D-glucan and presence of asthma 
and asthma-related symptoms among school-age children 
First author 
(Year published) 
Location(s) 
Study 
design 
Study 
population 
(Sample size) 
Method of dust sample 
collection and levels of 
endotoxin exposure 
Operational definition of 
outcomes  
Findings and strength of 
association 
Tischer C183 
(2015) 
Germany 
Spain 
The Netherlands 
 
Birth cohort  Children 
followed from 
birth to 10 
years of age 
(n = 1429) 
Method of dust sample 
collection: Vacuum. 
Dust samples were collected 
at 2–3 months of age 
Living room GM beta-
(1→3)-D-glucan levels: 
Concentration (µg/mg) =  
1.75 
Physician-diagnosed 
asthma at age 10 years:  
Defined as report of 
doctor-diagnosed asthma 
ever within the 10 year 
period. 
Current asthma at age 6 
years and at age 10 years 
Defined as meeting ≥2 of 
3 conditions: 1) doctor-
diagnosed asthma ever, 
2) wheezing in the past 
12 months, 3) asthma 
medication use in the 
past 12 months 
Beta-(1→3)-D-glucan 
exposure was not 
significantly associated 
with current asthma at 6 
years of age (OR = 1.04), 
at 10 years of age (OR = 
0.96). While beta-(1→3)-
D-glucan appeared to have 
reduced effects on doctor-
diagnosed asthma ever at 
10 years of age (OR = 
0.84), the association was 
not significant.   
Blatter J203 
(2014) 
Puerto Rico 
Case-
control 
6–14 years 
(n = 317) 
Method of dust sample 
collection: Vacuum. 
Dust samples from mattress 
surfaces, living room and 
kitchen areas were combined 
as a single lot for microbial 
analysis. 
Beta-(1→3, 1→6)-D-glucan 
range: 
Concentration (µg/mg): 0.01–
23.0. 
Exposure as assessed in 
quartiles: (1st Quartile: 0.01–
Asthma cases: Physician-
diagnosed asthma and 
wheeze in the prior year 
Control: No asthma or 
wheeze. 
There was no significant 
association between beta-
(1→3, 1→6)-D-glucan 
and being a case for 
asthma.  
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0.05; 2nd Quartile: 00.05–
0.14; 3rd Quartile: 0.14–0.29; 
4th Quartile: 0.30–23.0) 
Maheswaran D202 
(2014) 
Canada 
Prospective 
cohort 
Children 
followed up 
from birth to 
age 14 years 
(n = 422)  
 
Method of dust sample 
collection: Vacuum. 
Play area and mattress dust 
samples were combined into 
a single lot for analysis. 
Mean beta-(1→3)-D-glucan 
levels: 
Concentration (µg/g): 36.58 
(Winter), 53.90 (Spring), 
63.08 (Autum), 79.38 (Fall) 
Asthma (assessed at age 
7–10 years and ages 11–
14 years): Physician-
diagnosed asthma 
confirmed by pediatric 
allergist according to the 
Canadian Asthma 
Consensus guidelines. 
BHR (assessed at age 7–
10 years and ages 11–14 
years): Assessed with 
methacholine challenge 
test. PC20 ≥8mg/mL 
considered as positive. 
Atopy asthma: 
Physician-diagnosed 
asthma plus positive test 
to at least 1 of 16 tested 
allergens. 
At ages 7–10, beta-(1→3)-
D-glucan levels in house 
increased the risk of 
asthma (OR = 1.15), and 
atopic asthma (OR = 1.21), 
albeit non-significant. 
However, after adjusting 
for potential confounders, 
including endotoxin 
exposure, beta-(1→3)-D-
glucan exposure at age 7–
10 was significantly 
associated with persistent 
atopic asthma (OR = 1.79) 
and BHR (OR = 1.87) at 
age 11–14 in children with 
existing asthma 
conditions.  
In children without asthma 
at age 7–10, high beta-
(1→3)-D-glucan exposure 
at ages 7–10 years also 
significantly predicted 
BHR at ages 11–14 years 
(OR = 1.80).  
Tischer C182 
(2011) 
Germany 
The Netherlands 
Multicenter 
birth cohort 
study 
Children 
followed up 
from birth to 
age 6 years 
(n = 696) 
Method of dust sample 
collection: Vacuum 
Median beta-(1→3)-D-glucan 
levels: 
Germany 
Definitions of asthma 
outcome differed in the 
two locations 
Asthma 
In both the German and 
Dutch studies, no 
significant associations 
were observed between 
exposure to beta-(1→3)-
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Living room floor: 
Concentration (µg/g): 2,229 
Load (µg/m2): 445 
Mattress: 
Concentration (µg/g): 1,859 
Load (µg/m2): 421 
The Netherlands 
Living room floor: 
Concentration (µg/g): 2,137 
Load (µg/m2): 177 
Mattress: 
Concentration (µg/g): 1,662 
Load (µg/m2): 380 
Germany: Physician-
diagnosed asthma in the 
last 6 months between 
the 5th and 6th year of 
life.  
The Netherlands: Ever 
diagnosed asthma plus 
child had asthma past 12 
months 
Wheeze 
Definition of wheeze 
outcome was similar and 
defined as wheeze or 
whistling in the chest 
past 12 months 
Dry cough  
Germany: Ever have 
nocturnal chesty cough 
without a cold or 
bronchitis 
The Netherlands: 
Presence of nocturnal 
cough without a cold or 
an infection in the chest 
past 12 months.   
D-glucan and asthma and 
wheeze. However, in 
children with parental 
history of allergy, 
exposure to mattress beta-
(1→3)-D-glucan load was 
significantly associated 
with decreased risk of dry 
cough in the German study 
(OR = 0.65).   
 
Iossifova YY186 
(2009) 
USA 
Birth cohort Children 
followed up 
from birth to 
age 3 years 
 (n = 483) 
Method of dust sample 
collection: Vacuum  
Living room beta-(1→3)-D-
glucan range: 
Concentration (µg/g): 0.35–
960 
Exposure was assessed in 
quartiles (1st Quartile: 0.35–
Children classified as 
having high future 
asthma risk based on a 
validated Asthma 
Predictive Index (API) 
index score. 
Positive API if they 
reported recurrent 
The study showed 
different results at low and 
high beta-(1→3)-D-glucan 
exposure levels. Low beta-
(1→3)-D-glucan exposure 
(<22 µg/g) was associated 
with increased risk of 
positive API (OR = 3.4) 
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22 µg/g; 2nd Quartile: 22.1–
60.0 µg/g; 3rd Quartile: 60.1–
133.0; 4th Quartile: 133.1–
960 µg/g) 
 
wheezing at age 3 years 
and met at least 1 of 3 
major criteria (parental 
history of asthma, 
allergic sensitization to 
≥1 aeroallergens, and 
eczema) or 2 of 3 minor 
criteria (wheezing 
without a cold, 
physician-diagnosed 
allergic rhinitis, and 
allergic sensitization to 
milk or egg) 
whereas at high beta-
(1→3)-D-glucan exposure 
(>133 µg/g) children had 
reduced risk of positive 
API (OR = 0.6) at 3 years 
of age. Similar trends of 
associations were observed 
for wheezing with atopy at 
the age of 3 year. These 
associations were not 
significant 
Iossifova YY197 
(2007) 
USA 
Cohort 
study 
Children 
followed up 
from birth to 
age 2 years 
 (n = 574) 
Method of dust sample 
collection: Vacuum 
Play area beta-(1→3)-D-
glucan range: 
Concentration (µg/g): 3–900 
Exposure was assessed in 
quartiles (1st Quartile: 3–22 
µg/g; 2nd Quartile: 23–60 
µg/g; 3rd Quartile: 61–133; 4th 
Quartile: 134–900 µg/g) 
 
 
Recurrent wheeze: ≥2 
wheezing episodes in the 
past 12 months 
Recurrent wheezing 
combined with allergen 
sensitization: Recurrent 
wheezing plus positive 
test (≥3mm) to at least 
one of 15 common 
allergens  
Exposure to high beta-
(1→3)-D-glucan (within 
the 4th quartile) was 
significantly associated 
with reduced risk of 
recurrent wheezing (OR = 
0.39) as well as recurrent 
wheeze with allergen 
sensitization (OR = 0.13). 
The association was 
reversed for lower 
exposure (within the 1st 
quartile). Recurrent 
wheezing (OR = 3.04) and 
recurrent wheezing 
without allergic 
sensitization (OR = 4.89) 
were significantly and 
positively associated with 
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low (1→3)-D-glucan 
exposure level 
Douwes J189 
(2006) 
The Netherlands 
Birth 
Cohort  
Children of 
atopic mothers 
followed up 
from birth to 
4th year of life 
 (n = 696) 
Method of dust sample 
collection: Vacuum 
Play area (living room floor) 
median beta-(1→3)-D-glucan 
load: 
Load (µg/m2): 90 (smooth 
floor), 686 (carpet floor), 
1,005 (rug floor) 
Mattress median beta-(1→3)-
D-glucan load: 
µg/m2: 90 
Asthma: Report of 
physician-diagnosed 
asthma at any time in the 
past 4 years (Ever 
asthma) 
Wheeze symptoms: ≥1 
episodes in the first 3 
years 
High play area and 
mattress beta-(1→3)-D-
glucan (load or 
concentration) were not 
associated with doctor-
diagnosed asthma and 
wheeze. Further 
adjustment for other 
important confounders 
rendered models highly 
unstable.     
Schram-Bijkerk 
D204 
(2005) 
Austria 
Germany 
The Netherlands 
Sweden  
Switzerland 
Case-
control 
5–13 years 
(n = 14,893) 
Method of dust sample 
collection: Vacuum 
Mattress GM beta-(1→3)-D-
glucan levels: 
Cases 
Concentration (µg/g): 2,662 
Load (µg/m2): 402 
Controls 
Concentration (µg/g): 2,959 
Load (µg/m2): 519 
Wheeze: Parental report 
of wheeze in the past 12 
months or wheeze ever. 
Atopic: Positive SPT 
Cases: atopic and non-
atopic wheezers 
Controls: Non-atopic 
non-symptomatic.   
 
Overall, mattress beta-
(1→3)-D-glucan load was 
associated with reduced 
risk of atopic wheeze with 
a borderline significance. 
Similar reduced risk was 
observed for each country 
but was not statistically 
significant.  
The protective effects of 
beta-(1→3)-D-glucan were 
also observed in both farm 
and non-farm reference 
children. 
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Exposure to beta-(1→3)-D-glucan has also been found to be associated with lower lung 
function. In a study among 148 schoolchildren (aged 7–11 years) in Amsterdam, The 
Netherlands, high levels of (1→3)-β-D-glucan from living room floor dust samples was 
associated with 1.6-fold increase in peak expiratory flow (PEF) variability, particularly in atopic 
children with asthma symptoms.195 The lower lung function and higher PEF variability may 
suggest exacerbation of asthma conditions following exposure, after asthma has develop. That is, 
among subjects with asthma, biological contaminants may be associated with greater asthma 
severity by enhancing pre-existing allergic and non-allergic inflammation. A summary of studies 
investigating associations between beta-(1→3)-D-glucan and lung function as well as asthma 
severity indicators is presented in Table 2–6. 
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Table 2–6: Characteristics and results of studies investigating the association between beta-(1→3)-D-glucan and asthma severity 
indicators and lung function among children and adults 
First author 
(Year published) 
Location(s) 
Study 
design 
Study 
population 
(Sample size) 
Method of dust sample 
collection and levels of 
endotoxin exposure 
Operational definition of 
outcomes  
Findings and strength of 
association 
McSharry C196 
(2015) 
Scotland 
Cross-
sectional 
16–60 years 
(n = 55) 
 All 
participants 
have asthma) 
Method of dust sample 
collection: Vacuum. 
Median living room floor 
beta-(1→3)-D-glucan levels: 
Concentration (ng/g): 435 
Median bedroom room floor 
beta-(1→3)-D-glucan levels: 
Concentration (ng/g): 435 
Primary outcome: Lung 
function assessed with 
FEV1 before the use of a 
bronchodilator 
While high living room 
and bedroom beta-(1→3)-
D-glucan concentrations 
demonstrated trends 
toward decreased FEV1 
values (ρ = -0.173 and -
0.107, respectively), the 
correlations were not 
significant, p>0.10 in both 
cases. 
Tischer C183 
(2015) 
Multicenter 
across Europe  
Cross-
sectional 
20–44 years 
(n = 956) 
Method of dust sample 
collection: Vacuum 
Median mattress beta-(1→3)-
D-glucan level: 
Concentration (µg/mg): 0.87 
Primary outcome: Lung 
function assessed with 
FEV1 and FVC 
There was no evidence of 
association between beta-
(1→3)-D-glucan exposure 
and kung function. While 
high beta-(1→3)-D-glucan 
exposure appeared to 
decrease FEV1 (-10 mL/s) 
and FVC (-10 mL), the 
associations were not 
significant. 
Blatter J203 
(2014) 
Puerto Rico 
Case-
control 
6–14 years 
(n = 317) 
Method of dust sample 
collection: Vacuum. 
Dust samples from mattress 
surfaces, living room and 
kitchen areas were combined 
as a single lot for microbial 
analysis. 
Asthma cases: Physician-
diagnosed asthma and 
wheeze in the prior year 
Control: No asthma or 
wheeze. 
i) Primary outcomes: 
Lung function assessed 
Beta-(1→3, 1→6)-D-
glucan was significantly 
associated with decreased 
FEV1 with a dose-response 
trend (1st Quartile = 2.06 
L/s, 2nd Quartile = 2.03 
L/s, 3rd Quartile = 1.92 
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Beta-(1→3, 1→6)-D-glucan 
range: 
Concentration (µg/mg): 0.01–
23.0. 
Exposure as assessed in 
quartiles: (1st Quartile: 0.01–
0.05; 2nd Quartile: 00.05–
0.14; 3rd Quartile: 0.14–0.29; 
4th Quartile: 0.30–23.0) 
with FEV1, FVC, and 
FEV1/FVC. 
ii) Asthma severity 
indicator: ≥1 ED/urgent 
care visit for asthma past 
12 months 
L/s, 4th Quartile = 1.78 
L/s; p=0.02).  
Furthermore, among 
children with asthma, high 
beta-(1→3, 1→6)-D-
glucan exposure level (in 
the 4th quartile) was 
significantly associated 
with increased odds of 1 or 
more visits to the 
ED/urgent care for asthma 
in the past 12 months (OR 
= 8.76) after adjustment 
for potential confounders 
(OR = 8.76) 
Rylander R205 
(2006) 
Sweden 
Case-
control 
exposure 
study 
(n = 82) 
Exposed: 
Poultry worker 
= 42. Mean 
age = 45.2 
years. 
Unexposed: 
non-poultry 
worker = 40. 
Mean age = 
38.5 
Method of dust sample 
collection: Stationary dust 
sampling with Isopore filter 
calibrated at 2 l/m airflow for 
30–60 min sampling period. 
Dust samples were taken in 
the poultry house only. 
Mean airborne beta-(1→3)-
D-glucan level: 
Concentration (ng/m3): 20  
Primary outcome: 
Pulmonary function 
assessed with FEV1, 
FVC, and FEV1/FVC. 
Bronchial responsiveness 
assessed with 
methacholine challenge 
test (MCT) 
Baseline FEV1 was 
significantly lower in 
poultry workers compared 
to controls (101.1 vs. 
110.7, p<0.05). 
Following MCT, the 
average % decrease in 
FEV1 in poultry workers 
was significantly larger 
compared to controls (-
9.5% vs. -3.4%, p<0.001).  
Douwes J195 
(2000) 
The Netherlands 
Cross-
sectional 
7–11 years 
(n = 148) 
Method of dust sample 
collection: Vacuum 
Play area GM beta-(1→3)-D-
glucan levels: 
Concentration (µg/g): 
Asthmatics (743), Non-
Primary outcome: PEF 
variability (morning and 
evening) over a 16 week 
monitoring period in 
children with asthma and 
asthma symptoms. 
 
Univariate analysis 
showed that play area 
levels of play area beta-
(1→3)-D-glucan load was 
significantly associated 
with PEF-variability over 
the 16 week monitoring 
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symptomatic (612), 
Symptomatic (754) 
Load (µg/m2):  Asthmatics 
(167), Non-symptomatic 
(126), Symptomatic (169) 
Mattress GM beta-(1→3)-D-
glucan levels: 
Concentration (µg/g): 
Asthmatics (903), Non-
symptomatic (718), 
Symptomatic (792) 
Load (µg/m2):  Asthmatics 
(283), Non-symptomatic 
(276), Symptomatic (293)  
 
period in asthmatic (OR = 
1.45) and symptomatic 
(OR = 1.33) children. The 
associations were stronger 
particularly in atopic 
children (ORs = 1.63 for 
asthmatic and 1.58 for 
symptomatic). The 
association remained 
significant after adjusting 
for potential confounders, 
including endotoxin 
exposure levels (OR > 
1.5). No association was 
found for mattress beta-
(1→3)-D-glucan levels. 
Rylander R206 
(1996) 
Sweden 
Laboratory 
inhalation 
challenge 
study 
Adults Method of dust sample 
collection: N/A 
Subject exposed to aerosol of 
beta-(1→3)-D-glucan for 4 
hours.  
Primary outcomes: 
Airway responsiveness 
assessed with MCT and 
respiratory symptoms 
Beta-(1→3)-D-glucan 
caused an increase in the 
severity of respiratory 
symptoms determined by 
throat and chest irritation. 
Also, significant airway 
responsiveness was 
observed following 
exposure to beta-(1→3)-
D-glucan. 
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2.12 Summary of literature review and restatement of research rationale  
Asthma is the most common chronic disease among children. The pathophysiology of asthma is 
complex and involves multicellular processes resulting in phenotypic heterogeneity of the 
disease. Central to the various phenotypic patterns is the presence of underlying airways 
inflammation.  
Furthermore, markers of asthma can vary between children, although these markers may 
sometime overlap as asthma is a multifactorial disease.  
The NAEPP guidelines58 recommend that asthma severity be assessed using a 
combination of frequency of clinical respiratory symptoms (day- and night-time symptoms) and 
objective lung function criteria (determined with forced expiratory volume in one second 
[FEV1]).  
Asthma appears to be less common in rural compared to urban children. Environmental 
factors including endotoxin exposures in rural settings have mostly been implicated for the 
urban-rural asthma differences. However, reports from Australia, Canada, Europe, and USA 
suggest that respiratory symptoms suggestive of asthma could be higher and even worse in 
children living in rural compared to those in urban settings.116,118,207,208 From this, it can be 
inferred that there may be under-diagnosis of asthma in rural areas. 
Methods to evaluate the presence or absence of asthma include symptoms history and 
lung function assessment. However, this is not often conducted in many epidemiological studies 
investigating childhood asthma due to cost and convenience.   
Epidemiological studies on asthma and microbial exposures have reported conflicting 
evidence with some showing indoor endotoxin exposures have protective effects while others 
showed risk or no association effects. Characterization of objective measures of asthma 
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phenotypes and their associations with objectively measured indoor microbial exposures are 
important as they may help explain some on the discrepancies.  
Similarly, studies examining the relationships between asthma severity and indoor 
microbial exposures have often focused on reports of symptom frequency by questionnaire 
without completing clinical evaluation to assess degree of asthma severity. Characterization of 
objective measures of asthma severity indicators and their associations with objectively 
measured indoor microbial exposures should also be investigated.  
By addressing these research gaps, data from the study will aid in identifying issues 
around asthma diagnosis along an urban-rural gradient and address the indoor microbial 
exposure associated with asthma severity and phenotypic expression among children with 
asthma. This could be important in improving asthma outcomes and patient care in children with 
asthma.   
2.13 Research objectives 
The overall aim of this study is to examine urban-rural asthma diagnostic pattern, as well as to 
investigate the relationships between indoor microbial exposures [endotoxin and beta-(1→3)-D-
glucan as biomarkers of bacterial and fungal exposure, respectively] and asthma phenotypes and 
severity among children with asthma in Saskatchewan. Toward this goal, the following specific 
objectives are proposed: 
2.13.1 Objective 1: To assess asthma diagnostic patterns along an urban-rural gradient by 
investigating difference in proportion of diagnosed asthma based on survey-based and algorithm-
based asthma classification. 
2.13.1.1 Hypothesis: Rural children will experience under-diagnosis of asthma more compared 
to urban children.  
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2.13.2 Objective 2: To examine associations between asthma phenotypes and endotoxin and 
beta-(1→3)-D-glucans of exposure. 
2.13.2.1 Hypothesis: Endotoxin and beta-(1→3)-D-glucan exposure will be associated with 
reduced risk of atopic asthma compared to non-atopic asthma but will be associated with 
increased risk of exercise-induced bronchospasm compared to non-exercise-induced 
bronchospasm. 
2.13.3 Objective 3: To examine associations between asthma severity and endotoxin and beta-
(1→3)-D-glucans of exposure.   
2.13.3.1 Hypothesis 1: Endotoxin and beta-(1→3)-D-glucans exposure will be associated with 
increased risk of moderate/severe asthma compared to mild asthma.  
2.13.3.2 Hypothesis 2: Endotoxin and beta-(1→3)-D-glucans exposure will be associated with 
.decreased lung function in children with asthma. 
2.14 References 
1. International Study of Asthma and Allergy in Childhood/International Union Against 
Tuberculosis and Lung Disease. The Global Asthma Report 2011. Available: 
http://www.theunion.org/index.php/en/newsroom/news/item/1837-global-asthma-report-
2011-launched. 
2. Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Respir Med. 
2007;101(3):378–388.  
3. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global 
strategy for asthma management and prevention: GINA executive summary. Eur Respir 
J. 2008;31(1):143–178 
  
87 
 
4. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma 
and wheezing in the first six years of life. The Group Health Medical Associates. N Engl 
J Med. 1995;332(3):133–138. 
5. Bonsignore MR, Profita M, Gagliardo R, Riccobono L, Chiappara G, Pace E, et al. 
Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola 
experience. Eur Respir Rev. 2015;24(135):30–39.  
6. Lambrecht BN, Hammad H. Asthma: the importance of dysregulated barrier immunity. 
Eur J Immunol. 2013 Dec;43(12):3125–3137.  
7. Barnes PJ. Th2 cytokines and asthma: an introduction. Respir Res. 2001;2(2):64–65.  
8. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. 
Nat Immunol. 2005 Feb;6(2):135–142.  
9. Kaur D, Saunders R, Berger P, Siddiqui S, Woodman L, Wardlaw A, et al. Airway 
smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth 
muscle migration in asthma. Am J Respir Crit Care Med. 2006;174(11):1179–188.  
10. Bonini M, Palange P. Exercise-induced bronchoconstriction: new evidence in 
pathogenesis, diagnosis and treatment. Asthma Res Pract. 2015;1:2. 
11. Reuter S, Stassen M, Taube C. Mast cells in allergic asthma and beyond. Yonsei Med J. 
2010;51(6):797–807.  
12. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. Th2 cytokines and 
asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res. 
2001;2(2):71–79.  
13. Possa SS, Leick EA, Prado CM, Martins MA, Tiberio IF. Eosinophilic inflammation in 
allergic asthma. Front Pharmacol. 2013;4:46.  
  
88 
 
14. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical 
studies. Proc Am Thorac Soc. 2009;6(3):256–259.  
15. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. 
Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033–1039.  
16. Liang Z, Zhao H, Lv Y, Li R, Dong H, Liu L, et al. Moderate accuracy of peripheral 
eosinophil count for predicting eosinophilic phenotype in steroid-naive non-atopic adult 
asthmatics. Intern Med. 2012;51(7):717–722.  
17. Molfino NA. Targeting of eosinophils in asthma. Expert Opin Biol Ther. 
2012;12(7):807–809.  
18. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of 
an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-
responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148.  
19. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic 
evaluation of severe asthma. Persistent inflammation associated with high dose 
glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737–743.  
20. Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, et al. 
Relationship between airway inflammation, hyperresponsiveness, and obstruction in 
asthma. J Allergy Clin Immunol. 2001;108(5):753–758. 
21. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and 
targeted therapies. J Allergy Clin Immunol. 2012;130(4):829–842.  
22. Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to 
clinical practice. Can Respir J. 2010;17(4):e85–93.  
23. Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–1372. 
  
89 
 
24. Bisgaard H, Bonnelykke K. Long-term studies of the natural history of asthma in 
childhood. J Allergy Clin Immunol. 2010;126(2):187–197. 
25. Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al. Outcome 
of asthma and wheezing in the first 6 years of life: follow-up through adolescence. Am J 
Respir Crit Care Med. 2005;172(10):1253–1258.  
26. Midodzi WK, Rowe BH, Majaesic CM, Saunders LD, Senthilselvan A. Predictors for 
wheezing phenotypes in the first decade of life. Respirology. 2008;13(4):537–545. 
27. Lowe LA, Simpson A, Woodcock A, Morris J, Murray CS, Custovic A. Wheeze 
phenotypes and lung function in preschool children. Am J Respir Crit Care Med. 
2005;171(3):231–237. 
28. Global Initiative for Asthma. Global strategies for asthma management and prevention. 
2011. Available: 
http://www.qu.edu.qa/pharmacy/professional_development/documents/GINA_Report_20
11-1.pdf. Accessed: December 13, 2013.  
29. National Institutes of Health (NIH)/National Heart LBIN. Expert Panel Report 3: 
Guidelines for the diagnosis and management of asthma. Full Report 2007. Revised 
August 2007. Report No.: NIH Publication #04-4051. 2007. 
30. Chung KF, Wenzel S, European Respiratory Society/American Thoracic Society Severe 
Asthma International Guidelines Task F. From the authors: International European 
Respiratory Society/American Thoracic Society guidelines on severe asthma. Eur Respir 
J. 2014;44(5):1378–1379 
  
90 
 
31. Lougheed MD, Leniere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, et al. Canadian 
Thoracic Society 2012 guideline update: Diagnosis and management of asthma in 
preschoolers, children and adults: executive summary. Can Respir J. 2012;19(6):e81–88. 
32. Pescatore AM, Dogaru CM, Duembgen L, Silverman M, Gaillard EA, Spycher BD, et al. 
A simple asthma prediction tool for preschool children with wheeze or cough. J Allergy 
Clin Immunol. 2014;133(1):111–118. 
33. Ng MC, How CH. Recurrent wheeze and cough in young children: is it asthma? 
Singapore Med J. 2014;55(5):236–241.  
34. Remes ST, Pekkanen J, Remes K, Salonen RO, Korppi M. In search of childhood 
asthma: questionnaire, tests of bronchial hyperresponsiveness, and clinical evaluation. 
Thorax. 2002;57(2):120–126. 
35. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International 
Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur 
Respir J. 1995;8(3):483–491. 
36. Cornish RP, Henderson J, Boyd AW, Granell R, Van Staa T, Macleod J. Validating 
childhood asthma in an epidemiological study using linked electronic patient records. 
BMJ. 2014;4(4):e005345.  
37. Jenkins MA, Clarke JR, Carlin JB, Robertson CF, Hopper JL, Dalton MF, et al. 
Validation of questionnaire and bronchial hyperresponsiveness against respiratory 
physician assessment in the diagnosis of asthma. Int J Epidemiol. 1996;25(3):609–616. 
38. Yang CL, To T, Foty RG, Stieb DM, Dell SD. Verifying a questionnaire diagnosis of 
asthma in children using health claims data. BMC Pulm Med. 2011;11:52.  
  
91 
 
39. Hederos CA, Hasselgren M, Hedlin G, Bornehag CG. Comparison of clinically 
diagnosed asthma with parental assessment of children's asthma in a questionnaire. 
Pediatr Allergy Immunol. 2007;18(2):135–141.  
40. Hansen TE, Evjenth B, Holt J. Validation of a questionnaire against clinical assessment 
in the diagnosis of asthma in school children. J Asthma. 2015;52(3):262–267. 
41. Coates AL, Graham BL, McFadden RG, McParland C, Moosa D, Provencher S, et al. 
Spirometry in primary care. Can Respir J. 2013;20(1):13–21.  
42. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. 
Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. 
43. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative 
strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. 
44. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF, Jr., Sorkness CA. 
Classifying asthma severity in children: mismatch between symptoms, medication use, 
and lung function. Am J Respir Crit Care Med. 2004;170(4):426–432. 
45. Fuhlbrigge AL. Asthma severity and asthma control: symptoms, pulmonary function, and 
inflammatory markers. Curr Opin Pulm Med. 2004;10(1):1–6.  
46. Paull K, Covar R, Jain N, Gelfand EW, Spahn JD. Do NHLBI lung function criteria 
apply to children? A cross-sectional evaluation of childhood asthma at National Jewish 
Medical and Research Center, 1999-2002. Pediatr Pulmonol. 2005;39(4):311–317.  
47. Brouwer AF, Visser CA, Duiverman EJ, Roorda RJ, Brand PL. Is home spirometry 
useful in diagnosing asthma in children with nonspecific respiratory symptoms? Pediatr 
Pulmonol. 2010;45(4):326–332. 
48. Jat KR. Spirometry in children. Prim Care Respir J. 2013;22(2):221–229. 
  
92 
 
49. Moeller A, Carlsen KH, Sly PD, Baraldi E, Piacentini G, Pavord I, et al. Monitoring 
asthma in childhood: lung function, bronchial responsiveness and inflammation. Eur 
Respir Rev. 2015;24(136):204–215.  
50. Gerald LB, Grad R, Turner-Henson A, Hains C, Tang S, Feinstein R, et al. Validation of 
a multistage asthma case-detection procedure for elementary school children. Pediatrics. 
2004;114(4):e459–468. 
51. Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al. 
An official American Thoracic Society clinical practice guideline: exercise-induced 
bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016–1027. 
52. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines 
for methacholine and exercise challenge testing-1999. This official statement of the 
American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J 
Respir Crit Care Med. 2000;161(1):309–329. 
53. de Marco R, Cerveri I, Bugiani M, Ferrari M, Verlato G. An undetected burden of asthma 
in Italy: the relationship between clinical and epidemiological diagnosis of asthma. Eur 
Respir J. 1998;11(3):599–605.  
54. Sears MR, Jones DT, Holdaway MD, Hewitt CJ, Flannery EM, Herbison GP, et al. 
Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children. 
Thorax. 1986;41(4):283–289. 
55. Haby MM, Anderson SD, Peat JK, Mellis CM, Toelle BG, Woolcock AJ. An exercise 
challenge protocol for epidemiological studies of asthma in children: comparison with 
histamine challenge. Eur Respir J. 1994;7(1):43–49. 
  
93 
 
56. Jones A. Asymptomatic bronchial hyperreactivity and the development of asthma and 
other respiratory tract illnesses in children. Thorax. 1994;49(8):757–761. 
57. Riedler J, Reade T, Dalton M, Holst D, Robertson C. Hypertonic saline challenge in an 
epidemiologic survey of asthma in children. Am J Respir Crit Care Med. 1994;150(6 Pt 
1):1632–1639. 
58. National Asthma Education and Prevention Program Expert Panel Report 3. Guidelines 
for the Diagnosis and Management of Asthma. US Department of Health Services and 
the National Heart Lung and Blood Institute, October 2007. NIH Publication 08-5846. 
Available: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf. 2007. 
59. Cowen MK, Wakefield DB, Cloutier MM. Classifying asthma severity: objective versus 
subjective measures. J Asthma. 2007;44(9):711–715. 
60. Stout JW, Visness CM, Enright P, Lamm C, Shapiro G, Gan VN, et al. Classification of 
asthma severity in children: the contribution of pulmonary function testing. Arch Pediatr 
Adolesc Med. 2006;160(8):844–850. 
61. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, 
et al. Uniform definition of asthma severity, control, and exacerbations: document 
presented for the World Health Organization Consultation on Severe Asthma. J Allergy 
Clin Immunol. 2010;126(5):926–238. 
62. Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE. Severity 
assessment in asthma: An evolving concept. J Allergy Clin Immunol. 2005;116(5):990–
995. 
  
94 
 
63. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al. A new 
perspective on concepts of asthma severity and control. Eur Respir J. 2008;32(3):545–
554. 
64. Bush A, Zar HJ. WHO universal definition of severe asthma. Curr Opin Allergy Clin 
Immunol. 2011;11:115–121. 
65. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 
2006;368(9537):804-–83.  
66. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of 
severe asthma in childhood: confirmation by cluster analysis of children in the National 
Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research 
Program. J Allergy Clin Immunol. 2011;127(2):382-9 e1–13. 
67. Konradsen JR, Nordlund B, Lidegran M, Pedroletti C, Gronlund H, van Hage M, et al. 
Problematic severe asthma: a proposed approach to identifying children who are severely 
resistant to therapy. Pediatr Allergy Immunol. 2011;22(1 Pt 1):9–18. 
68. Pekkanen J, Lampi J, Genuneit J, Hartikainen AL, Jarvelin MR. Analyzing atopic and 
non-atopic asthma. Eur J Epidemiol. 2012;27(4):281–286.  
69. Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D. Allergic vs 
nonallergic asthma: what makes the difference? Allergy. 2002;57(7):607–613. 
70. Ronchetti R, Jesenak M, Rennerova Z, Barreto M, Ronchetti F, Villa MP. Relationship 
between atopic asthma and the population prevalence rates for asthma or atopy in 
children: atopic and nonatopic asthma in epidemiology. Allergy Asthma Proc. 
2009;30(1):55–63. 
  
95 
 
71. Saglani S. Viral infections and the development of asthma in children. Ther Adv Infect 
Dis. 2013;1(4):139–150. 
72. Webley WC, Hahn DL. Infection-mediated asthma: etiology, mechanisms and treatment 
options, with focus on Chlamydia pneumoniae and macrolides. Respir Res. 
2017;18(1):98.  
73. Xie M, Wenzel SE. A global perspective in asthma: from phenotype to endotype. Chinese 
Med J. 2013;126(1):166–174.  
74. Campo P, Rodriguez F, Sanchez-Garcia S, Barranco P, Quirce S, Perez-Frances C, et al. 
Phenotypes and endotypes of uncontrolled severe asthma: new treatments. J Investig 
Allergol Clin Immunol. 2013;23(2):76–88.  
75. Wenzel SE, Busse WW, National Heart L, Blood Institute's Severe Asthma Research P. 
Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin 
Immunol. 2007;119(1):14–21. 
76. Adcock IM, Ford PA, Bhavsar P, Ahmad T, Chung KF. Steroid resistance in asthma: 
mechanisms and treatment options. Curr Allergy Asthma Rep. 2008;8(2):171–178.  
77. Chung KF. Clinical management of severe therapy-resistant asthma. Expert Rev Respir 
Med. 2017;11(5):395–402.  
78. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. 
Nat Med. 2012 May 04;18(5):716-25.  
79. Edgecombe K, Latter S, Peters S, Roberts G. Health experiences of adolescents with 
uncontrolled severe asthma. Arch Dis Child. 2010;95(12):985–991.  
  
96 
 
80. Weiler JM, Brannan JD, Randolph CC, Hallstrand TS, Parsons J, Silvers W, et al. 
Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol. 
2016;138(5):1292–1295. 
81. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, et al. 
Outcome in adulthood of asymptomatic airway hyperresponsiveness in childhood: a 
longitudinal population study. Pediatr Pulmonol. 2002;34(3):164–171.  
82. Depner M, Fuchs O, Genuneit J, Karvonen AM, Hyvarinen A, Kaulek V, et al. Clinical 
and epidemiologic phenotypes of childhood asthma. Am J Respir Crit Care Med. 
2014;189(2):129–138. 
83. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster 
analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–
224.  
84. Just J, Gouvis-Echraghi R, Rouve S, Wanin S, Moreau D, Annesi-Maesano I. Two novel, 
severe asthma phenotypes identified during childhood using a clustering approach. The 
Eur Respir J. 2012;40(1):55–60. 
85. Siroux V, Basagana X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, et al. Identifying 
adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38(2):310–317. 
86. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of 
asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J 
Respir Crit Care Med. 2010;181(4):315–323.  
87. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends 
in the prevalence of asthma symptoms: phase III of the International Study of Asthma 
and Allergies in Childhood (ISAAC). Thorax. 2007;62(9):758–766.  
  
97 
 
88. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the 
prevalence and severity of asthma symptoms: phase three of the International Study of 
Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64(6):476–483.  
89. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive 
summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478.  
90. ISAAC Steering Committee. Worldwide variations in the prevalence of asthma 
symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur 
Respir J. 1998;12:315–335. 
91. Canada ASo. Asthma Facts and Statistics. 2013. Available: 
http://www.asthma.ca/corp/newsroom/pdf/asthmastats.pdf. 
92. Garner R, Kohen D. Changes in the prevalence of asthma among Canadian children. 
Health Rep. 2008;19(2):45–50. 
93. Thomas EM. Recent trends in upper respiratory infections, ear infections and asthma 
among young Canadian children. Health Rep. 2010;21(4):47–52.  
94. Statistics Canada. Facts & Figures: Asthma in Canada. 2009. Available: 
http://www.med.uottawa.ca/sim/data/Asthma_e.htm. 
95. Senthilselvan A, Lawson J, Rennie DC, Dosman JA. Stabilization of an increasing trend 
in physician-diagnosed asthma prevalence in Saskatchewan, 1991 to 1998. Chest. 
2003;124(2):438–448. 
96. Gershon AS, Guan J, Wang C, To T. Trends in asthma prevalence and incidence in 
Ontario, Canada, 1996-2005: a population study. Am J Epidemiol. 2010;172(6):728–736. 
  
98 
 
97. Bedouch P, Marra CA, FitzGerald JM, Lynd LD, Sadatsafavi M. Trends in asthma-
related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population 
based-cohort study. PloS One. 2012;7(12):e50949. 
98. Prince Edward Island Health and Wellness. Prince Edward Island Asthma Trends. 2011. 
Available: http://www.gov.pe.ca/photos/original/dhw_epi_asthma.pdf. 
99. Parsons MA, Beach J, Senthilselvan A. Association of living in a farming environment 
with asthma incidence in Canadian children. J Asthma. 2017;54(3):239–249. 
100. Senthilselvan A. Prevalence of physician-diagnosed asthma in Saskatchewan, 1981 to 
1990. Chest. 1998;114(2):388–392.  
101. Statistics Canada. The 1996-97 National Population Health Survey, Ottawa, ON: Health 
Statistics Division. 1998. Available: 
http://data.library.utoronto.ca/datapub/codebooks/cstdli/nphs/1997/82_567_e.pdf.  
102. Chen Y, Helen J. Asthma. Health reports / Statistics Canada, Canadian Centre for Health 
Information = Rapports sur la sante / Statistique Canada, Centre canadien d'information 
sur la sante. 2004;16:43. 
103 Saskatchewan Ministry of Health. Prevalence of asthma, COPD, diabetes, and 
hypertension in Saskatchewan, 2010/11. 2013. 
104. Rennie DC, Lawson JA, Cockcroft DW, Senthilselvan A, McDuffie HH. Differences in 
respiratory symptoms and pulmonary function in children in 2 Saskatchewan 
communities. Ann Allergy Asthma Immunol. 2004;92(1):52–59. 
105. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. 
Worldwide time trends in the prevalence of symptoms of asthma, allergic 
  
99 
 
rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat 
multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. 
106. Lawson JA, Janssen I, Bruner MW, Madani K, Pickett W. Urban-rural differences in 
asthma prevalence among young people in Canada: the roles of health behaviors and 
obesity. Ann Allergy Asthma Immunol. 2011;107(3):220–228. 
107. Kozyrskyj A, Becker A. Rural-urban differences in atopic and nonatopic asthma in 
children. Epidemiology. 2006;17(6):S276. 
108. Kozyrskyj AL, Becker AB. Rural-urban differences in asthma prevalence. J Allergy Clin 
Immunol. 2004;113(2):S306. 
109. Milligan KL, Matsui E, Sharma H. Asthma in Urban Children: Epidemiology, 
Environmental Risk Factors, and the Public Health Domain. Curr Allergy Asthma Rep. 
2016;16(4):33.  
110. Lawson JA, Rennie DC, Cockcroft DW, Dyck R, Afanasieva A, Oluwole O, et al. 
Childhood asthma, asthma severity indicators, and related conditions along an urban-rural 
gradient: A cross-sectional study. BMC Pulm Med. 2017;17(4) 
111. Brozek G, Lawson J, Shpakou A, Fedortsiv O, Hryshchuk L, Rennie D, et al. Childhood 
asthma prevalence and risk factors in three Eastern European countries - the Belarus, 
Ukraine, Poland Asthma Study (BUPAS): an international prevalence study. BMC Pulm 
Med. 2016;16(11):1–11. 
112. Zhu WJ, Ma HX, Cui HY, Lu X, Shao MJ, Li S, et al. Prevalence and Treatment of 
Children's Asthma in Rural Areas Compared with Urban Areas in Beijing. Chin Med J. 
2015 Sep 5;128(17):2273-7.  
  
100 
 
113. Vlaski E, Lawson JA. Urban-rural differences in asthma prevalence among young 
adolescents: The role of behavioural and environmental factors. Allergol Immunopathol. 
2014;43(2):131–141. 
114. Lawson JA, Janssen I, Bruner MW, Hossain A, Pickett W. Asthma incidence and risk 
factors in a national longitudinal sample of adolescent Canadians: a prospective cohort 
study. BMC Pulm Med. 2014;14:51. 
115. Kausel L, Boneberger A, Calvo M, Radon K. Childhood asthma and allergies in urban, 
semiurban, and rural residential sectors in Chile. Scientific World J. 2013;2013:937–935.  
116. Guner SN, Gokturk B, Kilic M, Ozkiraz S. The prevalences of allergic diseases in rural 
and urban areas are similar. Allergol Immunopathol. 2011;39(3):140–144.  
117. Kolokotroni O, Middleton N, Nicolaou N, Pipis S, Priftis KN, Milton DK, et al. 
Temporal changes in the prevalence of childhood asthma and allergies in urban and rural 
areas of Cyprus: results from two cross sectional studies. BMC Public Health. 
2011;11:858. 
118. Valet RS, Gebretsadik T, Carroll KN, Wu P, Dupont WD, Mitchel EF, et al. High asthma 
prevalence and increased morbidity among rural children in a Medicaid cohort. Ann 
Allergy Asthma Immunol. 2011;106(6):467–473.  
119. Pesek RD, Vargas PA, Halterman JS, Jones SM, McCracken A, Perry TT. A comparison 
of asthma prevalence and morbidity between rural and urban schoolchildren in Arkansas. 
Ann Allergy Asthma Immunol. 2010;104(2):125–131. 
120. Ma Y, Zhao J, Han ZR, Chen Y, Leung TF, Wong GW. Very low prevalence of asthma 
and allergies in schoolchildren from rural Beijing, China. Pediatr Pulmonol. 
2009;44(8):793–799. 
  
101 
 
121. Sole D, Cassol VE, Silva AR, Teche SP, Rizzato TM, Bandim LC, et al. Prevalence of 
symptoms of asthma, rhinitis, and atopic eczema among adolescents living in urban and 
rural areas in different regions of Brazil. Allergol Immunopathol. 2007;35(6):248–253. 
122. El-Sharif N, Abdeen Z, Qasrawi R, Moens G, Nemery B. Asthma prevalence in children 
living in villages, cities and refugee camps in Palestine. Eur Respir J. 2002;19(6):1026–
1034. 
123. Genuneit J. Exposure to farming environments in childhood and asthma and wheeze in 
rural populations: a systematic review with meta-analysis. Pediatr Allergy Immunol. 
2012;23(6):509–518. 
124. Jhun I, Phipatanakul W. Early exposure to dogs and farm animals reduces risk of 
childhood asthma. Evid Based Med. 2016;21(2):80.  
125. Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S, et al. Exposure 
to farming in early life and development of asthma and allergy: a cross-sectional survey. 
Lancet. 2001;358(9288):1129–1133. 
126. Sozanska B, Pearce N, Dudek K, Cullinan P. Consumption of unpasteurized milk and its 
effects on atopy and asthma in children and adult inhabitants in rural Poland. Allergy. 
2013;68(5):644–650. 
127. von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nat Rev 
Immunol. 2010;10(12):861–868.  
128. Stein MM, Hrusch CL, Gozdz J, Igartua C, Pivniouk V, Murray SE, et al. Innate 
Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med. 
2016;375(5):411–421.  
  
102 
 
129. Douwes J, Cheng S, Travier N, Cohet C, Niesink A, McKenzie J, et al. Farm exposure in 
utero may protect against asthma, hay fever and eczema. Eur Respir J. 2008;32(3):603–
611. 
130. Akinbami LJ, Simon AE, Rossen LM. Changing Trends in Asthma Prevalence Among 
Children. Pediatrics. 2016;137(1).  
131. Chrischilles E, Ahrens R, Kuehl A, Kelly K, Thorne P, Burmeister L, et al. Asthma 
prevalence and morbidity among rural Iowa schoolchildren. J Allergy Clin Immunol. 
2004;113(1):66–71.  
132. Hirshon JM, Weiss SR, LoCasale R, Levine E, Blaisdell CJ. Looking beyond urban/rural 
differences: emergency department utilization by asthmatic children. J Asthma. 
2006;43(4):301–306. 
133. Withy K, Davis J. Followup after an emergency department visit for asthma: urban/rural 
patterns. Ethn Dis. 2008;18(2 Suppl 2):S2-247–251. 
134. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different? Eur Respir 
Rev. 2013;22(127):44–52. 
135. Horner SD. Childhood asthma in a rural environment: implications for clinical nurse 
specialist practice. CNS. 2008;22(4):192–198. 
136. Schatz M, Camargo CA, Jr. The relationship of sex to asthma prevalence, health care 
utilization, and medications in a large managed care organization. Ann Allergy Asthma 
Immunol. 2003;91(6):553–558. 
137. Vink NM, Postma DS, Schouten JP, Rosmalen JG, Boezen HM. Gender differences in 
asthma development and remission during transition through puberty: the TRacking 
  
103 
 
Adolescents' Individual Lives Survey (TRAILS) study. J Allergy Clin Immunol. 
2010;126(3):498–504. 
138. Burke W, Fesinmeyer M, Reed K, Hampson L, Carlsten C. Family history as a predictor 
of asthma risk. Am J Prev Med. 2003;24(2):160–169. 
139. London SJ, James Gauderman W, Avol E, Rappaport EB, Peters JM. Family history and 
the risk of early-onset persistent, early-onset transient, and late-onset asthma. 
Epidemiology. 2001;12(5):577–583. 
140. Black MH, Smith N, Porter AH, Jacobsen SJ, Koebnick C. Higher prevalence of obesity 
among children with asthma. Obesity. 2012;20(5):1041–1047.  
141. Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol. 
2005;115(5):897–909.  
142. Ronmark E, Andersson C, Nystrom L, Forsberg B, Jarvholm B, Lundback B. Obesity 
increases the risk of incident asthma among adults. Eur Respir J. 2005;25(2):282–288.  
143. Gilliland FD, Berhane K, Islam T, McConnell R, Gauderman WJ, Gilliland SS, et al. 
Obesity and the risk of newly diagnosed asthma in school-age children. Am J Epidemiol. 
2003;158(5):406–415.  
144. von Kries R, Hermann M, Grunert VP, von Mutius E. Is obesity a risk factor for 
childhood asthma? Allergy. 2001;56(4):318–322.  
145. Sharma S, Tailor A, Warrington R, Cheang M. Is obesity associated with an increased 
risk for airway hyperresponsiveness and development of asthma? Allergy Asthma Clin 
Immunol. 2008;4(2):51–58. 
146. Juel CT. Obesity and asthma : Impact on severity, asthma control and response to 
therapy. Respir Care. 2013;58(5)867–973. 
  
104 
 
147. Taylor B, Mannino D, Brown C, Crocker D, Twum-Baah N, Holguin F. Body mass index 
and asthma severity in the National Asthma Survey. Thorax. 2008;63(1):14–20. 
148. Juel CT, Ulrik CS. Obesity and asthma: impact on severity, asthma control, and response 
to therapy. Respir Care. 2013;58(5):867–873. 
149. McDaniel M, Paxson C, Waldfogel J. Racial disparities in childhood asthma in the 
United States: evidence from the National Health Interview Survey, 1997 to 2003. 
Pediatrics. 2006;117(5):e868–77. 
150. Bai Y, Hillemeier MM, Lengerich EJ. Racial/ethnic disparities in symptom severity 
among children hospitalized with asthma. J Health Care Poor Underserved. 
2007;18(1):54–61. 
151. Smith LA, Hatcher-Ross JL, Wertheimer R, Kahn RS. Rethinking race/ethnicity, income, 
and childhood asthma: racial/ethnic disparities concentrated among the very poor. Public 
Health Rep. 2005;120(2):109–116. 
152. Gao Z, Rowe BH, Majaesic C, O'Hara C, Senthilselvan A. Prevalence of asthma and risk 
factors for asthma-like symptoms in Aboriginal and non-Aboriginal children in the 
northern territories of Canada. Can Respir J. 2008;15(3):139–145. 
153. Senthilselvan A, Niruban SJ, King M, Majaesic, Veugelers P, Laing L, et al. Prevalence 
and risk factors of asthma in First Nations children living on reserves in Canada. Can J 
Public Health. 2015;106(8):e483–e488. 
154. Statistics Canada. 2016 Census Program. http://www12.statcan.gc.ca/census-
recensement/index-eng.cfm?GEOCODE=47#keystats. 2016. 
  
105 
 
155. Chen CM, Morgenstern V, Bischof W, Herbarth O, Borte M, Behrendt H, et al. Dog 
ownership and contact during childhood and later allergy development. Eur Respir J. 
2008;31(5):963–973.  
156. Karimi M, Mirzaei M, Baghiani Moghadam B, Fotouhi E, Zare Mehrjardi A. Pet 
exposure and the symptoms of asthma, allergic rhinitis and eczema in 6-7 years old 
children. Iranian J Allergy Asthma Immunol. 2011;10(2):123–127. 
157. Takkouche B, Gonzalez-Barcala FJ, Etminan M, Fitzgerald M. Exposure to furry pets 
and the risk of asthma and allergic rhinitis: a meta-analysis. Allergy. 2008;63(7):857–864. 
158. Carlsen KCL, Roll S, Carlsen KH, Mowinckel P, Wijga AH, Brunekreef B, et al. Does 
Pet Ownership in Infancy Lead to Asthma or Allergy at School Age? Pooled Analysis of 
Individual Participant Data from 11 European Birth Cohorts. PloS One. 
2012;7(8):e43214. 
159. Chen CM, Tischer C, Schnappinger M, Heinrich J. The role of cats and dogs in asthma 
and allergy--a systematic review. Int J Hyg Environ Health. 2010;213(1):1–31.  
160. Roost HP, Kunzli N, Schindler C, Jarvis D, Chinn S, Perruchoud AP, et al. Role of 
current and childhood exposure to cat and atopic sensitization. European Community 
Respiratory Health Survey. J Allergy Clin Immunol. 1999;104(5):941–947.  
161. Eller E, Roll S, Chen CM, Herbarth O, Wichmann HE, von Berg A, et al. Meta-analysis 
of determinants for pet ownership in 12 European birth cohorts on asthma and allergies: a 
GA2LEN initiative. Allergy. 2008;63(11):1491–1498. 
162. Gent JF, Belanger K, Triche EW, Bracken MB, Beckett WS, Leaderer BP. Association of 
pediatric asthma severity with exposure to common household dust allergens. Environ 
Res. 2009;109(6):768–774. 
  
106 
 
163. Jaakkola JJ, Gissler M. Maternal smoking in pregnancy, fetal development, and 
childhood asthma. Am J Public Health. 2004;94(1):136–140. 
164. Li YF, Langholz B, Salam MT, Gilliland FD. Maternal and grandmaternal smoking 
patterns are associated with early childhood asthma. Chest. 2005;127(4):1232–1241. 
165. Strachan DP, Cook DG. Health effects of passive smoking. 6. Parental smoking and 
childhood asthma: longitudinal and case-control studies. Thorax. 1998;53(3):204–212. 
166. Gonzalez-Barcala FJ, Pertega S, Sampedro M, Lastres JS, Gonzalez MA, Bamonde L, et 
al. Impact of parental smoking on childhood asthma. J Pediatr. 2013;89(3):294–299. 
167. Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH. Smoking and 
asthma. J Am Board Fam Med. 2011;24(3):313–322.  
168. Mannino DM, Homa DM, Redd SC. Involuntary smoking and asthma severity in 
children: data from the Third National Health and Nutrition Examination Survey. Chest. 
2002;122(2):409–415. 
169. Hanrahan JP, Tager IB, Segal MR, Tosteson TD, Castile RG, Van Vunakis H, et al. The 
effect of maternal smoking during pregnancy on early infant lung function. Am Rev 
Respir Dis. 1992;145(5):1129–1135. 
170. Milner AD, Marsh MJ, Ingram DM, Fox GF, Susiva C. Effects of smoking in pregnancy 
on neonatal lung function. Arch Dis Child Fetal Neonatal Ed. 1999;80(1):F8–14.  
171. Kanchongkittiphon W, Mendell MJ, Gaffin JM, Wang G, Phipatanakul W. Indoor 
environmental exposures and exacerbation of asthma: an update to the 2000 review by 
the Institute of Medicine. Environ Health Perspect. 2015 Jan;123(1):6–20. 
172. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009;71:489–507.  
  
107 
 
173. Gereda JE, Leung DY, Thatayatikom A, Streib JE, Price MR, Klinnert MD, et al. 
Relation between house-dust endotoxin exposure, type 1 T-cell development, and 
allergen sensitisation in infants at high risk of asthma. Lancet. 2000;355(9216):1680–
1683. 
174. Doreswamy V, Peden DB. Modulation of asthma by endotoxin. Clin Exp Allergy. 
2011;41(1):9–19.  
175. Sordillo JE, Sharma S, Poon A, Lasky-Su J, Belanger K, Milton DK, et al. Effects of 
endotoxin exposure on childhood asthma risk are modified by a genetic polymorphism in 
ACAA1. BMC Medical Genet. 2011;12:158. 
176. Lawson JA, Dosman JA, Rennie DC, Beach J, Newman SC, Senthilselvan A. The 
association between endotoxin and lung function among children and adolescents living 
in a rural area. Can Respir J. 2011;18(6):e89–94. 
177. Thorne PS, Kulhankova K, Yin M, Cohn R, Arbes SJ, Jr., Zeldin DC. Endotoxin 
exposure is a risk factor for asthma: the national survey of endotoxin in United States 
housing. Am J Respir Crit Care Med. 2005;172(11):1371–1377. 
178. Gehring U, Strikwold M, Schram-Bijkerk D, Weinmayr G, Genuneit J, Nagel G, et al. 
Asthma and allergic symptoms in relation to house dust endotoxin: Phase Two of the 
International Study on Asthma and Allergies in Childhood (ISAAC II). Clin Exp Allergy. 
2008;38(12):1911–1920. 
179. Perzanowski MS, Miller RL, Thorne PS, Barr RG, Divjan A, Sheares BJ, et al. Endotoxin 
in inner-city homes: associations with wheeze and eczema in early childhood. J Allergy 
Clin Immunol. 2006;117(5):1082–1089. 
  
108 
 
180. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al. Environmental 
exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med. 
2002;347(12):869–877. 
181. Lawson JA, Dosman JA, Rennie DC, Beach JR, Newman SC, Crowe T, et al. Endotoxin 
as a determinant of asthma and wheeze among rural dwelling children and adolescents: a 
case-control study. BMC Pulm Med. 2012;12:56. 
182. Tischer C, Gehring U, Chen CM, Kerkhof M, Koppelman G, Sausenthaler S, et al. 
Respiratory health in children, and indoor exposure to (1,3)-beta-D-glucan, EPS mould 
components and endotoxin. Eur Respir J. 2011;37(5):1050–1059. 
183. Tischer C, Casas L, Wouters IM, Doekes G, Garcia-Esteban R, Gehring U, et al. Early 
exposure to bio-contaminants and asthma up to 10 years of age: results of the HITEA 
study. Eur Respir J. 2015;45(2):328–337.  
184. Karvonen AM, Hyvarinen A, Gehring U, Korppi M, Doekes G, Riedler J, et al. Exposure 
to microbial agents in house dust and wheezing, atopic dermatitis and atopic sensitization 
in early childhood: a birth cohort study in rural areas. Clin Exp Allergy. 2012 
Aug;42(8):1246-56.  
185. Rosenbaum PF, Crawford JA, Anagnost SE, Wang CJ, Hunt A, Anbar RD, et al. Indoor 
airborne fungi and wheeze in the first year of life among a cohort of infants at risk for 
asthma. J Exposure Sci Environ Epidemiol. 2010;20(6):503–515. 
186. Iossifova YY, Reponen T, Ryan PH, Levin L, Bernstein DI, Lockey JE, et al. Mold 
exposure during infancy as a predictor of potential asthma development. Ann Allergy 
Asthma Immunol. 2009;102(2):131–137. 
  
109 
 
187. Rennie DC, Lawson JA, Kirychuk SP, Paterson C, Willson PJ, Senthilselvan A, et al. 
Assessment of endotoxin levels in the home and current asthma and wheeze in school-
age children. Indoor Air. 2008;18(6):447–453. 
188. Campo P, Kalra HK, Levin L, Reponen T, Olds R, Lummus ZL, et al. Influence of dog 
ownership and high endotoxin on wheezing and atopy during infancy. J Allergy Clin 
Immunol. 2006;118(6):1271–1278. 
189. Douwes J, van Strien R, Doekes G, Smit J, Kerkhof M, Gerritsen J, et al. Does early 
indoor microbial exposure reduce the risk of asthma? The Prevention and Incidence of 
Asthma and Mite Allergy birth cohort study. J Allergy Clin Immunol. 2006;117(5):1067–
1073. 
190. El-Sharif N, Douwes J, Hoet P, Nemery B. Childhood asthma and indoor aeroallergens 
and endotoxin in Palestine: a case-control study. J Asthma. 2006;43(3):241–247.  
191. Gillespie J, Wickens K, Siebers R, Howden-Chapman P, Town I, Epton M, et al. 
Endotoxin exposure, wheezing, and rash in infancy in a New Zealand birth cohort. J 
Allergy Clin Immunol. 2006;118(6):1265–1270. 
192. Horick N, Weller E, Milton DK, Gold DR, Li R, Spiegelman D. Home endotoxin 
exposure and wheeze in infants: correction for bias due to exposure measurement error. 
Environ Health Perspect. 2006;114(1):135–140. 
193. Tavernier GO, Fletcher GD, Francis HC, Oldham LA, Fletcher AM, Blacklock G, et al. 
Endotoxin exposure in asthmatic children and matched healthy controls: results of 
IPEADAM study. Indoor Air. 2005;15(Suppl 10):25–32.  
  
110 
 
194. Lawson JA, Dosman JA, Rennie DC, Beach J, Newman SC, Senthilselvan A. 
Relationship of endotoxin and tobacco smoke exposure to wheeze and diurnal peak 
expiratory flow variability in children and adolescents. Respirology. 2011;16(2):332–339. 
195. Douwes J, Zuidhof A, Doekes G, van der Zee SC, Wouters I, Boezen MH, et al. (1-->3)-
beta-D-glucan and endotoxin in house dust and peak flow variability in children. Am J 
Respir Crit Care Med. 2000;162(4 Pt 1):1348–13454. 
196. McSharry C, Vesper S, Wymer L, Howieson S, Chaudhuri R, Wright GR, et al. 
Decreased FEV1 % in asthmatic adults in Scottish homes with high Environmental 
Relative Moldiness Index values. Clin Exp Allergy. 2015;45(5):902–927. 
197. Iossifova YY, Reponen T, Bernstein DI, Levin L, Kalra H, Campo P, et al. House dust 
(1-3)-beta-D-glucan and wheezing in infants. Allergy. 2007;62(5):504–513. 
198. Rabinovitch N, Liu AH, Zhang L, Rodes CE, Foarde K, Dutton SJ, et al. Importance of 
the personal endotoxin cloud in school-age children with asthma. J Allergy Clin Immunol. 
2005;116(5):1053–1057. 
199. Rizzo MC, Naspitz CK, Fernandez-Caldas E, Lockey RF, Mimica I, Sole D. Endotoxin 
exposure and symptoms in asthmatic children. Pediatr Allergy Immunol. 1997;8(3):121–
126. 
200. Michel O, Ginanni R, Duchateau J, Vertongen F, Le Bon B, Sergysels R. Domestic 
endotoxin exposure and clinical severity of asthma. Clin Exp Allergy. 1991;21(4):441–
448.  
201. Michel O, Duchateau J, Sergysels R. Effect of inhaled endotoxin on bronchial reactivity 
in asthmatic and normal subjects. J Appl Physiol. 1989;66(3):1059–1064. 
  
111 
 
202. Maheswaran D, Zeng Y, Chan-Yeung M, Scott J, Osornio-Vargas A, Becker AB, et al. 
Exposure to Beta-(1→3)-D-glucan in house dust at age 7-10 is associated with airway 
hyperresponsiveness and atopic asthma by age 11-14. PloS One. 2014;9(6):e98878. 
203. Blatter J, Forno E, Brehm J, Acosta-Perez E, Alvarez M, Colon-Semidey A, et al. Fungal 
exposure, atopy, and asthma exacerbations in Puerto Rican children. Ann Am Thorac Soc. 
2014;11(6):925–932. 
204. Schram-Bijkerk D, Doekes G, Douwes J, Boeve M, Riedler J, Ublagger E, et al. Bacterial 
and fungal agents in house dust and wheeze in children: the PARSIFAL study. Clin Exp 
Allergy. 2005;35(10):1272–1278.  
205. Rylander R, Carvalheiro MF. Airways inflammation among workers in poultry houses. 
Int Arch Occup Environ Health. 2006;79(6):487–490.  
206. Rylander R. Airway responsiveness and chest symptoms after inhalation of endotoxin or 
beta-(1→3)-D-Glucan. Indoor Built Environ. 1996;5:106–111. 
207. Ownby DR. Asthma in rural America. Ann Allergy Asthma Immunol. 2005;95(5 Suppl 
1):S17–22. 
208. Rodriguez A, Vaca M, Oviedo G, Erazo S, Chico ME, Teles C, et al. Urbanisation is 
associated with prevalence of childhood asthma in diverse, small rural communities in 
Ecuador. Thorax. 2011;66(12):1043–1450. 
 
 
 
 
  
112 
 
 
CHAPTER 3 
METHODOLOGY 
3.1 Overview 
This section describes the general methodology for the study including the study design, study 
population, data collection methods, and dust sample preparation and analysis procedures. Since 
this is a manuscript-style dissertation, methodologies specific to Objectives 1, 2, and 3 are 
further described in their manuscript sections (Chapters 4, 5 and 6, respectively).   
3.2 Study design 
This study used a cross-sectional design and incorporated three stages of data collection that 
included cross-sectional survey, clinical assessment, and home dust collection (Figure 3–1). Data 
from Stages 1 and 2 formed the basis of Objective 1 (Asthma diagnosis). The asthma population 
identified in Objective 1 and data from Stages 1, 2 and 3 formed the basis of Objectives 2 
(asthma phenotypes) and 3 (asthma severity).  
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†No report of physician-diagnosed asthma but a positive response to any or a combination of 
asthma-related symptoms. 
‡Based on a 3-stage asthma case-detection algorithm.1 
§Based on NAEPP asthma severity classification guidelines.2 
EIB: Exercise-induced bronchospasm. 
Figure 3–1: Flow chart of study design and data collection procedures. 
Asthma 
(Doctor-diagnosed) 
No Asthma 
(No asthma-like 
Symptoms or Asthma) 
                    Stage 2: Clinical testing 
 Pulmonary function test (PFT)  
 Exercise challenge testing (ECT) 
 Allergy skin prick testing (SPT) 
Stage 3: Home dust collection 
Asthma-like 
Symptoms 
(At-Risk-for-Asthma)† 
 
Probable asthma 
(Positive for asthma) 
 Asthma phenotype categories 
 Asthma severity categories§ 
 Mild intermittent 
 Mild persistent 
 Moderate persistent 
 Severe persistent 
No asthma  
Determine children’s asthma category  
[Based on survey response symptom history] 
Stage 1: Children’s cross-sectional survey 
(2015) 
 
Algorithm-based asthma classification‡  
(Based on symptom history, spirometry, and exercise-challenge test) 
Based on SPT 
 Atopic 
 Non-atopic 
 
Based on ECT 
 EIB 
 No EIB 
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3.3 Study location    
The study was conducted in the province of Saskatchewan, Canada. Children were recruited 
from Regina (approximately population size of 200,0003), Prince Albert (approximately 
population size of 35,0004) and the rural or farm towns surrounding Prince Albert 
(approximately population size <2,500) (Figure 3–2). These areas were chosen based on their 
population size and density as well as the lack of previous asthma research in these areas. For 
this study, location of dwelling for children were considered as “Large Urban”, “Small Urban” or 
“Rural” depending on if a child lives in Regina, Prince Albert or the small towns, farm or 
acreages outside of Prince Albert; respectively. The urban-rural gradient chosen for the study 
parallels Statistics Canada definitions based on modified Beale codes where the definitions of 
large urban, small urban, and rural in this study match those of small metropolitan (urban 
settlements of 50,000 to 249,999 people), non-metropolitan small city zone (20,000-49,999 
people) and rural (<2,500 people).5 
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Figure 3–2: Map of Saskatchewan showing Regina, Prince Albert, and towns around Prince 
Albert as study locations (Source: Saskatchewan Rivers Public School Division Website: 
https://www.srsd119.ca/?page_id=483).  
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3.4 Data collection  
This study was conducted during spring, fall and winter seasons (May 2015 to April 2016). The 
survey component was conducted between May 2015 and November 2015. Clinical testing 
(spirometry, exercise challenge testing, and skin prick testing) and home dust sample collection 
were completed concurrently between December 2015 and April 2016.  
3.4.1 Subject recruitment and study population 
In 2013, children from Kindergarten to Grade 8 (approximately 5–14 years) were initially 
recruited into a cross-sectional survey from schools using an urban-rural gradient (n = 3,509) as 
previously described.6 Meetings were held with the school division directors followed by 
communication with school principals prior to any data collection. Schools in the large urban 
center were randomly selected (35 schools) due to the large number of schools. All schools in the 
Prince Albert Region (12 schools) and the surrounding areas (9 schools) under the same school 
division administration were selected for small urban and rural settings. Children had the option 
of participating in further survey and clinical testing. In 2015, we re-approached those who gave 
the consent (n = 1,348) and repeated the same cross-sectional survey followed by a clinical 
component (spirometry, exercise challenge testing, allergy skin testing) and environmental home 
dust collection component in those children and parents who consented to each of the procedure. 
All children, now from Grade 2 to 10 (approximately 7–17 years), were eligible to participate. 
Study packages, including an information letter, survey and pre-paid return envelope, were 
mailed to parents for completion.  
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3.4.2 Survey instrument and operational definitions of asthma  
The survey questionnaire used standardized questions from the International Study of Asthma 
and Allergy in Childhood (ISAAC),7,8 the American Thoracic Society Children’s Respiratory 
Disease,9 and the questionnaires used previously in Saskatchewan Lung Health studies.10,11 The 
questionnaires included the core asthma, allergy, and respiratory symptoms questions as well as 
information on general health, parental health history, environmental exposure, and 
sociodemographic factors as well as housing characteristics (Appendix 3). Based on responses to 
the questionnaire, children were classified into one of three categories as follows (Figure 3–1): 
i) Diagnosed asthma: Defined as a positive response on the questionnaire to either of 
the following questions: “Has this child ever been diagnosed as having asthma by a 
doctor?”, “In the past 12 months, has this child taken medicine that your doctor 
prescribed for a breathing problem” 
ii) At-risk-for-asthma: Defined as no report of diagnosed asthma but a positive 
response to any or a combination of the following questions: “Has this child ever had 
wheezing or whistling in the chest at any time in the past?”, “Has this child ever had 
wheezing or whistling in the chest in the past 12 months?”, “Has your child had a dry 
cough at night apart from a cough associated with a cold or chest infection?”, “Has 
this child woken up at night because of cough?”  
iii) No asthma: Defined as no reports of physician-diagnosed asthma and no asthma-like 
symptoms or taking medication for breathing. 
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3.4.3 Pulmonary function assessment   
All children in the three asthma categories who consented to lung function testing performed 
pulmonary function testing using the PC-based Easy-On ultrasonic spirometer (ndd Medical 
Technologies, Zurich, Switzerland) in accordance with the American Thoracic Society 
recommendations for children.12 After withholding short acting inhaled bronchodilator therapy in 
children with asthma for at least 6 hours before test, children completed at least three, but not 
more than seven, maneuvers in a sitting position while wearing a nose clip. All tests were 
performed in the child’s school. However, children who were absent from school on the test date 
or whose parents wanted to be present during testing had testing completed at home. Children 
were tested by experienced technicians who were blinded to the asthma status of each child. 
The best of 3 acceptable and reproducible efforts of FVC, FEV1, FEV1/FVC, and FEF25%–
75% were recorded for each child. Reference equations based on the recently developed all-age, 
multi-ethnic Global Lung Function Initiative (GLI) was used to determine predicted values.13 
Spirometry was not performed on subjects who answered yes to questions regarding any of the 
following conditions in the past 3 months: “heart or abdominal surgery,” and “hospitalization for 
any heart problems.” As part of the pulmonary function testing, anthropometric data (height, 
weight, and waist circumference) was also obtained. Height was measured against a wall using a 
fixed tape measure with subjects standing in socks and in their normal indoor clothing. Weight 
was measured with subjects standing on a calibrated flat scale with their socks on and dressed in 
normal indoor clothing. Waist circumference was measured between the lowest rib and iliac 
crest, horizontally through the narrowest part of the torso.   
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3.4.4 Exercise challenge testing (ECT) 
In order to consider a marker of BHR, all children who performed spirometry also performed 
ECT if they consented. The ECT involves stepping up and down on a 6 inch Aerobic Stepper 
(Merrybody Sport, China). The level of exercise intensity was selected to maintain a heart rate 
(HR) ≈150–200 beats per minute while stepping continuously for 5 minutes after reaching the 
target heart rate. HR was monitored throughout the exercise with a Polar heart rate monitor 
(Polar Electro, Woodbury, NY) attached to the chest wall by a strap. If necessary, study 
personnel also stepped with the children to provide encouragement. Spirometry was repeated 3 
and 10 minutes after cessation of the exercise. These times have been reported to coincide with 
the predicted maximal decrease in FEV1 and FEF25%–75% and the expected recovery period in 
children.2 To determine whether EIB has occurred, percent change in FEV1 or FEF25%–75% values 
from the baseline values after the exercise was computed. Children with >15% decrease in FEV1 
or a ≥25% decrease in FEF25%–75% from baseline at any of the post exercise testing intervals (3 or 
10 minutes) were considered to have EIB based on recommended guidelines.14,15 
3.4.5 Allergy skin prick testing (SPT) 
Skin prick test (SPT) reactivity to six common, non-food allergens, was also completed. The 
allergens included Alternaria, Cladosporium, Aspergillus, house dust mite mix, local grass, and 
cat dander (Omega Laboratory, Montreal, QC, Canada). Two controls including a histamine 
positive control and a saline negative control were used to reduce false positives and false 
negatives. SPT was performed on the volar side of the child’s forearm with the standardized 
allergen extracts according to recommended protocol of practice.16 The wheal size diameter was 
measured after 15 minutes. Subjects was considered positive for atopy if a positive reaction to at 
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least one of the applied allergens is raised ≥3 mm compared to the saline control. All SPTs in the 
study were performed by trained technicians who were blinded to the asthma status of each child. 
3.4.6 Home dust collection 
Dust samples were collected from the floor of child’s play area as well as the mattress on which 
the child slept. Dust was used to measure endotoxin and beta-glucan [beta-(1→3)-D-glucan] 
exposure. Dust was collected by using one of two Solaris Turbo Plus vacuum cleaners (Model: 
Miele S514, Germany). The power for the two cleaners was set at 950 W which exceeds the 
minimum power recommended according to the ISAAC protocol.17 Prior to data collection, the 
two vacuum cleaners (VC) were calibrated for flow rate and static pressure at the College of 
Engineering, University of Saskatchewan. The flow rate vs. static pressure curves for each of the 
two cleaners were found to be similar prior to data collection (VC 1: R2 = 0.9996; VC 2: R2 = 
0.9999) and post data collection (VC 1: R2 = 0.9998; VC 2: R2 = 0.9986).  
The X-Cell-100 dust collection filter socks (Midwest Filtration LLC, OH, USA; Figure 
3–3) were used to obtain dust samples. The pore size of the filter was between 4.0 and 12.3 
microns. The filter socks were in sterile condition from the manufacturer. Prior to data 
collection, each filter sock was placed into individual Ziploc bags which were labeled with a 
unique identification number (ID) and no other information (for confidentiality and blinding 
reasons). Each filter bag was then weighed using the Adventurer Balance (Model AR1530, 
Ohaus Corp, Pine Brook, NJ, USA) at the Canadian Center for Health and Safety in 
Agriculture’s National Agricultural and Industrial Hygiene Laboratory (CCHSA’s–NAIHL) in 
the D-Wing of the Health Sciences Academic Complex at the University of Saskatchewan.  
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Figure 3–3: The X-Cell 100 Dust Sampling Sock used for dust sample collection (Source: 
Midwest Filtration LL website:  http://www.midwestfiltration.com/dust-sampling.php). 
In each home and for different locations within the home (play area or mattress), a new 
filter sock was placed into the distal end of the extension tube of vacuum cleaners and sealed 
with a clean crevice device tool that was placed over the distal end of the extension tube for dust 
collection. Sampling area and time for dust collection followed the standardized ISAAC 
protocol.17 Floors with wall to wall carpet had 2m2 vacuumed for 4 minutes while smooth floor 
with at least 4m2 of carpet had 2m2 vacuumed for 4 minutes. Completely smooth floor or floor 
with one or two small carpets had 4m2 vacuumed for 4 minutes. For mattresses, dust sample 
collection was completed with the bottom sheet (the sheets that the child slept on) in place over 
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the mattress during vacuuming with comforters, pillows, and duvets removed. The length and 
width of the mattress were measured and the whole area of the mattress was vacuumed for 2 
minutes. In order to correct for any modifying factors during the dust sampling process, a blank 
sample was collected for every sixth house visited according to recommended protocol.17   
Following dust sample collection, filter socks were placed back in the Ziploc bag and 
transported to CCHSA’s–NAIHL for further processing. At the CCHSA’s–NAIHL laboratory, 
the filter socks containing the dust samples were weighed after dust sample collection by the 
same person that weighed them prior to data collection, using the same scale. To minimize errors 
in dust weight, pre- (filter socks only) and post-data collection (filters socks with dust sample) 
weights were completed in triplicate and the average weight recorded. Differences in pre- and 
post-data collection weights were recorded and the samples were stored desiccated in a fridge at 
4ºC until extraction and analysis.  
3.4.7 In-home assessment 
During home visit for dust sample collection, the technician conducted a brief inspection of the 
home to visually assess indoor home characteristics. The technician walked through the major 
rooms in the house including the child’s bedroom, living room, kitchen, bathroom, and dining 
areas. In each location, the presence of mold or dampness was noted. In addition, the technician 
noted the presence of a mildew odor or musty smell, presence of pets and the presence of air 
quality equipment such as heating sources (firewood or natural gas), air conditioners, humidifier, 
dehumidifier, or heat recovery ventilator (HRV) system.  
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3.5 Dust sample extraction procedures  
The step-by-step procedures for dust extraction are shown in Appendix 4. Dust samples were 
sieved through a 300 µm mesh sieve, weighed and stored desiccated at 40C. Prior to extraction, 
samples were brought to room temperature and 10 mg (0.010 g) of sieved dust sample was 
measured into a 50 mL conical tube for extraction. Dust samples were extracted with 20 mL 
0.05% Tween-20 solution (GE Healthcare Bio-Science, Mississauga, ON, Canada) in pyrogen-
free distilled water and shaken at 325 revolution per minute (RPM) for 2 hours using the Thermo 
Scientific MaxQ 2000 Bench Top Shaker (ThermoFisher Scientific, Mississauga, ON, Canada). 
The extracted solution was then centrifuged at 1,000 g (gravity force; g-force) for 15 minutes 
using the Sorvall ST 16R centrifuge (ThermoFisher Scientific, Mississauga, ON, Canada) to 
obtain supernatants. The supernatants were then aliquoted in approximately 1.0 mL into 1.5 mL 
microcentrifuge tubes and stored at -80ºC pending endotoxin and beta-(1→3)-D-glucan analyses.   
3.6 Microbial endotoxin and beta-(1→3)-D-glucan analysis procedures 
Frozen aliquots were allowed to attain room temperature before analysis.  
An aliquot of the supernatant was diluted 1 in 10, and was used to measure endotoxin. 
Endotoxin analysis was performed using the Limulus Amoebocyte Lysate (LAL) assay according 
to manufacturer’s recommendations (Appendix 4). Briefly, 100 µL of five endotoxin standards 
(range from 0.005–50 EU/mL) extracts and the LAL reagent water blank were dispensed into a 96-
well plate (Appendix 5) and used to construct a standard curve from which the endotoxin activity of 
the samples were calculated. After 10 minutes incubation at 37ºC, 100 µL of the Kinetic-QCL was 
added to each of the well to activate enzymatic reaction. The absorbance was monitored at 405 nm 
for 2 hours, using the ELx808 spectrophotometric plate reader (BioTek, Winooski, VT, USA). The 
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activated enzyme releases p-nitroaniline (pNA) from a synthetic substrate, producing a yellow color. 
Using the initial absorbance reading of each well as its own blank, the time required before the 
appearance of a yellow color was determined and considered as the reaction time. The amount of 
endotoxin present is inversely proportional to the reaction time. The concentration of endotoxin in 
unknown samples was referenced to a standard curve and computed using linear correlations. The 
kinetic LAL assay is optimized to be linear from 0.005 EU/mL to 50.0 EU/mL. Endotoxin levels 
were expressed as concentration [endotoxin units per milligram of dust sample (EU/mg)] and as load 
[EU per square meter of sampled area (EU/m2)]. 
 Soluble beta-(1→3)-D-glucan levels in the second aliquot were measured with the 
Glucatell assay kit based on the Kinetic Onset Time protocol according to manufacturer’s 
specifications (Associate of Cape Cod, East Falmouth, MA) (Appendix 4). Similar to endotoxin 
analysis, 100 µL of six beta-(1→3)-D-glucan standards (range from 3.125–100 µg/mg) extracts 
and the Glucatell reagent water blank were dispensed into a 96-well plate (Appendix 5) and used to 
construct a standard curve from which the beta-(1→3)-D-glucan activity of the samples were 
calculated. In contrast to the endotoxin analysis, the absorbance of the beta-(1→3)-D-glucan was 
monitored at 405 nm for 1 hour using the ELx808 spectrophotometric plate reader (BioTek, 
Winooski, VT, USA). The Glucatell assay is a modified LAL assay but is based upon the same 
principles described for endotoxin. The only difference is that, rather than activating factor C 
originally used for endotoxin detection, the Glucatell assay activates factor G leading to a series 
of enzymatic reactions.18 Due to the removal or disabling of factor C from the enzymatic reaction 
pathways, the glucan-specific LAL assay does not cross-react with endotoxin allowing for beta-
(1→3)-D-glucan detection while avoiding false positive results.19,20 Similar to endotoxin, beta-
(1→3)-D-glucan levels were expressed as concentration [per gram of sampled dust (µg/g)] and 
loading [per square meter of sampled area (µg/m2)].  
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3.7 General statistical analysis considerations 
Statistical analyses were completed with the Statistical Package for the Social Science (SPSS) 
Version 24 (SPSS Inc. Armonk, NY: IBM Corp.) and the Statistical Analysis System (SAS) 
Version 9.4 (SAS Institute Inc., Cary, NC, USA). Statistical significance was defined by an alpha 
level of 0.05. For each objective, descriptive analyses using frequencies and proportions for 
categorical variables and means with standard deviations for continuous variables were 
completed.  
Following descriptive analyses, multiple logistic regression and multiple linear regression 
models were fitted as appropriate to examine association of endotoxin and beta-(1→3)-D-glucan 
with asthma phenotypes or severity as appropriate (Objectives 2 and 3, respectively). Strengths 
of association were assessed by the odds ratio (OR) and 95% confidence interval (95%CI) if 
logistic regression model was used and by beta coefficient (standard error) if linear regression 
model was used. 
3.7.1 Analysis for Objective 1 
 The main outcomes for Objective 1 were survey-based asthma classification (report of 
physician-diagnosed asthma) and algorithm-based asthma classification [positive for asthma 
based on combinations of survey symptoms report and clinical testing (spirometry and ECT)]. 
Proportions of children “positive for asthma” by survey-based and algorithm-based methods 
were compared for each location using the McNemar test for correlated proportions. Lung 
function variables were also compared by location of residence using one-way between-group 
analysis of variance (ANOVA) and analysis of covariance (ANCOVA) as appropriate. A more 
detailed description of the statistical analysis is located in Chapter 4.  
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3.7.2 Analysis for Objective 2 
The outcomes for Objective 2 were asthma phenotypes assessed, separately, as atopic vs. non-
atopic asthma (based on atopic sensitization) and EIB vs. no EIB (based on results of ECT). 
Multiple logistic regression models were fitted to test the association between endotoxin and 
beta-(1→3)-D-glucan exposure with asthma phenotypes. Separate models were fitted for play 
area and mattress endotoxin and beta-(1→3)-D-glucan exposure variables. Variables were 
entered into the model based on the purposeful selection procedure by Hosmer to account for 
potential confounders.21 A more detailed description of the statistical analysis is located in 
Chapter 5. 
3.7.3 Analysis for Objective 3 
The outcomes for Objective 3 were asthma severity categories (mild persistent asthma vs. 
moderate/severe persistent asthma) as determined by the NAEPP asthma severity classification 
guidelines2 as well as lung function. Similar analyses and models for Objective 2 were used for 
Objective 3 to examine the relationships between endotoxin and beta-(1→3)-D-glucan exposure 
with asthma severity. In addition, multiple linear regression models were fitted to examine 
associations between endotoxin and beta-(1→3)-D-glucan exposure and lung function variables. 
A more detailed description of the statistical analysis is located in Chapter 6. 
3.8 Sample size and power calculation summary 
The main purpose of the study was to investigate urban-rural asthma diagnosis patterns, as well 
as the relationships between indoor microbial exposures [endotoxin and beta-(1→3)-D-glucan as 
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biomarkers of exposure] and asthma phenotypes and severity among children with asthma in 
Saskatchewan. The sample size to achieve these objectives was calculated using the G*Power 
statistical software (Version 3.1.7). All sample size estimates were calculated based on two-
tailed analysis with alpha level set at 0.05 while power was set at 80% (1-β).  
The initial sample size calculation for this study suggested a total sample size of n = 540 
for Objective 1, n = 125 for Objective 2, and n = 85 for Objective 3 (Appendix 6). In the end, we 
had n = 335 for Objective 1, n = 99 for Objective 2, and n = 102 for Objective 3. While the 
sample size obtained (n = 335) was below the initial estimated sample size (n = 540), statistically 
significant associations were observed for each objective suggesting that the power of the study 
was sufficient for some of the associations investigated.  Despite this, there were some relatively 
strong strengths of association observed in the analyses for Objective 3 that did not reach 
statistical significance. This could be an indication that power was not sufficient for all 
associations considered. 
3.9 Ethical approval 
Ethical approval was obtained from the University of Saskatchewan Biomedical Research Ethics 
Board (Bio # 14–162). The original ethical approval for the study is Bio # 11–03 with annual 
progress and amendment completed (Appendix 7). In addition to these approvals, the local 
Catholic School Board and Public School Board in each location of the study approved the study. 
Finally, prior to taken part in the study, parents/legal guardians/legal caregivers were required to 
complete a consent form and children were required to complete an assent form (Appendix 8). 
These forms were included as extra pages in the survey questionnaires mailed to the address of 
participants. Completion and return of questionnaire including the consent and assent pages 
implied voluntary consent by the children and their custodians. During the clinical assessment 
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and home dust collection, parents/guardians/caregivers and the participating children were 
further asked to confirm their voluntary participation in the study. 
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4.1 Abstract 
Background: Studies have reported lower asthma prevalence in rural compared to urban areas. 
While environmental factors have mostly been implicated for these differences, the lower asthma 
prevalence could also be linked to asthma under-diagnosis in rural children.  
Objectives: We investigate if rural children experience under-diagnosis of asthma more 
compared to urban children.   
Methods: In 2013, we conducted a cross-sectional survey of schoolchildren (5–14 years) across 
an urban-rural gradient in Saskatchewan, Canada. In 2015, we approached those who gave 
consent for further testing (now age 7–17 years) to repeat the survey, and to conduct clinical 
testing (spirometry and exercise challenge testing). Based on survey responses, children were 
classified into “no asthma”, “at-risk-for-asthma”, and “diagnosed asthma”. We then classified 
asthma status as either “no asthma” or “probable asthma” based on a validated asthma algorithm.    
Results: The study population of 335 schoolchildren was comprised of 73.4% from large urban, 
13.7% from small urban and 12.8% from rural. Proportion with report of physician-diagnosed 
asthma was 28.5% (Large urban), 34.8% (Small urban), and 20.9% (Rural). Mean percent 
predicted FEV1 and FEF 25%–75% were lower in rural compared to small urban and large urban 
children (p<0.05). Among those not classified as diagnosed asthma by the survey, the algorithm 
further identified the presence of asthma in 5.5% large urban, 8.1% small urban, and 18.8% rural 
children (p=0.03).  
Conclusion: The study revealed evidence of asthma under-diagnosis in rural areas and further 
supports the use of objective measures in addition to symptoms history when investigating 
asthma across urban-rural gradients.  
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4.2 Introduction 
More than 13% of school-age children are estimated to have diagnosed asthma in Canada,1 with 
childhood asthma being a leading cause of morbidity and medical expenses among children.2,3 
While the burden of asthma is high among children,4 its prevalence varies geographically with 
most studies reporting lower asthma prevalence in rural compared to urban areas.5–10 
Environmental factors have mostly been implicated for these differences. However, the 
association could also be linked to possible under-diagnosis of asthma in rural children.   
In a national sample of Canadian adolescents, asthma prevalence was lower in rural 
compared to urban children but no differences were observed in the prevalence of wheeze 
symptoms.7 Rural US children had a lower report of diagnosed asthma compared to urban 
children despite increased report of asthma-related symptoms among rural children.11 In our 
recent study in Saskatchewan, Canada, similar results were observed where rural children had a 
lower prevalence of asthma despite increased prevalence of wheeze among children with 
asthma.12 Results from these studies suggest that diagnostic differences may be contributing to 
the lower asthma prevalence among rural children.  
While there are clinical assessment methods such as spirometry and fractional exhaled 
nitric oxide (FENO) that may aid the diagnosis of asthma, no one test alone is considered as 
standard diagnostic test for asthma in children.13,14 To date, assessments are largely based on 
history and response to pharmacotherapy.15 However, while the expression of recurring 
symptoms of wheeze may provide evidence of asthma among children,13,16 objective lung 
function assessment is recommended to improve diagnostic accuracy.17,18 It is uncommon in 
population-based epidemiological studies when investigating geographic variations in asthma 
prevalence to conduct clinical investigations. The use of symptom history in combination with 
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clinical assessment may help in assessing the true burden of childhood asthma along an urban-
rural gradient.   
Our overall aim was to investigate if rural children experience more asthma under-diagnosis 
compared to urban children. We hypothesized that the addition of an objective clinical test would 
better identify cases of true asthma. As part of this investigation, we investigated differences in 
lung function and exercise challenge test (ECT) results along an urban-rural gradient and 
whether the addition of clinical measures (lung function testing and ECT) improved the 
diagnostic classification of asthma.  
4.3 Methods 
4.3.1 Study design and location  
This was a cross-sectional study conducted across an urban-rural gradient in the province of 
Saskatchewan, Canada. The study locations included Regina (population approximately 
200,00019), Prince Albert (population approximately 35,00020), and the rural area (small town, 
farm and non-farm) in the region around Prince Albert (population <2,500 people). Location of 
dwelling was classified as “Large Urban”, “Small Urban”, or “Rural” based on whether the child 
lived in Regina, Prince Albert or the rural farm and non-farm locations surrounding Prince 
Albert, respectively. The urban-rural gradient parallels Statistics Canada definitions based on 
modified Beale codes where definitions of large urban, small urban, and rural match those of 
small metropolitan (urban settlements of 50,000 to 249,999 people), non-metropolitan small city 
zone (20,000–49,999 people), and rural (<2,500 people).21  
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4.3.2 Study population, selection and recruitment 
Participants in this study were from an initial 2013 cross-sectional study of schoolchildren 
attending Kindergarten to Grade 8 as previously described.12 The 2013 cross-sectional survey 
was conducted to investigate the prevalence of childhood asthma and asthma-related symptoms 
in the region. At this time, children had the option of participating in further survey and clinical 
testing. In 2015, we approached those who gave previous consent for follow-up, repeated the 
survey, and conducted clinical assessments. The current study population was comprised of 
children in Grades 2 to 10 (approximately 7–17 years). Study packages, including an information 
letter, survey and pre-paid return envelope, were mailed to parents for self-completion.  
In order to obtain accurate information on current respiratory symptoms that correspond 
to lung function values in our studied population, the results presented in the current study were 
based on data from the 2015 survey only, which was completed just prior to lung function 
testing. 
The study was approved by the University of Saskatchewan Biomedical Research Ethics 
Board (Bio #: 14–162). Completion and return of the survey implied voluntary consent for the 
questionnaire portion. All children and a parent provided written assent and consent, 
respectively, prior to clinical testing.  All school divisions involved approved the study. 
4.3.3 Data collection instruments 
4.3.3.1 Survey instrument and operational definition 
Surveys were based on standardized questionnaires from the International Study of 
Asthma and Allergy in Childhood (ISAAC),22,23 the American Thoracic Society Children’s 
Respiratory Disease,24 and questionnaires used previously in Saskatchewan lung health 
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studies.25,26 The ISAAC questionnaire has been shown to have high validity when compared to 
physician assessment of asthma16,27 and have been used across a range of pediatric groups.28,29 
Questions about respiratory and allergic symptoms, general health, parental health history, 
environmental exposures, and socio-demographic factors as well as housing characteristics were 
included. Children were classified into one of 3 asthma categories based on questionnaire 
responses (survey-based asthma classification): “diagnosed asthma”, “at-risk-for-asthma”, or “no 
asthma”.  Physician-diagnosed asthma (probable asthma) was defined as a positive response to: 
“Has this child ever been diagnosed as having asthma by a doctor?” and/or a positive response 
to: “Has this child taken prescribed asthma medication in the past 12 months?” At-risk-for 
asthma was defined as positive responses to wheeze or whistling symptoms or other respiratory 
symptoms such as cough and shortness of breath but no diagnosed asthma or asthma medication. 
Furthermore, the definition of at-risk-for-asthma in this study was based on symptoms report but 
not on risk factors such as parental history of asthma or allergy. Similar definition of at-risk-for-
asthma in this study has also been used in previous studies.11,30 
4.3.3.2 Pulmonary function assessment 
Of the 335 children who participated in the study, a total of 288 (86%) performed spirometry 
testing. Spirometry assessment was completed according to recommended standards for 
children17,18 using the Easy-on-PC spirometer (ndd Medical Technologies, Zurich, Switzerland). 
Some subjects were excluded from testing because they were unable to perform the test due to 
existing medical conditions (n = 3). Subjects who were unwilling to perform the test (did not 
consent to testing) were also excluded (n = 44). There were no significant differences across 
diagnosis groups or urban-rural gradient among the 44 subjects that refused to participate in 
pulmonary function tests (p>0.05 for both). Tests were performed in the child’s school or at 
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home within normal indoor temperature (range: 21ºC–28ºC) and relative humidity (range: 35%–
45%). Children were tested by experienced technicians who were blinded to the asthma status of 
each child. Data were assessed for quality and completeness by the same technicians. At least 
three successful and repeatable maneuvers were performed for each child. Lung function values 
for forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC 
ratio, and forced expiratory flow between 25% and 75% of FVC (FEF25%-75%) were obtained. 
Predicted values were based on the all-age, multi-ethnic Global Lung Function Initiative (GLI) 
reference equation.31 
4.3.3.3 Exercise Challenge Testing (ECT) 
Because children with stable asthma could produce normal spirometry results,32 all children were 
further tested with ECT33 shortly after spirometry assessment to help identify children with a 
positive indication of asthma. Tests were also performed in the same location where the child 
performed spirometry testing (i.e. either child’s school or at home). Of the 288 subjects who 
performed spirometry testing, 281 (98%) further completed the ECT by stepping up and down on 
a 6 inch Aerobic Stepper (Merrybody Sport, China). After attaining exercise intensity level 
(stepping rate) that placed their heart rate between 150–200 beats per minute, children were 
required to step continuously for 5 minutes at the target heart rate. Heart rates were monitored 
throughout the exercise with a Polar heart rate monitor (Polar Electro, Woodbury, NY). 
Spirometry was repeated 3 and 10 minutes after cessation of exercise. These times have been 
reported to coincide with the predicted maximal decrease in FEV1 and FEF25%–75% and the 
expected recovery period in children.34   
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4.3.3.4 Algorithm-based asthma classification 
Following questionnaire responses and clinical testing, we used the validated asthma algorithm 
developed by Gerald et al30 (Appendix 9) to identify children positive for asthma. All children 
who had FEV1/FVC ratio <80% upon spirometry testing; or if they demonstrated a >15% 
decrease in FEV1 or a ≥25% decrease in FEF25%–75% from baseline at any of the post exercise 
testing intervals (3 or 10 minutes) were considered to be positive for asthma (probable 
asthma).32,35 The spirometry and ECT results were finally used to classify children into two 
distinct asthma groups: “positive for asthma” or “no asthma”. 
4.3.4 Statistical analysis 
Statistical analyses were completed with the Statistical Package for the Social Sciences (SPSS) 
Version 24 (SPSS Inc. Armonk, NY: IBM Corp.) and the Statistical Analysis System (SAS) 
Version 9.4 (SAS Institute Inc., Cary, NC, USA). Categorical demographics, environmental and 
respiratory symptoms were compared between locations of dwelling using the independent 
samples chi-squared (χ2) and Fisher’s exact tests as appropriate. A one-way between-group 
analysis of variance (ANOVA) was conducted to compare differences in mean values for percent 
predicted lung function variables between locations of dwelling. Scheffe pairwise post hoc 
comparisons were used to assess if there were statistically different levels of lung function 
between locations following the overall ANOVA assessment. These analyses were also repeated 
after stratification by asthma status. Finally, proportions of children “positive for asthma” by 
survey-based and algorithm-based methods were compared for each location using the McNemar 
test for correlated proportions. Finally, to confirm if rural children are more likely to be 
misclassified for asthma based on survey report of physician-diagnosed asthma, we created a 
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variable for asthma misclassification using the survey-based and algorithm-based asthma 
classification. Asthma misclassification was given if the subject had no affirmative response to 
physician-diagnosed asthma question on the survey but identified as positive for asthma based on 
the asthma case-detection algorithm. Logistic regression analysis was performed to assess 
associations between location of dwelling and asthma misclassification adjusting for age, sex, 
ethnicity, smoke exposure, parental education level, and parental history of allergy.       
4.4 Results 
4.4.1 Study population characteristics 
A total of 335 children participated in the current study and differed significantly in some 
characteristics (age, parental education, tobacco smoke exposure, and parental history of allergy) 
compared to the original group in 2013 survey (Table 4–1).  Of the 335 children that participated 
in 2013, most (73%) were large urban, 14% were small urban, and 13% were rural residents. The 
socio-demographic, personal and environmental characteristics of the participants by location of 
dwelling are shown in Table 4–2. Compared to large urban and small urban, rural children, on 
the average, were approximately 2 years older, 2 kg heavier, and travelled 28 minutes longer to 
access medical care. Rural children were more likely to be female and Caucasian compared to 
small urban and large urban children. Small urban children had a higher proportion of parents 
who smoked, parents with a history of allergic diseases, and were more likely to be exposed to 
secondhand tobacco smoke compared to children from large urban and rural locations. In terms 
of indoor environmental characteristics, rural children were more likely to own a pet but less 
likely to live in homes that have natural gas heating, an air conditioner, or a humidifier compared 
to urban children.  
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4.4.2 Previous self-reported asthma-related symptoms based on questionnaire reports  
Based on the parental response to the questionnaire, proportion with report of physician-
diagnosed asthma, at-risk-for-asthma and absence of asthma was 28.4%; 36.1% and 35.5%, 
respectively. However, rural children with physician-diagnosed asthma had a higher proportion 
of chronic bronchitis compared to large urban children while small urban at-risk-for-asthma 
children had a higher proportion of cough symptoms compared to large urban children (Table 4–
3). Although results were not statistically significant, a higher proportion of urban compared to 
rural children reported taking prescribed asthma medications if they had physician-diagnosed 
asthma (70% vs. 66.7%; p=0.89) and if they were at-risk-for-asthma (22.7% vs. 13.3%; p=0.46); 
respectively.     
4.4.3 Pulmonary function measures among participants 
Lung function variables differed significantly by location of home (Table 4–4). Overall, mean 
percent predicted FEV1 and FEF25%–75% were lower in the rural children compared to small urban 
and large urban groups. However, after stratification by survey-based asthma classification 
status, the lower mean values for FEV1 and FEF25%–75% seen in the rural group were only found 
in the at-risk-for-asthma children and not in the diagnosed asthma or no asthma groups. Figure 
4–1 presents the comparison of lung function variables indicative of bronchial 
hyperresponsiveness (FEV1 and FEF25%–75%) before and after exercise. Baseline absolute values 
before exercise and at 3 and 10 minutes after exercise were significantly lower in the at-risk-for-
asthma rural children in comparison to at-risk-for-asthma large urban and small urban children 
(p<0.05 for both FEV1 and FEF25%–75%) but not in the diagnosed or no asthma groups. Similarly, 
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change in baseline FEV1 and FEF25%– 75% after cessation of exercise were also significantly lower 
in at-risk-for-asthma rural children compared to at-risk-for-asthma large urban children.  
4.4.4 Investigation of the algorithm-based asthma classification system  
Figure 4–2 shows the results of the asthma case-detection algorithm procedure. Among those not 
classified as asthma by survey (“No asthma” and “At-risk-for-asthma” groups), the combination 
of spirometry and ECT identified 5.5% (large urban), 8.1% (small urban), and 18.8% (rural) 
more children as positive for asthma; p=0.026. Among those classified as asthma by survey, 
31.6% met the spirometry and ECT criteria for asthma diagnosis (Large urban = 57.1%, Small 
urban = 14.3%, and Rural = 28.6%). Overall, in addition to the 95 children with physician-
diagnosed asthma identified by survey questionnaire, the algorithm further identified 21 children 
positive for asthma for a combined total of 116 children positive for asthma. In each of the 
location of dwelling, the proportions of children with positive indication of asthma from the 3-
stage asthma case detection algorithm (those classified as having probable asthma with the 
questionnaire and those classified as having probable asthma with spirometry or ECT) were 
higher compared to those identified as positive for asthma by survey questionnaire alone, and 
was statistically significant for rural settings (34.9% vs. 20.9%; Figure 4–3). 
To ensure that confounding was not the reason for under-diagnosis, we assessed 
associations between location of dwelling and asthma misclassification using logistic regression 
analysis. After adjusting for age, sex, ethnicity, parental smoking, parental education level, and 
parental history of allergy, rural [odds ratio (OR) = 8.19, 95%CI: 2.31–29.10) children were 
significantly more likely to be misclassified as “no asthma” compared to large urban children 
when asthma diagnosis was based on survey report of physician-diagnosed asthma.  
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Finally, since exercise-induced bronchospasm can be thought of as a unique entity, we 
also completed the analysis after exclusion of those with positive ECT. The results showed that 
the proportion of children positive for asthma was 30.6% (Large Urban), 37.8% (Small Urban), 
and 31.3% (Rural) which are similar to and confirm our results when using ECT. Also, after 
excluding children with positive ECT from the “No asthma” group, the proportion of children 
with positive indication of asthma using the asthma case-detection algorithm was 31.7% (Large 
Urban), 40% (Small Urban), and 34.9% (Rural). 
4.5 Discussion 
The current study revealed potential evidence of asthma under-diagnosis in rural areas. 
Compared to large urban and small urban children, rural children without a history of diagnosed 
asthma based on survey responses were more likely to be reclassified as positive for asthma 
when objective measures (spirometry and ECT) were used. Also, children at-risk-for-asthma in 
rural areas had lower lung function than other locations. 
Many of the previous studies that have investigated urban-rural differences in childhood 
asthma used survey questionnaire in assessing variations in asthma burden across locations of 
dwelling. Findings from these studies showed lower asthma prevalence in rural compared to 
urban children.6,7,10,36,37 Furthermore, when questionnaire reports of asthma diagnosis and 
symptoms were both considered, asthma diagnosis has been shown to be lower in rural children 
despite symptoms consistent with asthma diagnosis being similar across an urban-rural 
gradient7,38 or even higher in rural compared to urban children.11 In the Canadian portion of the 
International Health Behavior in School-Aged Children (HBSC) study (aged 6–10 years), 
Lawson et al found an urban-rural gradient for asthma prevalence, with lower asthma in rural 
areas, but the prevalence of wheeze was similar across locations.7 In a separate study that 
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compared results from two cross-sectional studies conducted at two different intervals (1994 and 
2002) among 6–7 and 13–14 years old children in 8 different centers in Italy, there was a 
significant increase in doctor-diagnosed asthma among urban compared to rural children despite 
similar prevalence of asthma-related symptoms between the two locations.38 Another study 
among schoolchildren (aged 4–17 years) from Arkansas, USA, showed similar results where 
rural children had an increased report of asthma-related respiratory symptoms and a slightly 
lower prevalence of physician-diagnosed asthma compared to urban children.11 These results 
suggest that the apparent lower prevalence of childhood asthma in rural locations may be linked 
to under-diagnosis. This may be particularly important among children with asthma-related 
symptoms.  
In this report, we have confirmed these data using questionnaires but also lung function 
measures. Among children in the at-risk-for-asthma group, rural children had significantly lower 
lung function compared to their small urban and large urban counterparts. These results were not 
seen among the asthma and no asthma groups, which had similar lung function across the urban-
rural gradient. This may be due to better asthma management among the asthma group. 
Furthermore, the values for FEV1 and FEV1/FVC (both >80%) among the at-risk-for-asthma 
rural children indicate relatively good lung function at present. However, the fact that these 
values were significantly lower in this group compared to large urban and small urban children 
may indicate possible future decline in lung function particularly if the at-risk-for-asthma rural 
children continue to be unrecognized for asthma diagnosis resulting in suboptimal management 
of their respiratory conditions. This is further evidenced from the Dunedin birth cohort study in 
New Zealand (n = 613) where children with persistent wheeze at age 9 and 13 years had 
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significantly lower lung function (as measured by FEV1, FEV1/FVC, and FEF25%–75%) at age 26 
years relative to those without persistent wheezing.39 
While urban-rural environmental exposures, particularly farming exposures in the rural 
areas, has been the most common explanation for low asthma prevalence in rural locations,40–42 
accessibility of healthcare services for diagnosis may also play an important role. We did not 
access the potential role of accessibility to healthcare services in the current study. However, we 
found that rural parents travelled approximately 28 minutes longer, on average, compared to 
large urban and small urban dwelling parents to receive healthcare for their child (p<0.001). 
Similarly, in a US-based cross-sectional study, rural residents were found to travel approximately 
15 kilometers longer, on average, compared to urban residents to access healthcare services.43 
Thus, the decision to take a child to a healthcare facility for asthma diagnosis and subsequent 
treatment/management of asthma conditions could have financial implications in rural settings 
that are not always seen in the urban areas.  
Speculatively, individuals living in rural areas may choose to visit a physician differently 
than urban populations, which could be due to access issues. This barrier to healthcare services 
might have contributed to failure to properly diagnose asthma among symptomatic rural children 
since rural children who might otherwise be eligible for asthma diagnosis must also have the 
means to travel to the location of care before they can be diagnosed. In a study among 6–14 year 
olds schoolchildren (n = 3,090) in two rural Iowa counties in USA, asthma prevalence in the 
rural areas was reported to rival those in large cities.44 However, approximately 42% of the rural 
children with frequent symptoms of asthma (night- or day-time cough, wheeze or shortness of 
breath) reported ever been given a diagnosis of asthma by a physician. We suggest that objective 
tests are necessary when investigating asthma prevalence, especially across geographical 
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locations, realizing that differential patient presenting or survey reports of physician diagnosis of 
asthma may be underestimating the true burden of asthma across urban-rural gradient. 
The primary result of this study showed that rural compared to large urban children were 
more likely to experience asthma under-diagnosis. However, we must also evaluate the 
possibility of asthma over-diagnosis among the large urban children. Among children with 
survey-based report of physician-diagnosed asthma, only 30 (31.6%) met the spirometry and 
ECT criteria for asthma diagnosis (Large urban = 57.1%, Small urban = 14.3%, and Rural = 
28.6%; p=0.03). Therefore, it is possible that the higher proportion of survey-based physician-
diagnosed asthma in the large urban children may be due to some labeling bias or over-diagnosis 
of asthma in children living in large urban areas. Due to better access to healthcare services in 
the large urban children, other respiratory symptoms similar to but not directly related to asthma 
diagnosis might have been misinterpreted as asthma upon presentation to hospitals, resulting in 
asthma over-diagnosis in the large urban children. However, since the asthma diagnosis and 
management guidelines are standardized,35 asthma management should be similar between urban 
and rural locations in Canada.45 The most plausible explanation for the remaining 68% of the 
survey-based physician-diagnosed asthma children for not meeting the spirometry and ECT 
criteria for asthma diagnosis could be that their asthma conditions were well controlled. Most of 
the children in the physician-diagnosed asthma compared to at-risk-for-asthma group (76.3% vs. 
26.4%; p<0.001) had been taking inhaled corticosteroid in the past 12 months. 
This study has some limitations. The participation rate we experienced was low, 
especially in the small urban and rural locations. It is important to bear in mind that participants 
for this kind of cross-sectional field study are frequently hard to reach, especially in the small 
urban and rural locations where many participants live on farms and only a low number of 
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participating students are found per school. However, as our results indicated statistical 
significant differences, the power of the study was sufficient to show the hypothesized effect. 
Also, we cannot exclude the possibility that there may be response bias in our sample as 
indicated by differences in some of the participants’ characteristics in the current study compared 
to the original group in 2013. While this may inflate some of the estimates observed in this 
study, we would expect that this would occur non-differentially between locations of dwelling 
allowing our interpretation of the results to still remain valid. Also, the potential presence of a 
biased sample in the current study may not be a major problem since we were interested in 
asthma diagnostic differences within each location of dwelling as opposed to asthma prevalence 
differences across location of dwelling. The algorithm used to identify subjects for asthma in the 
current study incorporated ECT as part of the asthma case-detection procedure.30 While exercise-
induced bronchospasm resulting from ECT can also occur in individuals without asthma, ECT 
has demonstrated a 57% sensitivity and 90% specificity in identifying children with positive 
indication of asthma.46 To ensure that we were not falsely diagnosing asthma in some children, 
we reanalyzed the data excluding those with positive ECT. The results were similar to what we 
obtained when using ECT. Finally, participants in this study were from an urban-rural gradient in 
the province of Saskatchewan, Canada. Since our definition of urban-rural gradient parallels the 
Statistics Canada definitions which considers population size, density, and distance to 
metropolitan areas,21 our findings might also reflect similar urban-rural patterns in asthma 
diagnosis if children of similar age range were screened for asthma using same asthma algorithm 
in other provinces.  
Our study also had several strengths. We used a standardized and validated survey 
instrument.22,23 In addition to this, we used objective measures of lung health (spirometry and 
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ECT) as part of a well-developed and validated asthma case-detection algorithm30 across all the 
regions included in this study. This algorithm has high sensitivity (82%) and specificity (93%) 
when compared to clinical assessment of asthma by a physician as “gold standard”. Finally, all 
equipment, techniques, and quality control for testing were based on those recommended by 
standard guidelines17,18 and were identical across all locations so that bias in the observed urban-
rural differences in lung function would be minimized.  
In conclusion, there is little published information about an urban-rural gradient in 
asthma diagnosis. This study provides evidence of rural under-diagnosis of asthma and further 
supports the use of objective measures in addition to symptom history when investigating asthma 
across an urban-rural gradient.  Rural children with asthma-like symptoms following 
questionnaire screening who do not have physician-diagnosed asthma nevertheless were found to 
have reduced lung function. This provides important evidence that the often reported lower 
prevalence of asthma in rural compared to urban areas may be due, in part, to asthma under-
diagnosis in rural locations.  
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Table 4–1: Comparison of characteristics between participants in the 2013 baseline survey and those in the 2015 follow-up study 
 Did not complete the clinical 
testing phase 
(2013)  
(n = 3338) 
Completed the clinical 
testing phase 
(2015) 
(n = 335) 
p-value 
Personal characteristics    
Mean age (±SD), years 9.52 (2.76) 9.03 (2.52) <0.001 
% Female 50.6 48.5 0.46 
% > high school (maternal) 73.7 86.1 <0.001 
% > high school (paternal) 67.2 78.3 <0.001 
Ethnic background    
 % Caucasian  62.6 79.8 <0.001 
 % Others  37.4 20.2  
Tobacco smoke exposure    
% Maternal smoking 18.7 4.6 <0.001 
% Paternal smoking 24.3 12.9 <0.001 
% Either parent smoking 31.3 14.7 <0.001 
Indoor characteristics    
% Pet ownership 52.2 53.2 0.73 
% Dampness in home 16.3 19.2 0.18 
% Home mold 12.2 11.0 0.55 
% Air conditioner 71.2 76.7 0.04 
% Air filter 63.2 64.9 0.57 
% Humidifier 38.3 41.5 0.29 
Parental history of asthma and allergies    
% Parental history of asthma 16.9 20.9 0.07 
% Parental history of allergy 37.3 50.1 <0.001 
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Table 4–2: Socio-demographic, personal and environmental characteristics of the study population (n = 335) by location of dwelling 
 Location of dwelling 
 Large Urban  
(n = 246) 
Small Urban  
(n = 46) 
Rural  
(n = 43) 
p-value* 
Personal characteristics     
Mean age (±SD), years 10.8 (2.6) 11.0 (2.7) 12.7 (2.7) <0.001 
% Female 43.5 56.5 58.1 0.08 
Ethnic background      
 % Caucasian 78.3 73.9 93.0 0.05 
 % Others 21.6 26.1 7.0  
% > high school (maternal) 87.2 82.6 83.7 0.63 
% > high school (paternal) 81.6 73.8 64.3 0.03 
Secondhand tobacco smoke exposure     
% Maternal smoking 4.1 10.9 4.7 0.17† 
% Paternal smoking 7.9 20.5 7.1 0.02† 
% Either parent smoking 9.0 22.7 9.3 0.02† 
Indoor characteristics     
% Pet ownership 11.8 26.1 27.9 0.04 
% Dampness in home 20.1 31.8 31.0 0.10 
% Home mold 13.5 8.7 19.0 0.36 
Heating sources     
          % Natural Gas 97.1 100.0 70.7 <0.001† 
           % Electricity 2.2 0 4.9  
           % Others 0.8 0 24.4  
% Air conditioner 82.9 80.4 44.2 <0.001 
% Humidifier 37.0 10.9 16.3 <0.001 
Parental history of asthma and allergies     
% Parental history of asthma 19.9 30.4 16.3 0.20 
% Parental history of allergic disease 34.6 54.3 37.2 0.04 
Distance to healthcare     
Time travelled to access healthcare (±SD), minutes 12.7 (16.8) 12.8 (15.5) 40.93 (24.0) <0.001 
*p-values reflect ANOVA (for continuous variables) or χ2 test (for categorical variables) comparison for each characteristic. 
†Statistical difference assessed by the Fisher’s exact test because of small cell sizes (expected values <5). 
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Table 4–3: Profile of lung health indicators among at-risk-for-asthma and diagnosed asthma groups by location of dwelling 
 Location of dwelling 
At-Risk-for-asthma Large Urban (n = 89) Small Urban (n = 17) Rural (n = 15) p-value* 
% Ever wheeze 46.9 50.0 60.0 0.64 
% Current wheeze 16.1 23.5 33.3 0.26† 
% Chronic bronchitis 7.9 0 0 0.23† 
% Current cough 23.5 58.8 26.7 0.004 
% Cough disturbing sleep 43.8 52.9 46.7 0.78 
% Wheeze with exercise 51.7 58.8 73.3 0.28 
% Taking breathing medications past 12 months 22.7 11.8 13.3 0.46† 
Diagnosed asthma Large Urban (n = 70) Small Urban (n = 16) Rural (n = 9) p-value* 
% Current asthma 81.4 87.5 100.0 0.32† 
% Ever wheeze 86.4 80.0 100.0 0.37† 
% Current wheeze 56.1 53.3 66.7 0.80 
% Chronic bronchitis 1.4 6.3 33.3 0.003† 
% Current cough 42.9 62.5 55.6 0.31† 
% Cough disturbing sleep 48.6 68.8 44.4 0.31 
% Wheeze with exercise 78.6 87.5 87.5 0.63† 
% Taking breathing medications past 12 months 70.0 75.0 66.7 0.89† 
*p-values reflect χ2 tests comparison for each variable. 
†Statistical difference assessed by the Fisher’s exact test because of small cell sizes (expected values <5). 
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Table 4–4: Baseline mean (±SD) percent predicted lung function variables by location of dwelling and asthma status 
Location of dwelling 
Overall Large Urban (n = 219) Small Urban (n = 37) Rural (n = 32) p-value* 
FVC (L/s) 98.7 (12.7) 101.2 (9.6) 95.0 (10.9) 0.10 
FEV1 (L/s)
§ 96.0 (13.3) 98.2 (10.9) 89.3 (12.9)‡ 0.011 
FEV1/FVC 96.8 (6.9) 96.4 (6.6) 93.6 (10.1) 0.07 
FEF25%–75% (L/s)
§ 88.6 (23.1) 91.6 (20.2) 78.8 (20.4)‡‡ 0.040 
No asthma Large Urban (n = 77) Small Urban (n = 10) Rural (n = 13) p-value* 
FVC (L/s) 98.0 (10.1) 97.4 (8.7) 97.6 (9.5) 0.97 
FEV1 (L/s) 96.2 (11.4) 95.8 (13.9) 94.5 (9.7) 0.89 
FEV1/FVC 97.6 (5.8) 97.3 (8.5)  96.7 (8.3) 0.88 
FEF25%–75% (L/s) 90.0 (21.3) 92.2 (24.4) 87.7 (14.9) 0.87 
At-Risk-for asthma Large Urban (n = 75) Small Urban (n = 14) Rural (n = 14) p-value* 
FVC (L/s) 98.3 (13.9) 100.1 (10.3) 90.9 (12.3) 0.12 
FEV1 (L/s)
§ 96.7 (13.4) 98.0 (9.6) 82.1 (13.7)‡ <0.001 
FEV1/FVC§ 98.0 (6.0) 97.3 (5.01) 90.0 (12.3)‡ <0.001 
FEF25%–75% (L/s)
§  92.2 (23.0) 92.0 (17.4) 67.2 (22.2) ‡ <0.001 
Diagnosed asthma Large Urban (n = 67) Small Urban (n = 13) Rural (n = 5) p-value* 
FVC (L/s) 100.0 (14.1) 105.2 (8.4) 99.8 (7.8) 0.42 
FEV1 (L/s) 95.0 (15.2) 100.2 (10.1) 96.0 (8.7) 0.48 
FEV1/FVC 94.5 (8.5) 94.6 (6.7) 95.8 (2.5) 0.94 
FEF25%–75% (L/s) 83.1 (24.4) 90.7 (21.0) 87.8 (11.9) 0.54 
*p-values reflect ANOVA comparison for each lung function variable across locations of dwelling. 
§Scheffe pairwise post hoc comparisons: ‡p<0.05 (Rural compared to large urban and compared to small urban); ‡‡p<0.05 (Rural 
compared to small urban alone). 
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Figure 4–1: Mean lung function variables indicative of bronchial hyperresponsiveness (FEV1 and FEF25%–75%) at baseline and after 
cessation of exercise by location of dwelling and asthma status.  
**p<0.05 (Scheffe pairwise post hoc comparisons): Rural compared to large urban and compared to small urban children. 
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Questionnaire sent home 
(n=1348) 
Returned questionnaire 
335 (25%) 
No asthma 
119 (35.5%) 
Possible asthma‡ 
121 (36%) 
Probable asthma (A) 
95 (28%) 
Performed spirometry 
103 (84%) 
Performed spirometry 
85 (89%) 
Performed spirometry 
100 (83%) 
Positive for asthma (C) 
4 (3.9%) 
Negative for asthma  
99 (96.1%) 
Performed step test* 
99 (100%) 
Positive for asthma (B) 
2 (2%) 
Negative for asthma 
98 (98%) 
Performed step test* 
98 (100%) 
Negative for asthma  
77 (90.6%) 
Positive for asthma  
8 (9.4%) 
Performed step test* 
77 (100%) 
‡Children with asthma related symptoms but no survey report of physician-diagnosed asthma.  
*Positive for asthma based on > 15% decrease in FEV1 or ≥ 25% decrease in FEF25%–75% from baseline. 
Total new cases positive for asthma with spirometry and ECT: B + C + D + E = 21 subjects. 
Total positive for asthma with questionnaire, spirometry and ECT: A + B + C + D + E = 116 subjects. 
Positive for asthma  
22 (28.6%) 
Positive for asthma (E) 
8 (8.1%) 
No asthma 
91 (91.1%) 
Positive for asthma (D) 
7 (7.1%) 
No asthma 
91 (92.9%) 
Negative for asthma  
55 (71.4%) 
Figure 4–2: Asthma case-detection procedure based on the 3-stage asthma case detection algorithm by Gerald et al.30 
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Figure 4–3: Comparison of proportion of survey-based vs. algorithm-based children with a positive indication of asthma by location of 
dwelling.  
*Statistically significant when compared to proportion of cases detected with questionnaire alone (p<0.05) based on McNemar’s test. 
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5.1 Abstract 
Background: Both protective and risk associations have been reported between microbial 
exposures and childhood asthma. The paradoxical relationships may be dependent on asthma 
phenotype of children with the disease.  
Objective: We investigated the associations between exposure to endotoxin and beta-(1→3)-D-
glucans in house dust with atopic asthma and exercise-induced bronchospasm in children with 
asthma.     
Methods: A clinical cross-sectional study was performed among 335 schoolchildren (aged 7–17 
years) in the province of Saskatchewan, Canada. Children with asthma were identified (n = 
116/335) by a validated algorithm that included questionnaire diagnosis and clinical testing. 
Atopic asthma status was determined by skin prick testing while exercise-induced bronchospasm 
was evaluated by exercise challenge testing. Levels of endotoxin and beta-(1→3)-D-glucans 
exposures were measured in dust samples from the child’s mattress and play area floors. Logistic 
regression analyses were used to explore associations between endotoxin and beta-(1→3)-D-
glucan with each asthma phenotype separately. 
Results: Among the 116 children with asthma, 44.4% were atopic and 22.4% had exercise-
induced bronchospasm. Exposure to high play area endotoxin concentration [adjusted odds ratio 
(aOR) = 0.15, 95%CI: 0.02–0.95] and load (aOR = 0.13, 95%CI: 0.02–0.99) were associated 
with decreased risk of atopic asthma, independent of beta-(1→3)-D-glucan exposure. In contrast, 
exercise-induced bronchospasm was positively associated with high mattress endotoxin 
concentration (aOR = 7.80, 95%CI: 1.13–53.69). There were no consistent and significant 
associations between beta-(1→3)-D-glucan and atopic asthma or exercise-induced 
bronchospasm. 
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Conclusion: The study demonstrated that the association with indoor microbial exposure may 
depend on asthma phenotypes. The lack of association with beta-(1→3)-D-glucan indicates that the 
effect might be particularly attributable to endotoxin. 
Keywords: Asthma phenotypes, Atopic asthma, Exercise-induced bronchospasm, House dust, 
Endotoxin, Beta-(1→3)-D-Glucan, Children 
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5.2 Introduction 
Indoor microbial exposure has been suggested to influence the presence of respiratory disorders, 
including childhood asthma.1 However, the associations are conflicting. Endotoxin has been 
reported to have protective,2,3 risk effects,4–6 and no association7,8 for childhood asthma. Similar 
protective9–11 and risk12,13 effects have also been observed for beta-(1→3)-D-glucan. Reasons for 
the paradoxical effects are unclear but could be linked to different presentations of the disease in 
children with asthma.    
This is further justified given that asthma is a complex disease with multiple presenting 
phenotypes, including allergic and non-allergic asthma. Previous studies of endotoxin have 
shown more consistent associations with allergic sensitization.3,14,15 Studies have also shown that 
exposure to endotoxin is inversely associated with asthma and wheeze among atopic 
children.16,17 Beta-(1→3)-D-glucans have also been found to have such reduced effects on 
recurrent wheezing10 but positively associated with impaired lung function, primarily among 
atopic children.18 
Endotoxin is a component of the outer cell wall of gram-negative bacteria capable of 
initiating strong immune modulatory and pro-inflammatory responses.19,20 Similarly, beta-
(1→3)-D-glucan, a structural component of cell wall of most fungi, is a potent agent capable of 
inducing adverse and protective effects for respiratory health effects.3,18 As such, endotoxin and 
beta-(1→3)-D-glucan exposures may exhibit varied patterns of associations for asthma, resulting 
in differential clinical presentation in children who have the disease.   
Furthermore, in both allergic and non-allergic asthma, bronchial hyperressponsiveness 
(BHR) represents a predominant feature of clinical presentation.21 Exercise-induced 
bronchospasm (EIB) is one method of assessing BHR, but currently there are limited studies 
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investigating the effects of house dust endotoxin and beta-(1→3)-D-glucan exposures on EIB 
among children with asthma.  
In the present study, we investigated the association between house dust endotoxin and 
beta-(1→3)-D-glucan exposure with asthma phenotypes based on atopic sensitization or EIB in 
children with asthma. We hypothesized that exposure to high levels of house dust endotoxin and 
beta-(1→3)-D-glucan will be inversely related to atopic asthma but positively related to EIB. 
This may provide some insight into the clinically relevant effects of indoor microbial exposures 
and asthma phenotypes among children with asthma for better childhood asthma management. 
5.3 Methods 
5.3.1 Study population, selection, and recruitment 
We conducted a cross-sectional study among schoolchildren with asthma (aged 7–17 years) in 
the province of Saskatchewan, Canada from 2015–2016. Participants in this study were part of 
an initial 2013 cross-sectional survey of schoolchildren as previously described.22 In the 2013 
survey, those who consented to participate in further testing were re-approached in 2015. At this 
time, we repeated the survey and completed clinical testing (spirometry, exercise challenge 
testing, and skin prick test) as well as home dust sample collection. A total of 335 schoolchildren 
completed the survey. 
The study was approved by the University of Saskatchewan Biomedical Research Ethics 
Board (Bio #: 14–162). Completion and return of the survey implied voluntary consent for the 
questionnaire portion. All children and a parent provided written assent and consent, 
respectively, prior to clinical testing and home dust collection. Furthermore, all school divisions 
involved approved the study. 
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5.3.2 Survey questionnaire 
We used standardized and validated questions from the International Study of Asthma and 
Allergy in Childhood (ISAAC),23,24 the American Thoracic Society Children’s Respiratory 
Disease,25 and questionnaires used previously in the Saskatchewan Lung Health studies2,26 to 
obtain information on respiratory health (including physician-diagnosed asthma), general health, 
parental health history, environmental exposure, sociodemographic factors as well as housing 
characteristics. A total of 335 schoolchildren completed and returned the survey questionnaire.  
5.3.3 Spirometry and exercise challenge testing (ECT) 
Of the 335 subjects with survey responses, 288 (86%) performed spirometry and ECT. During 
home or school visits, trained field technicians performed spirometry assessments according to 
recommended standards for children.27,28 Measurements of forced expiratory volume in one 
second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow 
(FEF25%–75%) were done using the Easy-on PC spirometer (ndd Medical Technologies, Zurich, 
Switzerland). Some subjects were excluded from testing because they were unable to perform the 
test due to existing medical conditions (n = 3).  
ECT was also completed based on recommended protocols.29 Briefly, children stepped up 
and down on a 6 inch step at a heart rate between 150–200 beats per minute for 5 minutes. Heart 
rates were monitored throughout the exercise with a Polar heart rate monitor (Polar Electro, 
Woodbury, NY). Spirometry was repeated 3 and 10 minutes after cessation of exercise.  
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5.3.4 Skin prick test (SPT) 
All SPTs were completed at the school or during home visits. Tests were completed on the 
forearm using a panel of six common and standardized allergen extracts according to 
recommended protocol:30 cat, local grass, Aspergillus, Alternaria, Cladosporium, and house dust 
mite (Omega Laboratory, Montreal QC, Canada). Two controls: a histamine positive control and 
a saline negative control were used to reduce false positives and false negatives. The wheal size 
diameter was measured after 15 minutes. Subjects was considered positive for atopy if a positive 
reaction to at least one of the applied allergens is raised ≥3 mm compared to the saline control. 
All SPTs in the study were performed by trained technicians who were blinded to the asthma 
status of each child. 
5.3.5 Classification of asthma 
The asthma classification criteria was based on the validated asthma case-detection algorithm.29 
This algorithm has high sensitivity (82%) and specificity (93%) when compared to clinical 
assessment of asthma by a physician as “gold standard”. Based on the parental response to the 
questionnaire, children were classified as “diagnosed asthma” if they had positive responses to 
the questions: “Has this child ever been diagnosed as having asthma by a doctor?” and/or “Has 
this child taken prescribed asthma medication in the past 12 months?” Children who were 
otherwise classified as “no asthma” based on survey responses but who had FEV1/FVC ratio 
<80% upon spirometry testing; or demonstrated a >15% decrease in FEV1 or a ≥25% decrease in 
FEF25%–75% from baseline after cessation of exercise were considered to be positive for 
asthma.31,32 Overall, a total of 116 children were identified to have asthma and formed the study 
population for the results reported in the current study.  
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5.3.6 Classification of asthma phenotypes  
Two phenotype-defined asthma outcomes were considered in the current study. This included 
phenotype assessment based on: 1) atopic status (atopic vs. non-atopic asthma) for the n = 116 
children with asthma, and 2) EIB status also for the n = 116 children using the ECT results (EIB 
vs. no EIB). Atopic asthma was defined as sensitization (≥3 mm in wheal diameter compared to 
saline control after 15 minutes) to one or more allergens from SPT in the presence of diagnosed 
asthma. EIB was defined as >15% fall in FEV1 from baseline after cessation of exercise.   
5.3.7 Collection and analysis of dust samples to quantify endotoxin and beta-(1→3)-D-glucan 
exposure  
Vacuumed dust samples were obtained from the floor of play area and from mattress surfaces by 
trained personnel according to standardized protocols.33 Briefly, carpet floors had 2 m2 
vacuumed while smooth floors had 4 m2 vacuumed. Dust collection from the mattress surfaces 
was completed after all duvets, blankets and sheets that the child slept under were removed. The 
entire surface area of the mattress was then vacuumed for 2 minutes. Dust samples were 
weighed, sieved through a 300 µm mesh sieve, and stored desiccated at 4C until extraction and 
analysis.  
 Prior to analysis, samples were brought to room temperature and 10 mg of sieved dust 
was weighed out for extraction. Dust samples were extracted with 20 mL 0.05% Tween 20 
(Fisher Scientific, Mississauga, ON, Canada) in pyrogen-free water (GE Healthcare Bio-Science, 
Mississauga, ON, Canada)34 and shaken at 325 revolutions per minute (RPM) for 2 hours. The 
extracted solution was then centrifuged (Sorvall ST 16R, Thermo Fisher Scientific, Mississauga, 
ON, Canada) at 1000 x g for 15 minutes to obtain supernatant and 1 mL aliquots were stored at -
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80ºC until analysis. An aliquot of the supernatant was diluted 1 in 10, and was used to measure 
endotoxin by the chromogenic Limulus Amoebocyte Lysate (LAL) Kinetic QCL assay according 
to manufacturer’s specifications (Lonza, Walkersville, MD, USA). Water soluble fraction of 
beta-(1→3)-D-glucan was measured in the second aliquot using the Glucatell assay kit with a 
beta-(1→3)-D-glucan-specific inhibition enzyme based on the Kinetic Onset Time protocol 
according to manufacturer’s specifications (Associate of Cape Cod, East Falmouth, MA, USA).35  
To quantify endotoxin and beta-(1→3)-D-glucan levels, the absorbance of endotoxin and 
beta-(1→3)-D-glucan was monitored at 405 nm for 2 hours and 1 hour, respectively, using the 
Biotek ELx808 plate reader and Gen5 v 2.06 software (BioTek, Winooski, VT, USA). Values 
were compared to standard curves prepared for endotoxin (0.005 EU/mL–50 EU/mL) and beta-
(1→3)-D-glucan (3.125 pg/mL–100 pg/mL). Endotoxin and beta-(1→3)-D-glucan levels were 
recorded as concentration (per gram of sampled dust) and load (per square meter of sampled 
area); expressed as EU/mg and EU/m2 for endotoxin and µg/g and µg/m2 for beta-(1→3)-D-
glucan. Results were reported as such given that concentration and load represent different 
aspects of indoor microbial exposure (dose and burden).36 To ensure quality, the assays were 
conducted using reagents from a single lot. Laboratory technicians were blinded to disease status 
of each child and to the indoor location where each dust was sampled (i.e. whether sample was 
from child’s play area or mattress surface). 
5.3.8 Statistical analysis 
Categorical variables were compared, separately for atopic vs. non-atopic and EIB vs. no EIB, 
using the independent samples chi-square (χ2) and Fisher’s exact tests as appropriate while 
continuous variables were compared using the independent sample Student t-test. Mean 
endotoxin and beta-(1→3)-D-glucan concentration and load for play area and mattress were 
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expressed as geometric mean (GM). Correlation between log transformed play area and mattress 
endotoxin and beta-(1→3)-D-glucan was also assessed using Pearson’s correlation coefficient 
(r). 
Multiple logistic regression models were then fitted to test the association between 
endotoxin and beta-(1→3)-D-glucan exposure with asthma phenotypes expressed as either atopic 
vs. non-atopic asthma (non-atopic asthma as reference) or EIB vs. no EIB (no EIB as reference). 
Separate independent models were fitted for each of play area and mattress dust including: i) a 
univariate model for each endotoxin (concentration and load) and beta-(1→3)-D-glucan 
(concentration and load); ii) main effects model for endotoxin; iii) main effects models for beta-
(1→3)-D-glucan; and iv) main effects plus endotoxin and beta-(1→3)-D-glucan. Variables were 
included in the models based on statistical significance identified in the univariate analyses, 
clinical importance, and the effect the removal of a variable had on the beta coefficient of other 
variables in the model.37 The additional variables included in the model were sex, age, parental 
education (≤ high school vs. > high school), parental smoking (yes vs. no), parental history of 
asthma and allergy (yes vs. no), pet ownership (yes vs. no), home dampness (yes vs. no), and 
location of residence (urban vs. rural). Endotoxin and beta-(1→3)-D-glucan remained, a priori, 
in all models. Levels of endotoxin and beta-(1→3)-D-glucan were modelled as categorical 
variables in tertiles to define low (1st tertile), medium (2nd tertile), and high (3rd tertile) levels 
because the relationships with moderate/severe asthma did not meet the linear assumption when 
log-transformed (ln) endotoxin and beta-(1→3)-D-glucan were used. Low (1st tertile) was used 
as reference level. Throughout the analyses, generalized estimating equations (GEE) were used 
to account for clustering within families. The Hosmer-Lemeshow test was used to assess model 
Goodness-of-Fit. 
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The strength of the associations were assessed using odds ratios (ORs) and their 95% 
confidence interval (CI). Statistical significance was defined by an alpha level of p≤0.05. All 
analyses were completed with the Statistical Package for the Social Science (SPSS) Version 24 
(SPSS Inc. Armonk, NY: IBM Corp.) and the Statistical Analysis System (SAS) Version 9.4 
(SAS Institute Inc., Cary, NC, USA).   
5.4 Results 
5.4.1 Subject characteristics, respiratory symptoms and exposure characteristics 
Of the 116 children identified with asthma, 99 (85.3%) completed SPT while all had completed 
ECT. Of these, 71/99 (71.7%) were atopic and 26/116 (22.4%) had EIB. When we considered 
overlap in phenotype categories, 54 (54.5%) had atopic asthma alone, 6 (6.1%) had EIB alone, 
17 (17.2%) had both atopic asthma and EIB, and 22 (22.2%) had non-atopic asthma and no EIB. 
Table 5–1 presents an overview of the distribution of socio-demographic, home characteristics, 
and early life characteristics when phenotypes were assessed as atopic vs. non-atopic or as EIB 
vs. no EIB. The distribution of sex and age were similar between atopic and non-atopic asthma 
groups. However, compared to children with atopic asthma, children with non-atopic asthma 
were more likely to live in modern homes (p=0.03). Children with no EIB, on average, were 
older with a higher BMI and were more likely to have parents with history of allergic disease 
compared to children with EIB (p<0.05). The distribution of all other characteristics was similar 
and not statistically significant between the asthma phenotype groups. Respiratory symptoms 
were also similar among the asthma groups except for ever wheeze which was significantly 
higher in EIB compared to no EIB group (Table 5–2).  
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Endotoxin and beta-(1→3)-D-glucan were at detectable levels in all house dust samples 
(Appendix 10). Overall, endotoxin ranges were as follows: play area (2.20 EU/mg–6.55 EU/mg 
and 8.19 EU/m2–12.76 EU/m2); and mattress (0.69 EU/mg–6.21 EU/mg and 6.02 EU/m2–12.18 
EU/m2) (Appendix 10). Geometric mean endotoxin and beta-(1→3)-D-glucan levels in play 
areas and mattresses did not differ when we compared atopic to non-atopic asthma or EIB to no 
EIB groups (Table 5–3). Play area endotoxin load correlated with play area beta-(1→3)-D-
glucan load (r = 0.43, p<0.001). Similarly, mattress endotoxin concentration correlated with 
mattress beta-(1→3)-D-glucan concentration (r = 0.44, p<0.001). All other correlations, though 
statistically significant, were generally weak (r<0.3) (Appendix 11). 
5.4.2 Associations between house dust endotoxin and beta-(1→3)-D-glucan exposure levels 
and atopic asthma  
When asthma phenotypes were assessed based on atopic status only, unadjusted regression 
analyses showed that high play area endotoxin concentration and load were negatively associated 
with atopic asthma (OR = 0.25, 95%CI: 0.07–0.91) (Table 5–4). Multiple logistic regression 
analysis (Model II) showed similar statistically significant associations in the high endotoxin 
group [endotoxin concentration: adjusted odds ratio (aOR) = 0.15, 95%CI: 0.03–0.86; endotoxin 
load: aOR = 0.11, 95%CI: 0.02–0.75]. To determine if the associations found for high play area 
endotoxin concentration and load were independent of beta-(1→3)-D-glucan levels, we adjusted 
for beta-(1→3)-D-glucan concentration and load as appropriate in addition to covariates included 
in Model II (Model IV). Independent of play area beta-(1→3)-D-glucan levels, the negative 
association between atopic asthma and high play area endotoxin concentration (aOR = 0.15, 
95%CI: 0.02–0.95) and load (aOR = 0.13, 0.02–0.99) remained significant.  
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5.4.3 Associations between house dust endotoxin and beta-(1→3)-D-glucan exposure levels 
and exercise-induced bronchospasm 
Table 5–5 presents the associations between endotoxin and beta-(1→3)-D-glucan with EIB when 
phenotypes were assessed based on ECT, irrespective of atopic status. Exposure to high level of 
mattress endotoxin concentration was significantly associated with EIB both at the univariate 
level (OR = 4.64, 95%CI: 1.15–18.75; Model I) and after adjusting for potential covariates (aOR 
= 6.13, 95%CI: 1.12–33.52; Model II). We also determined whether the increased risk of EIB 
associated with high mattress endotoxin concentration was related to beta-(1→3)-D-glucan 
levels in the mattress dust (Model IV). The results showed that independently of mattress beta-
(1→3)-D-glucan concentration and other potential confounders identified in Model II, the 
positive association between mattress endotoxin concentration and EIB remained statistically 
significant and became stronger (aOR = 7.80, 95%CI: 1.13–53.69). The associations for beta-
(1→3)-D-glucan exposure levels with EIB were inconsistent and non-significant whether 
expressed as concentration or as load.  
5.5 Discussion 
In the current study, high endotoxin measures in play area dust were inversely associated with 
atopic asthma. When asthma was assessed based on EIB status, this pattern was reversed with 
EIB positively associated with high mattress endotoxin concentration. Beta-(1→3)-D-glucan 
levels in house dust showed no significant effect neither on atopic asthma nor EIB.  
In the Allergy and Endotoxin Study (ALEX) conducted among children (aged 6–13 
years) in Austria, Germany, and Switzerland,16 Braun-Fahrlander et al demonstrated that 
endotoxin load in samples of dust derived from children’s mattresses were inversely associated 
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with atopic asthma. Consistent with results in this previous study, we also demonstrated an 
inverse relationship between high endotoxin levels and atopic asthma, but the associations were 
limited to play area endotoxin levels. It may be difficult to directly compare our results with the 
ALEX study because the study modelled endotoxin as continuous variable while we modelled it 
as a categorical variable based on tertiles. However, our study results are similar to the results of 
a cross-sectional study in Palestine among 6–12 years old children38 where medium and high (the 
second and third tertiles) endotoxin levels in play area floor dust were found to be inversely 
associated with atopic wheeze (report of wheeze in the past 12 months) in a dose response 
manner.  
In the current study, the association between atopic asthma and endotoxin exposure was 
not consistent between the two locations of dust sampling (play areas and mattress surfaces). 
While studies have shown that mattress endotoxin levels decreased the risk of allergic 
sensitization15,39 and atopic asthma,16 we expanded on previous studies by showing that, among 
children with asthma, the associations may be limited to play area endotoxin. Reasons for the 
observed associations are unclear in this study but may be related to differences in the 
determinants of endotoxin in different locations in the homes2,26 (Appendix 12) or differences in 
endotoxin’s length of 3-hydroxyl fatty acids (3-OHFAs) chain.40 In a US study that characterized 
the types of endotoxin in house dust samples based on the length of fatty acid chain, Park et al40 
showed that shorter-chain 3-OHFAs (C10:0, C12:0, and C14:0) were positively correlated with 
endotoxin activity while longer-chain groups tend to have negative correlation (C16:0) or no 
correlation (C18:0). Furthermore, mattress dust endotoxin contained longer-chain 3-OHFA (C16:0) 
while dusts from family room area floors contained predominantly shorter-chain 3-OHFAs 
(C10:0, C12:0, and C14:0). These observations may explain some of the inconsistencies in reported 
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associations between indoor endotoxin levels and respiratory diseases. For example, a study 
among 2,209 schoolchildren (aged 11–15 years) in China found reduced risk of respiratory 
symptoms (wheeze and attack of breathlessness) with shorter endotoxin 3-OHFA chain while 
longer 3-OHFA chain lengths tended to be positively associated with respiratory symptoms.41 
Similar results were also observed for wheeze with shorter lengths of endotoxin 3-OHFA in a 
Malaysian study.42 Based on the presence of shorter 3-OHFA chain length in play area floor dust 
compared to mattress dust 40 coupled with reduced risk of respiratory symptoms associated with 
shorter endotoxin 3-OHFA in the China41 and Malaysia42 studies, it is plausible that the 3-OHFA 
in our samples may also differ in chain length structures between play area and mattress dust 
endotoxin. This may assist in explaining our results.  
There is evidence that inhaled endotoxin exposure can induce BHR. However, these 
effects have only been found in adults43,44 and an animal study.45 In a clinical bronchial challenge 
test among adults with asthma in Belgium, Michel et al44 found a significant reduction in FEV1 
(≥10% decrease) which lasted between 15–45 minutes following inhalation of 20 µg of 
endotoxin extract. Similarly, a study in Australia showed significant BHR (measured as 
increased influx of neutrophil into bronchoalveolar lavage fluid [BALF]) in rats challenged with 
lipopolysaccharide (LPS: a major constituent of bacterial endotoxin) if exposure occurs early in 
the sensitization process.45 We also found similar trends of associations in the current study, 
albeit with a different bronchial challenge test (exercise challenge test) and source of endotoxin 
exposure (settled house dust). High mattress endotoxin level was significantly associated with 
increased risk of EIB. Furthermore, the result suggests that EIB response to endotoxin may be 
dose related with a statistically significant and stronger association found for high endotoxin 
exposure (aOR = 7.80, 95%CI: 1.13–53.69) than for the association at medium endotoxin 
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exposure (aOR = 2.46, 95%CI: 0.35–17.55) endotoxin exposure levels. This is consistent with 
dose-response relationship results observed in an endotoxin exposure challenge test study among 
77 adults which demonstrated significant bronchoconstriction (decreased in FEV1) following 
inhalation of 200 µg of endotoxin extract compared to inhalation of 30 µg.46  
Associations between play area endotoxin levels and EIB were not found in the present 
study. Possible explanations for the presence of EIB and high mattress endotoxin concentration 
and the lack of it for play area endotoxin levels may also be that children come into closer 
contact with microbial agents while sleeping and or differences in play and mattress areas 
endotoxin’s structure. Mattress dust contains longer-chain 3-OHFA40  and it is suggested that 
longer-chain 3-OHFAs (C12:0–C14:0) may elicit stronger and significant potent immunological 
effects compared to shorter-chain 3-OHFAs.47 Furthermore, studies have shown mattress dust to 
be the most reproducible source of house dust exposure48 with non-significant variation over a 
six-month period49 compared to play areas which may be regularly vacuumed.  
Exposure to beta-(1→3)-D-glucan has been suggested to be inversely related to 
wheezing10 and atopic sensitization10,15 and positively associated with atopic asthma13 and 
BHR.13,18 We observed non-significant trend towards reduced risk of atopic asthma linked to 
high play area beta-(1→3)-D-glucan levels. While this may be due to a low sample size, it is also 
possible that the relationship between beta-(1→3)-D-glucan exposure and childhood asthma may 
activate an independent pathway different from that associated with endotoxin exposure. In other 
words, the relationships may not be based on allergic reactions since, in most cases, beta-(1→3)-
D-glucan has been considered as non-immunogenic or non-allergic in humans.18  
Causation of childhood asthma remains poorly understood and most studies have ignored 
the distinction between atopic and non-atopic asthma even though these phenotypes may have 
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distinction mechanisms.50 The mechanism by which endotoxin is related to childhood asthma 
and allergy is still unclear but is currently believed to be linked to the imbalance between TH1 
and TH2 immune response cells. Allergic diseases are typically characterized by predominance of 
TH2 cells.
51 However, exposure to high levels of endotoxin inhibits the TH2 immune response 
and promotes TH1 immune responses, preventing atopic immune development and associated 
diseases.38,52 On the other hand, endotoxin is also considered as a pro-inflammatory agent  
potentiating the release of inflammatory mediators such as allergic release of histamine and 
neutrophils to induce BHR in humans.53 However, the presence of EIB in non-atopic subjects in 
the present study (6.1%) may further suggest that response to endotoxin exposure in children 
with asthma could also be mediated by a non-allergic mechanism. Investigations that 
demonstrate absence of an immediate skin prick test response to endotoxin extracts in atopic 
subjects may help to validate the claim for non-allergic mechanism.      
Consistent with the paradoxical effects of endotoxin exposure, we demonstrated that 
while endotoxin may protect from atopic asthma, it could also induce bronchoconstriction in 
children with existing asthma. It is interesting therefore to speculate that exposure to endotoxin 
may be involved in different pathways of the innate immune systems and thus different asthma 
phenotypes. For example, it is possible that associations with EIB represent acute effects of 
endotoxin exposure in children with asthma while the inverse association with atopic asthma 
may reflect long-term immune response, possibly from early life exposure, which shifts the 
immune response away from the atopic TH2 cells towards the less allergic TH1 to mitigate allergy 
and asthma.2,54 This is further evidenced from a study in Australia which demonstrates that LPS 
exposure has the potential to prevent allergic disease in rats only if the exposure occurs early (≤6 
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days) in the sensitization process.45 Beyond the 6 days period, such exposure further exacerbates 
allergic response and BHR.       
High endotoxin levels in the indoor environment could coexist with high beta-(1→3)-D-
glucan levels.13 Due to this, it may be difficult to consider the exposures independently. To 
parcel out the independent effects of endotoxin on the study outcomes, we adjusted for beta-
(1→3)-D-glucan levels in our endotoxin analysis models. The results showed no indications of 
stronger effects of endotoxin on either atopic asthma (Table 5–4 Model IV) or EIB (Table 5–5 
Model IV) compared to models without beta-(1→3)-D-glucan adjustment (Atopic asthma: Table 
5–4 Model II; EIB: Table 5–5 Model II). Similar analyses have been performed in a previous 
study in the Netherlands investigating the relationships between house dust endotoxin and beta-
(1→3)-D-glucan levels and peak expiratory flow (PEF) variability in children.18 In this study, 
however, the significant effect of endotoxin exposure on PEF variability from univariate analysis 
was lost following multivariate analysis which included adjustment for house dust beta-(1→3)-
D-glucan level. The methodological differences in defining outcome variables in our study 
(atopic asthma and EIB) and that of the Netherlands study (PEF variability) might have 
accounted for the observed varied results.     
While house dust beta-(1→3)-D-glucan has been shown to be positively associated with 
wheezing in infants10 and atopic sensitization in children (aged 2–4 years),15 our results suggests 
that that the associations between indoor endotoxin exposure, and atopic asthma as well as EIB 
may occur independently of beta-(1→3)-D-glucan levels in the indoor environment. This 
indicates that endotoxin exposure in the indoor environment may be more important to consider 
than beta-(1→3)-D-glucan.  This finding requires further confirmation and should be interpreted 
with caution due to relatively small sample size of the study; and also because a measure of 
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endotoxin does not capture all microbial exposure and qualitative differences in exposure which 
has been shown to better predict childhood asthma outcomes compared to single microbial 
marker55 should be completed. 
Limitations of our study should be considered. The participation rate for this study was 
low. It is important to note that participants in this study were recruited from urban and rural 
locations and were frequently hard to reach, especially those in rural locations. However, as our 
results indicated statistical significance for endotoxin, we believe that the power of the study was 
sufficient. The non-significant findings of beta-(1→3)-D-glucan exposure may partly be 
explained by other factors such as the non-immunogenic or non-allergic properties of beta-
(1→3)-D-glucan in humans18 or inadequate statistical power. We cannot exclude the possibility 
of selective avoidance as another potential source of bias in this study. For example, it is possible 
that allergic parents might tend to keep a cleaner indoor environment that could reduce exposure 
to dust as previously observed.56 We feel that there is no indication that this bias affects the 
results of our study. First, the results of the distribution of parental history of allergic disease 
were similar between atopic and non-atopic children with asthma (60% vs. 57%; p=0.76). 
Second, the associations between indoor endotoxin levels and home cleaning habits by parents 
have been shown to not differ by atopic status in previous studies.57,58 We used dust samples 
collected at a single time-point. While seasonal variation in house dust levels and microbial 
components may exist,59,60 a single time-point dust sample collection has been the most 
commonly used method in epidemiological studies due to convenience and cost constraints. In 
addition, provided sampling procedures are standardized, studies showed that sampling of settled 
dust is reproducible and that a single dust sampling for endotoxin analysis have little variation 
over time and reflects longer-term exposure to microbial products for at least 1 year period.61 We 
  
181 
 
acknowledge that this may not be true for all populations and there should be caution when 
comparing the results of this study to other studies that have used dust samples collected at 
multiple and different time intervals. Data collection for this study was at one point in time and 
used prevalent asthma cases. Therefore, the cross-sectional observational design of the study 
precludes us from drawing conclusion about causality.62 However, support for our findings 
comes from longitudinal study which showed reduced allergic sensitization in children following 
endotoxin exposure3 and animal studies which demonstrate significant BHR in rats challenged 
with LPS.45 Finally, the dust extraction analysis procedure used in this study is specific in 
determining the water soluble fraction of beta-(1→3)-D-glucan63 which may not represent the 
most potent fraction of beta-(1→3)-D-glucan compared to alkaline soluble fraction.64 This may 
be one of the reasons, in addition to small sample size, beta-(1→3)-D-glucan levels were not 
statistically associated with neither atopic asthma nor EIB in the current study. 
The strengths of our study included the use of objective measures for exposure and 
outcome assessments thus limiting the possibility of recall bias for the associations reported 
herein. We also used an established algorithm of case finding to minimize misclassification of 
asthma status.29 Clinical data and dust samples were collected by trained technicians using 
standardized protocols.27,28,30,33 Laboratory personnel were blinded to asthma status of each 
child. Furthermore, home dust collection was conducted concurrently with clinical data. Finally, 
we studied the effects of endotoxin and beta-(1→3)-D-glucan, simultaneously, on objectively 
measured asthma phenotypes (atopic and EIB) among children with asthma. Current studies that 
have assessed similar relationships between endotoxin exposures and BHR have only been 
conducted in adults43,44 and animal model.45  
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In summary, we demonstrated that environmental exposure to indoor microbial products 
as assessed by the measurement of house dust endotoxin levels was inversely associated with 
atopic asthma but positively associated with EIB in children with preexisting asthma conditions. 
Furthermore, the lack of association with beta-(1→3)-D-glucan levels, either when assessed 
separately or included in models for endotoxin, may indicate that the effects might be particularly 
attributable to endotoxin. 
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Table 5–1: Characteristics of the study population (n = 116) by asthma phenotype groups 
 Atopic 
asthma  
(n = 71)* 
Non-atopic 
asthma 
(n = 28)* 
p-value Exercise-induced 
bronchospasm  
(n = 26) 
Absence of  Exercise-
induced bronchospasm 
 (n = 90) 
p-value 
Mean age (±SD), years 10.9 (2.7) 11.0 (2.5) 0.86 10.0 (2.8) 11.3 (2.6) 0.04 
Body mass index (±SD), kg/m2 20.3 (5.0) 21.0 (4.8) 0.55 18.3 (2.6) 21.2 (5.3) <0.001 
% Female 32.4 32.1 0.98 26.9 37.8 0.31 
Ethnic background       
 % Caucasian 81.0 75.0 0.52 79.2 82.1 0.77† 
 % Others 19.0 25  20.8 17.9  
Physical activity       
   % Low 1.4 7.1 0.31 0.0 4.4 0.55 
   % Moderate 31.0 32.1  34.6 34.4  
   % High 67.6 60.7  65.4 61.1  
Parental education level       
% > high school (maternal) 80.0 88.9 0.38 84.0 83.1 1.00† 
% > high school (paternal) 76.1 84.6 0.37 91.7 75.6 0.09 
Tobacco smoke exposure       
% Parental smoking 13.2 14.3 1.00† 15.4 11.5 0.73† 
% Environmental tobacco smoke 7.0 10.7 0.68† 0.0 11.2 0.11 
Home characteristics       
% Modern home: 1980–Present 36.9 61.5 0.03 36.0 47.6 0.31 
% Gas heating 97.1 92.6 0.61† 96.2 94.2 0.36† 
% Home air filter 47.9 50.0 0.85 57.7 48.9 0.43 
% Home humidifier 28.2 28.6 0.97 30.8 28.9 0.85 
% Pet ownership 57.7 57.1 0.96 57.7 58.9 0.91 
% Carpet flooring 58.2 71.4 0.28 70.0 54.9 0.22 
% Home dampness 25.7 22.2 0.72 15.4 27.3 0.22 
% Visible mold 10.4 7.7 1.00† 12.5 11.6 1.00† 
Family history       
% Parental history of asthma 36.6 39.3 0.81 26.9 36.7 0.36 
% Parental history of allergic 
disease 
60.6 57.1 0.76 42.3 65.6 0.03 
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Early life characteristics       
% Breastfed 81.5 96.4 0.10 84.0 88.2 0.73 
% Attended daycare 70.8 69.2 0.89 72.0 66.3 0.59 
% Consumed raw farm milk 5.6 0 0.5† 3.8 5.6 1.00† 
% Contact with farm buildings 16.4 11.1 0.75† 15.4 18.1 1.00† 
% Contact with farm animals 15.9 14.8 1.00† 11.5 18.6 0.56† 
Intrauterine exposure 
characteristics 
      
% Mother consumed farm milk 0 3.6 0.28† 0.0 1.1 1.00† 
% Mother contact with farm 
animals 
12.7 14.3 1.00† 3.8 14.4 0.19† 
Location of residence       
% Urban 91.5 85.7 0.46† 96.2 84.4 0.19† 
% Rural 8.5 14.3  3.8 15.6  
*99/116 of the children identified to have asthma completed SPT.  
†Statistical difference assessed by the Fisher’s exact test due to small cell sizes (expected values <5). 
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Table 5–2: Respiratory symptoms among subjects by asthma phenotype status  
 Atopic asthma  
(n = 71) 
Non-atopic asthma 
(n = 28) 
p-value EIB 
(n = 26) 
No EIB 
 (n = 90) 
p-value 
Respiratory symptoms 
% Ever wheeze 75.4 80.0 0.64 84.7 50.0 <0.001 
% Wheeze past 12 month 51.4 48.0 0.77 52.9 40.0 0.26 
% Cough past 12 months 47.9 42.9 0.65 30.8 47.8 0.12 
% Chest congestion 13.8 22.2 0.36† 19.2 15.9 0.69 
% Chronic bronchitis 1.4 3.6 0.49† 3.8 4.4 1.00† 
% Nasal congestion 43.7 33.3 0.35 46.2 40.4 0.60 
% Hay fever 9.9 7.1 1.00† 3.8 10.0 0.45† 
†Statistical difference assessed by the Fisher’s exact test due to small cell sizes (expected values <5). 
EIB: Exercise-induced bronchospasm. 
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Table 5–3: Geometric mean of endotoxin and beta-(1→3)-D-glucan concentration and load in house dust from the play area floor and 
mattresses by asthma phenotypes 
 Atopic 
asthma  
(n = 71) 
Non-atopic 
asthma 
(n = 28) 
p-value EIB 
(n = 26) 
No EIB 
 (n = 90) 
p-value 
Play area GM (GSD) GM (GSD)  GM (GSD) GM (GSD)  
Endotoxin concentration (EU/mg) 51.3 (2.3) 63.4 (2.0) 0.30 54.3 (2.3) 52.2 (2.2) 0.84 
Endotoxin load (EU/m2) 20837.3 (2.5) 27783.6 (2.1) 0.20 23746.7 (2.4) 21857.5 (2.4) 0.70 
Beta-(1→3)-D-glucan concentration (µg/g) 9.0 (2.1) 9.1 (1.7) 0.92 9.2 (1.8) 8.9 (2.1) 0.85 
Beta-(1→3)-D-glucan load (µg/m2) 102.9 (5.9) 174.2 (4.2) 0.22 113.4 (6.9) 129.3 (6.4) 0.78 
Mattress 
      
Endotoxin concentration (EU/mg) 20.5 (2.3) 20.5 (2.1) 0.99 27.0 (2.6) 19.4 (2.3) 0.12 
Endotoxin load (EU/m2) 9631.6 (2.5) 9596.0 (2.3) 0.99 13242.7 (2.9) 8798.2 (2.5) 0.08 
Beta-(1→3)-D-glucan concentration (µg/g) 4.5 (1.9) 4.8 (1.8) 0.66 5.2 (2.5) 4.5 (1.8) 0.33 
Beta-(1→3)-D-glucan load (µg/m2) 45.8 (4.4) 49.9 (4.4) 0.82 58.1 (5.0) 42.4 (4.1) 0.39 
GM: Geometric mean; GSD: Geometric standard deviation. 
EU: Endotoxin units. 
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Table 5–4: Multiple logistic regression analyses describing the associations between endotoxin and beta-(1→3)-D-glucan levels† and 
atopic asthma 
 Model I 
OR (95%CI) 
Model II* 
aOR (95%CI) 
Model III* 
aOR (95%CI) 
Model IV*§ 
aOR (95%CI) 
Play area 
 
    
Endotoxin concentration (EU/mg)     
 Low 1.00 1.00 – 1.00 
 Medium 0.67 (0.17–2.65) 0.51 (0.10–2.57) – 0.42 (0.08–2.24) 
 High 0.25 (0.07–0.91)‡ 0.15 (0.03–0.86)‡ – 0.15 (0.02–0.95)‡ 
Endotoxin Load (EU/m2)     
Low 1.00 1.00 – 1.00 
Medium 0.67 (0.17–2.65) 0.48 (0.08–2.97) – 0.47 (0.07–3.11) 
High 0.25 (0.07–0.91)‡ 0.11 (0.02–0.75)‡ – 0.13 (0.02–0.99)‡ 
Beta-(1→3)-D-glucan concentration (µg/mg)     
Low 1.00 – 1.00 1.00 
Medium 1.14 (0.34–3.75) – 0.77 (0.17–3.45) 0.89 (0.18–4.36) 
High 0.91 (0.27–3.05) – 0.97 (0.23–4.13) 1.54 (0.32–7.55) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low 1.00 – 1.00 1.00 
Medium 0.39 (0.11–1.45) – 0.28 (0.05–1.48) 0.36 (0.06–2.04) 
High 0.40 (0.11–1.52) – 0.26 (0.05–1.48) 0.40 (0.06–2.60) 
Mattress     
Endotoxin concentration (EU/mg)     
Low 1.00 1.00 – 1.00 
Medium 0.71 (0.22–2.27) 0.53 (0.13–2.18) – 0.56 (0.13–2.40) 
High 0.90 (0.26–3.09) 0.66 (0.13–3.31) – 0.70 (0.13–3.91) 
Endotoxin Load (EU/m2)     
Low 1.00 1.00 – 1.00 
Medium 0.69 (0.21–2.30) 0.60 (0.14–2.59) – 0.63 (0.14–2.86) 
High 0.75 (0.22–2.59) 0.46 (0.10–2.18) – 0.48 (0.10–2.41) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
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Low 1.00 – 1.00 1.00 
Medium 1.40 (0.39–5.01) – 1.37 (0.25–7.39) 1.50 (0.27–8.42) 
High 0.71 (0.23–2.25) – 0.88 (0.22–3.61) 1.01 (0.22–4.54) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low 1.00 – 1.00 1.00 
Medium 0.86 (0.25–3.00) – 0.91 (0.21–4.03) 0.92 (0.21–4.09) 
High 0.78 (0.23–2.63) – 0.58 (0.13–2.58) 0.54 (0.11–2.56) 
EU: Endotoxin units. 
*Statistical comparisons between atopic and non-atopic asthma were completed using logistic regression with GEE to account for 
clustering within families. 
†Low, medium, and high levels for endotoxin and beta-(1→3)-D-glucan were determined based on their corresponding tertile values 
of the exposure distribution, separately, for play and mattress areas: Low (1st tertile), Medium (2nd tertile), and High (3rd tertile). 
Model I: Model with no adjustments for atopic asthma; Models II: Adjusted model for atopic asthma with endotoxin as an 
independent variable; Model III: Adjusted model for atopic asthma with beta-(1→3)-D-glucan as an independent variable. 
aOR: Adjusted odds ratio. Models II and III were adjusted for sex, age, parental education, parental smoke, parental history of asthma 
and allergy, pet ownership, home dampness, and location of residence. 
§In addition to adjusted variables in Models II and III, Model IV was mutually adjusted for endotoxin or beta-(1→3)-D-glucan as 
appropriate. That is, model with play area endotoxin concentration as an independent variable was adjusted for play area beta-(1→3)-
D-glucan concentration. Model with play area endotoxin load as an independent variable was adjusted for play area beta-(1→3)-D-
glucan load. Similar procedure was performed for mattress endotoxin and beta-(1→3)-D-glucan. 
‡p<0.05. 
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Table 5–5: Multiple logistic regression analyses describing the associations between endotoxin and beta-(1→3)-D-glucan levels† and 
exercise-induced bronchoconstriction 
 Model I 
OR (95%CI) 
Model II* 
aOR (95%CI) 
Model III* 
aOR (95%CI) 
Model IV*§ 
aOR (95%CI) 
Play area     
Endotoxin concentration (EU/mg)     
Low 1.00 1.00 – 1.00 
Medium 1.00 (0.31–3.24) 1.09 (0.24–5.03) – 1.05 (0.22–5.00) 
High  0.83 (0.25–2.78) 0.78 (0.14–4.29) – 0.62 (0.10–3.96) 
Endotoxin Load (EU/m2)     
Low 1.00 1.00 – 1.00 
Medium 1.50 (0.43–5.31) 1.96 (0.38–10.23) – 1.83 (0.30–11.44) 
High 1.79 (0.52–6.15) 2.31 (0.37–14.46) – 2.15 (0.30–15.18) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
Low  1.00 – 1.00 1.00 
Medium  2.09 (0.62–7.05) – 5.20 (0.68–39.75) 5.19 (0.62–43.09) 
High  1.24 (0.34–4.54) – 2.38 (0.42–13.64) 2.18 (0.35–13.47) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low 1.00 – 1.00 1.00 
Medium 0.67 (0.19–2.35) – 1.21 (0.23–6.46) 1.11 (0.19–6.41) 
High 1.19 (0.38–3.74) – 1.83 (0.32–10.33) 1.58 (0.23–10.82) 
Mattress     
Endotoxin concentration (EU/mg)     
Low 1.00 1.00 – 1.00 
Medium 2.77 (0.65–11.75) 2.07 (0.34–12.54) – 2.46 (0.35–17.55) 
High  4.64 (1.15–18.75)‡ 6.14 (1.12–33.52)‡ – 7.80 (1.13–53.69)‡ 
Endotoxin Load (EU/m2)     
Low 1.00 1.00 – 1.00 
Medium 1.94 (0.51–7.38) 0.58 (0.10–3.33) – .53 (0.09–3.10) 
High 2.70 (0.74–9.83) 2.67 (0.57–12.43) – 2.42 (0.49–11.84) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
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Low  1.00 – 1.00 1.00 
Medium  0.70 (0.21–2.28) – 0.52 (0.10–2.67) 0.42 (0.08–2.30) 
High  0.70 (0.21–2.28) – 0.76 (0.18–3.21) 0.44 (0.09–2.21) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low 1.00 – 1.00 1.00 
Medium 0.70 (0.21–2.28) – 0.62 (0.13–2.83) 0.55 (0.11–2.67) 
High 0.70 (0.21–2.28) – 0.46 (0.09–2.29) 0.38 (0.07–2.13) 
EU: Endotoxin units. 
*Statistical comparisons between EIB and no EIB groups were completed using logistic regression with GEE to account for clustering 
within families.  
†Low, medium, and high levels for endotoxin and beta-(1→3)-D-glucan were determined based on their corresponding tertile values 
of the exposure distribution, separately, for play and mattress areas: Low (1st tertile), Medium (2nd tertile), and High (3rd tertile). 
Model I: Model with no adjustments for EIB; Models II: Adjusted model for EIB with endotoxin as an independent variable; Model 
III: Adjusted model for EIB with beta-(1→3)-D-glucan as an independent variable. 
aOR: Adjusted odds ratio. Models II and III were adjusted for sex, age, parental education, parental smoke, parental history of asthma 
and allergy, pet ownership, atopic sensitization, home dampness, and location of residence. 
§In addition to adjusted variables in Models II and III, Model IV was mutually adjusted for endotoxin or beta-(1→3)-D-glucan as 
appropriate. That is, model with play area endotoxin concentration as an independent variable was adjusted for play area beta-(1→3)-
D-glucan concentration. Model with play area endotoxin load as an independent variable was adjusted for play area beta-(1→3)-D-
glucan load. Similar procedure was performed for mattress endotoxin and beta-(1→3)-D-glucan. 
‡p<0.05. 
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6.1 Abstract 
Background: Asthma severity can be affected by microbial exposures. However, less is known 
about the specific indoor agents aggravating the disease in children. This could aid childhood 
asthma management strategies and reduce morbidity.  
Objective: To examine associations between indoor endotoxin and beta-(1→3)-D-glucan 
exposures and asthma severity in children with asthma.     
Methods: We conducted a clinical cross-sectional study of schoolchildren aged 7–17 years in 
the province of Saskatchewan, Canada. Children with asthma (n = 116) were identified through a 
combination of survey responses and objective clinical assessments. Asthma severity categories 
among the children with asthma were based on recommended guidelines (mild asthma: >2 
days/week of daytime asthma symptoms, ≤4 night/month of nighttime asthma symptoms, and 
≥80% predicted FEV1; moderate/severe asthma: Continuous daytime asthma symptoms, frequent 
nighttime asthma symptoms, and ≤60% predicted FEV1). Levels of indoor endotoxin and beta-
(1→3)-D-glucan were measured in dust samples obtained from play area floors and child’s 
mattresses.  
Results: The study population of 116 children with asthma was comprised of 75.9% mild asthma 
and 24.1% moderate/severe asthma. Exposure to high mattress endotoxin concentration was 
positively associated with moderate/severe asthma [adjusted odds ratio (aOR) = 11.40, 95% 
confidence interval (CI): 1.45–89.43] while high beta-(1→3)-D-glucan concentration (aOR = 
0.16, 95%CI: 0.03–0.89) and load (aOR = 0.10, 95%CI: 0.02–0.72) in play areas were inversely 
associated with moderate/severe asthma. Furthermore, among the children with asthma, high 
mattress endotoxin concentration was significantly associated with lower FVC (p=0.01) and 
FEV1 (p=0.03). These associations were not seen for beta-(1→3)-D-glucan.  
  
201 
 
Conclusion: Our results showed differential effects of microbial exposures on childhood asthma 
severity and further highlight domestic endotoxin exposure effects on respiratory health 
outcomes in children with asthma. 
Key words: Asthma severity, Lung function, House dust, Endotoxin, Beta-(1→3)-D-glucan, 
Children.  
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6.2 Introduction 
Asthma is the most common chronic disease1 and a leading cause of morbidity among children 
in Canada, accounting for a great deal of economic burden per year.2  Examination of risk factors 
for asthma severity could identify exposures that aggravate the disease among children and aid 
attempts to reduce morbidity and subsequent healthcare utilization and costs. The National 
Asthma Education and Prevention Program (NAEPP) Expert Panel Report 2 guidelines3 
recommend that asthma severity be assessed using a combination of frequency of clinical 
respiratory symptoms (day- and night-time symptoms) and objective lung function criteria 
(determined with forced expiratory volume in one second [FEV1]).  
Exposures to dust mite,4,5 furred pets,6,7 and tobacco smoke8,9 have been shown to be 
associated with asthma severity. While exposure to indoor mold or dampness have also been 
reported to worsen asthma symptoms,10,11 to date, the impact of many indoor microbial 
components in the exacerbation of asthma remains poorly assessed.  
Evidence of associations between endotoxin, a component of gram-negative bacteria,12 
and childhood asthma is controversial with some studies showing protective,13,14 and adverse15–17 
effects as well as no association.18,19 Endotoxin is also seen as a pro-inflammatory agent, which 
means that it could also be associated with worsening asthma conditions.15–17 Indeed, it has been 
shown that endotoxin may aggravate asthma conditions in children with the disease, in terms of 
increased frequency of wheezing and asthma medication use3,17 suggesting that the indoor 
environment may play an important role in the management of childhood asthma. Most of the 
previous studies examining the relationships between asthma severity and endotoxin have 
focused on reports of the frequency of wheeze17,20 and asthma medication use.17 Additional 
indicators of severity, incorporating objective measures of disease severity, should be 
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investigated for better understanding of the associations between indoor microbial exposures and 
asthma severity in children. 
While beta-(1→3)-D-glucan represents a marker of both bacterial and fungal exposure,21 
its role in the exacerbation of asthma is also less well investigated with previous studies focusing 
on endotoxin exposure as a sole marker of indoor microbial exposure.17,22 Investigating the 
respiratory effects of endotoxin and beta-(1→3)-D-glucan exposures, in tandem, will further our 
knowledge of the relationships between indoor microbial exposure and asthma severity in 
children. 
In this study, we examined the relationships between house dust endotoxin and beta-
(1→3)-D-glucan exposure levels and asthma severity in schoolchildren with asthma. In addition, 
we also investigated the relationships between endotoxin and beta-(1→3)-D-glucan exposures 
and lung function in these children. Identifying specific microbial indoor exposure associated 
with asthma exacerbations is important as this could help guide asthma management among 
children and, ultimately, decrease associated morbidity and healthcare costs.  
6.3 Methods 
6.3.1 Study population, selection and recruitment 
A cross-sectional study with clinical components was conducted in the province of 
Saskatchewan, Canada from 2015–2016. The study population consisted of schoolchildren (aged 
7–17 years) who were part of an initial 2013 cross-sectional survey previously described.23 
Briefly, study packages, including an information letter, survey and pre-paid return envelope, 
were mailed to parents for self-completion in 2013. Those who consented to participate in further 
testing were re-approached in 2015. At this time, we repeated the survey in order to obtain 
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accurate information on current respiratory symptoms that correspond to lung function values in 
the participants. Subsequently, clinical testing (spirometry and exercise challenge testing) as well 
as home dust sample collection was completed in 2015–2016.  
The study was approved by the University of Saskatchewan Biomedical Research Ethics 
Board (Bio #: 14–162). Furthermore, all school divisions involved approved the study. 
Completion and return of the survey implied voluntary consent for the questionnaire portion. All 
children and a parent provided written assent and consent, respectively, prior to clinical testing 
and home dust collection.  
6.3.2 Survey questionnaire 
Parents completed a questionnaire based on the standardized and validated questions from the 
International Study of Asthma and Allergy in Childhood (ISAAC),24 the American Thoracic 
Society Children’s Respiratory Disease,25 and questionnaires used previously in the 
Saskatchewan Lung Health studies.13 Questions about respiratory health, general health, parental 
health history, environmental exposure, sociodemographic factors as well as housing 
characteristics were included.  
6.3.3 Spirometry and exercise challenge testing (ECT) 
During home or school visits, children performed spirometry assessment according to 
recommended standards26 using the Easy-on PC spirometer (ndd Medical Technologies, Zurich, 
Switzerland). Measurements of forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC), FEV1/FVC ratio, and forced expiratory flow (FEF25%–75%) were obtained. 
Predicted values were based on the all-age, multi-ethnic Global Lung Function Initiative (GLI) 
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reference equation.27 Children were excluded from testing if they were unable to perform the test 
due to existing medical conditions (n = 3).  
ECT was also completed based on recommended protocols.28 Briefly, children stepped up 
and down on a 6 inch step at a heart rate (HR) between 150–200 beats per minute for 5 minutes. 
Heart rates were monitored throughout the exercise with a polar Heart Rate monitor (Polar 
Electro, Woodbury, NY). Spirometry was repeated at 3 and 10 minutes after cessation of 
exercise.  
6.3.4 Classification of asthma 
Asthma was identified through a combination of survey responses and results from clinical 
assessments (spirometry and ECT). Children were classified as positive for asthma if they had 
positive response to the questions: “Has this child ever been diagnosed as having asthma by a 
doctor?” and/or a positive response to: “Has this child taken prescribed asthma medication in the 
past 12 months?” (n = 95). Otherwise, they were classified as “no asthma”. We then used the 
validated asthma case detection algorithm developed by Gerald et al28 to further identify children 
positive for asthma (n = 21). This was based on an FEV1/FVC ratio less than 80% upon 
spirometry testing and/or demonstrated a greater than 15% decrease in FEV1 or 25% or greater 
decrease in FEF25%–75% from baseline after cessation of exercise.
29,30 Overall, from this process, 
116 children were identified to have asthma. The algorithm has a high sensitivity (82%) and 
specificity (93%) when compared to clinical assessment of asthma by a physician.28  
6.3.6 Classification of asthma severity 
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The 116 children positive for asthma were classified into one of four asthma severity groups 
based on the NAEPP guidelines3: mild intermittent, mild persistent, moderate persistent, and 
severe persistent asthma. 
In the NAEPP guidelines, spirometry does not distinguish between mild intermittent and 
mild persistent asthma (both with FEV1 ≥80%), therefore the two severity groups were collapsed 
into one single group (mild intermittent/mild persistent asthma).31 Similarly, because it is 
difficult to reliably differentiate moderate persistent from severe persistent asthma based on self-
reported symptom frequency alone (i.e. differentiating between “daily” and “continual” daytime 
symptoms or defining “frequent” nights with symptoms),3,32 the two most severe groups 
(moderate and severe persistent asthma) were also collapsed into one severity group 
(moderate/severe persistent asthma). Overall, two asthma severity groups [mild intermittent/mild 
persistent asthma (mild asthma) and moderate/severe persistent asthma (moderate/severe 
asthma)] were considered as the primary outcomes for the current study; with mild asthma used 
as the reference group.    
6.3.7 Collection and analysis of dust samples to quantify endotoxin and beta-(1→3)-D-glucan 
exposure  
Settled dust samples were vacuumed from the floor of child’s play area and mattress surfaces 
adhering to recommended standardized protocols33 using pre-weighed X-Cell-100 filter socks 
with a pore size of approximately 4.0–12.3 microns (Midwest Filtration LLC, OH, USA). Carpet 
floors had 2 m2 vacuumed for 4 minutes while completely smooth floors (e.g. hardwood, 
laminate, or linoleum) had 4 m2 vacuumed for the same time duration. Dust collection from the 
mattress surfaces (with the bottom sheet on) was completed after all duvets, blankets and sheets 
that the child slept under were removed and the entire surface area of the mattress was then 
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vacuumed for 2 minutes. Dust samples were stored in a desiccator at 4ºC until extraction and 
analysis. 
Samples were brought to room temperature and 10 mg of sieved dust was weighed out 
for extraction. Dust samples were extracted with 20 mL 0.05% Tween 20 (Fisher Scientific, 
Mississauga, ON, Canada) in pyrogen-free water34 (GE Healthcare Bio-Science, Mississauga, 
ON, Canada) and shaken at 325 revolutions per minute (RPM) for 2 hours. The extracted 
solution was then centrifuged (Sorvall ST 16R, Thermo Fisher Scientific, Mississauga, ON, 
Canada) at 1000 x g for 15 minutes to obtain supernatant and 1 mL aliquots were stored at -80ºC 
until analysis. An aliquot of the supernatant was diluted 1 in 10, and was used to measure 
endotoxin in the chromogenic Limulus Amoebocyte Lysate (LAL) Kinetic QCL assay according 
to manufacturer’s specifications (Lonza, Walkersville, MD, USA). The water soluble fraction of 
beta-(1→3)-D-glucan was measured in a second aliquot using the Glucatell assay kit with a beta-
(1→3)-D-glucan-specific inhibition enzymes based on the Kinetic Onset Time protocol 
according to manufacturer’s specifications (Associate of Cape Cod, East Falmouth, MA, USA).35  
To quantify endotoxin and beta-(1→3)-D-glucan levels, the absorbance of endotoxin and 
beta-(1→3)-D-glucan was monitored at 405 nm for 2 hours and 1 hour, respectively, using the 
Biotek ELx808 plate reader (BioTek, Winooski, VT, USA). Values were compared to standard 
curves prepared for endotoxin (0.005EU/mL–50 EU/mL) and beta-(1→3)-D-glucan (3.125 
pg/mL–100 pg/mL). Endotoxin and beta-(1→3)-D-glucan levels were reported as concentration 
(per gram of sampled dust) and load (per square meter of sampled area) given that the two 
measures represent different aspects of indoor microbial exposure (dose and burden, 
respectively).36  
6.3.8 Statistical analysis 
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All analyses were completed using the Statistical Package for the Social Science (SPSS) Version 
24 (SPSS Inc. Armonk, NY: IBM Corp.) and the Statistical Analysis System (SAS) Version 9.4 
(SAS Institute Inc., Cary, NC, USA). Categorical variables were compared between asthma 
severity groups using the independent samples chi-square (χ2) and Fisher’s exact tests as 
appropriate while continuous variables were compared using the independent sample Student t-
test. Mean endotoxin and beta-(1→3)-D-glucan for play area and mattress were expressed as 
geometric mean (GM) and compared between severity groups. Comparison of absolute values of 
lung function variables between severity groups were completed using the analysis of covariance 
(ANCOVA) adjusted for age, sex, and height.  
We assessed the associations between endotoxin and beta-(1→3)-D-glucan levels and the 
dichotomous health outcome of asthma severity (mild asthma or moderate/severe asthma) using 
multiple logistic regression. Similarly, multiple linear regression models were fitted to assess the 
associations between endotoxin and beta-(1→3)-D-glucan levels and lung function variables 
(FVC, FEV1, FEV1/FVC, and FEF25%–75%). Additional variables included in the models were sex, 
age, height, parental smoking, home dampness, visible mold, asthma medication use, allergen 
sensitization, and location of residence. These variables were included based on statistical 
significance from the univariate analyses, clinical/biological importance, or the effect the 
removal of a variable had on the beta coefficient of other variables in the model.37,38 Endotoxin 
and beta-(1→3)-D-glucan remained, a priori, in all models. Levels of endotoxin and beta-
(1→3)-D-glucan were modelled as categorical variables in tertiles to define low (1st tertile), 
medium (2nd tertile), and high (3rd tertile) levels because the relationships with moderate/severe 
asthma did not meet the linear assumption when log-transformed (ln) endotoxin and beta-(1→3)-
D-glucan were used. Low, medium, and high levels were determined based on their 
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corresponding tertile values of the exposure distribution, separately, for play and mattress areas. 
The reference value was the lower endpoint of each of the tertiles. Separate independent models 
were fitted for each of play area and mattress dust including: i) a univariate model for each 
endotoxin (concentration and load) and beta-(1→3)-D-glucan (concentration and load); ii) main 
effects model for endotoxin; iii) main effects models for beta-(1→3)-D-glucan; and iv) main 
effects plus endotoxin and beta-(1→3)-D-glucan. Throughout the analyses, generalized 
estimating equations (GEE) were used to account for clustering within families. The Hosmer-
Lemeshow test was used to assess model Goodness-of-Fit. 
The strength of the associations were assessed using: i) odds ratio (OR) and their 95% 
confidence interval (CI) for categorical outcome variables (mild asthma vs. moderate/severe 
asthma), and ii) beta coefficients with their standard errors for continuous outcome variables 
(baseline lung function measurements). Statistical significance was defined by an alpha level of 
0.05.  
6.4 Results 
6.4.1 Characteristics of study population 
The socio-demographics characteristics for the study population are presented in Table 6–1. 
Distributions for most of the characteristics, including age, were similar between the two asthma 
severity groups (p>0.05). When comparing respiratory symptoms and asthma severity indicators 
between the two groups, children with moderate/severe asthma were more likely to experience 
night cough, wheeze during exercise, have greater than 3 episodes of asthma, speech limitations, 
and were more likely to miss school days compared to children with mild asthma (Table 6–2). 
Other asthma indicators were not statistically significant between the two groups. 
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Baseline lung function differed significantly between severity groups when assessed 
either as absolute or percent predicted values (Table 6–3). Mean FVC, FEV1, FEV1/FVC, and 
FEF25%–75% were all significantly lower in children with moderate/severe asthma compared to 
children with mild asthma.  
6.4.2 Mean endotoxin and beta-(1→3)-D-glucan exposure levels among asthma severity 
groups 
There were no statistically significant differences in mean (geometric) endotoxin levels between 
the two severity groups (Table 6–4). However, children with moderate/severe asthma had 
significantly lower play area beta-(1→3)-D-glucan concentration and load compared to the mild 
asthma group. 
6.4.3 Associations between endotoxin and beta-(1→3)-D-glucan exposure levels and asthma 
severity and lung function measures 
Mattress endotoxin concentration levels were significantly associated with increased risk of 
moderate/severe asthma in a dose response manner, independent of beta-(1→3)-D-glucan 
exposure levels (Table 6–5). This pattern was reversed for beta-(1→3)-D-glucan exposure levels. 
Play area beta-(1→3)-D-glucan levels were significantly associated with reduced risk of 
moderate/severe asthma independent of endotoxin exposure levels.  
To further investigate indicators of severity, we looked at the associations between 
endotoxin and beta-(1→3)-D-glucan exposure levels and frequency of wheeze in the past 12 
months. In contrast to overall severity assessed by the NAEPP guidelines, higher levels of 
mattress beta-(1→3)-D-glucan concentration was significantly associated with more frequent 
  
211 
 
wheeze (>3 episodes) in the past 12 months (aOR = 7.58, 95%CI: 1.17–72.76) while no 
significant association was observed for endotoxin. 
Table 6–6 presents the associations between endotoxin and beta-(1→3)-D-glucan 
exposures with lung function variables among the 116 children with asthma. Similar to the 
relationships between endotoxin and moderate/severe asthma, mattress endotoxin concentration 
levels were significantly associated with decreased absolute values for FVC [beta (β) = -0.32, SE 
= 0.12) and FEV1 (β = -0.27, SE = 0.12) after adjusting for potential confounders, including beta-
(1→3)-D-glucan levels. No such association was observed for beta-(1→3)-D-glucan levels.   
6.5 Discussion 
This study demonstrated varied associations between indoor microbial exposure and asthma 
severity outcomes depending on the specific microbial agent. Endotoxin exposure was positively 
associated with moderate/severe asthma while beta-(1→3)-D-glucan showed inverse 
associations. Also, endotoxin levels were associated with lower lung function but the association 
was non-existent for beta-(1→3)-D-glucan. However, beta-(1→3)-D-glucan was associated with 
increased wheeze frequency. These results suggest that while endotoxin may be more 
consistently associated with adverse lung health outcomes, beta-(1→3)-D-glucan has also shown 
associations with some indicators of asthma severity. These differential patterns may be acting 
through different mechanisms or may reflect different roles as a possible causal agent versus 
trigger.   
 The most recent update from the Institute of Medicine (IOM) on the review of indoor 
environmental exposures and asthma exacerbation showed evidence of associations between 
endotoxin exposure levels and asthma severity.39 In a cross-sectional study among 
schoolchildren with asthma (aged 6–13 years) in the USA, Rabinovitch et al40 demonstrated that 
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endotoxin levels had significant positive associations with asthma severity indices (measured as 
asthma symptom scores severe enough to prevent play or sleep in children). However, in this 
earlier study, endotoxin levels were measured from dust obtained from personal exposure 
monitoring of schoolchildren versus vacuumed dust sample used in the current study. In the 
National Survey of Lead and Allergens in Housing study, also in the USA, Thorne et al17 
reported that endotoxin levels in bedroom floor dust were significantly associated with increased 
frequency in the daily need for asthma medication. We add to the previous evidence by showing 
that high endotoxin levels significantly increased the risk of clinically defined moderate/severe 
asthma, further highlighting the potential clinical importance of microbial endotoxin exposure 
and asthma exacerbation in children with asthma.      
We also demonstrated an inverse association between high play area beta-(1→3)-D-
glucan levels and moderate/severe asthma. A Puerto Rican study among children (aged 6–14 
years) showed positive associations between high beta-(1→3, 1→6)-D-glucan exposure and 
asthma severity (measured as ≥1 visits to the emergency department [ED]/urgent care for 
asthma).41 Another study among schoolchildren with asthma in the Netherlands (aged 7–11 
years) also reported a significant association between high play area beta-(1→3)-D-glucan and 
increased peak expiratory flow (PEF) variability as an indicator of asthma severity.42 While the 
results of our study are in contrast to these two previous studies, one observational study in 
Australia found beta-(1→3)-D-glucan to be significantly associated with increased FEV1 as a 
measure of severity indicator.43 A separate study in the USA also showed that high beta-(1→3)-
D-glucan exposure level was inversely associated with frequency of recurrent wheezing in 
infants.44 These inconsistencies between studies could be explained by methodological 
discrepancies and/or differences. For example, in the Puerto Rico study, parental reports of ED 
  
213 
 
visits for asthma care were used as an asthma severity indicator while we used a combination of 
clinical symptoms and lung function variables based on NAEPP guidelines.3 Also, the 
inflammatory potency of beta-(1→3)-D-glucan also appears to be strongly dependent on the type 
and conformation of glucans in house dust. While we assayed beta-(1→3)-D-glucan in the 
current study, Blatter et al assayed beta-(1→3, 1→6)-D-glucan which has been reported to be a 
stronger inducer of inflammatory responses compared to beta-(1→3)-D-glucan.45  
Reasons for the observed inverse association between beta-(1→3)-D-glucan and 
moderate/severe asthma in the current study are unclear but could be related to the airway 
inflammatory pattern that may be present in our subjects (eosinophilic or neutrophilic 
inflammation). For example, an inhalation challenge study in guinea pigs showed that repeated 
exposures to beta-(1→3)-D-glucan induced a significant increase in eosinophil counts without an 
increase in neutrophils.46 While patients with severe asthma may differ from those with mild 
asthma in having higher eosinophil counts in their airways,47 studies by Wenzel et al showed that 
not all severe asthma patients have airway eosinophilia48 and that neutrophil counts are also 
higher than normal in the airways of subjects with severe asthma.49 Unfortunately, no 
measurement of eosinophil and neutrophil counts was undertaken in this study to investigate if 
the observed associations between beta-(1→3)-D-glucan and moderate/severe asthma was 
related to airway inflammatory patterns.  
Another possible explanation could be related to indoor mold level alteration through 
remediation strategies such as cleaning. A randomized controlled trial in the US assessed the 
effects of indoor mold reduction through moisture remediation strategies on asthma 
exacerbation.50 Compared to the controlled group, remediation group had a significantly lower 
rate of asthma exacerbation (measured as frequency of asthma symptoms in days and ≥2 ED visit 
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or ≥1 hospitalization for asthma past 12 months). In the current study, we observed borderline 
significant difference in report of indoor visible mold between moderate/severe and mild asthma 
group (8.4% vs. 22.2%, respectively; p=0.08). Since significant associations have been reported 
between indoor visible mold,51 moldy odor,52 and culturable mold spores51 with increased beta-
(1→3)-D-glucan concentration levels in house dust, it is possible that children with 
moderate/severe asthma in our study may be cleaning their homes more intensely with a focus on 
mold reduction. Such a practice might have reduced beta-(1→3)-D-glucan exposure producing 
the observed inverse association with moderate/severe asthma due to the cross-sectional nature 
of the study design.        
Finally, beta-(1→3)-D-glucan is positively associated with indoor relative humidity 
(RH)51 with indoor beta-(1→3)-D-glucan concentration levels significantly higher in summer 
compared to winter period.21 Dust sample collection for this study was completed between 
December 2015 and April 2016. As such, beta-(1→3)-D-glucan levels may be lower than levels 
required to induce adverse respiratory outcomes in the studied population due to the relatively 
colder, drier, and lower RH in winter compared to summer period.53 Alternatively, beta-(1→3)-
D-glucan compared to endotoxin may not be as an important measure of microbial activity in 
relation to childhood asthma in this region of Canada due to the low RH.     
We observed an increased risk of moderate/severe asthma with high mattress endotoxin 
concentration in the current study. While it may be argued that the above explanations for beta-
(1→3)-D-glucan should also be applicable to endotoxin exposures, it should be noted that 
endotoxin is ubiquitous in nature and represents a measure of gram-negative bacteria.12,52 For 
these reasons, it has been suggested that endotoxin concentration in dust samples is not 
necessarily associated with mold exposures in contrast to beta-(1→3)-D-glucan which is a gram-
  
215 
 
positive cell wall of most fungi, including mold.52 Additionally, beta-(1→3)-D-glucan is 
believed to be a less potent inducer of inflammatory reaction and respiratory symptoms than 
bacteria endotoxin.42 Therefore, it is not surprising that endotoxin behaves differently than beta-
(1→3)-D-glucan in their association with moderate/severe asthma in the current study. 
Individuals with asthma appear to have a heightened response to acute pulmonary effects 
of endotoxin. In a controlled challenge study among adults, Kitz et al54 found a significant 
decrease in FEV1 in those with asthma 90 mins after inhalation of endotoxin extracts compared 
to healthy controls. While the study showed the effects of acute exposure to endotoxin on lung 
function in adults, we complemented these results by looking at children with asthma in the 
current study. We found high mattress endotoxin levels were significantly associated with lower 
FVC and FEV1 in children with asthma. These findings are also consistent with a previous study 
among schoolchildren (aged 6–18 years) in Canada where higher indoor endotoxin level was 
inversely associated with decreased FEV1
22 and greater diurnal PEF variability.55 In another 
study in the US among schoolchildren (aged 6–13 years), personal endotoxin exposure was also 
associated with lower daily evening FEV1.
40 Results from our study further expanded the 
evidence in the IOM review39 and showed that the adverse respiratory effects of endotoxin in 
children with asthma may be independent of other microbial exposure in the indoor environment 
such as beta-(1→3)-D-glucan. In addition, the effects may not depend on asthma severity status 
of a child, but that once children develop asthma, they are more likely to be sensitive to the acute 
inflammatory effects of endotoxin compared to those without asthma. Although we controlled 
for asthma medication use in our models, further studies are needed in children with poorly 
controlled asthma to validate the magnitude of lung function declines associated with long-term 
acute and/or chronic endotoxin exposure in the indoor environment.   
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We did not find any statistically significant associations between beta-(1→3)-D-glucan 
and lung function in the current study. However, in a separate analysis that assessed the 
relationships between indoor microbial exposures and asthma severity indicators, mattress beta-
(1→3)-D-glucan concentration was significantly associated with report of more wheeze 
frequency (>3 episodes) in the past 12 months. The positive association between beta-(1→3)-D-
glucan concentration and increased episodes of wheeze (>3 episodes) in the past year and its lack 
of association with lung function may suggest that, in children with asthma, beta-(1→3)-D-
glucan exposure could be related to symptom exacerbation and not necessarily lung function 
impairment. Beta-(1→3)-D-glucan exposure might result in increased symptom severity but not 
enough to impair pulmonary function. Alternatively, it could be that beta-(1→3)-D-glucan levels 
in the homes of children involved in this study were lower than a level required to induce 
significant lung function impairment.  
Limitations of our study should be considered. The participation rate experienced was 
low. We recruited participants from urban and rural locations and were frequently hard to reach, 
especially in the rural locations. This might have led to low statistical power as was seen in the 
case of some strong estimates found for play area endotoxin and mattress beta-(1→3)-D-glucan 
levels but lacking statistical significance in this study. Dust samples were collected at a single 
time-point. As such, it is possible that the current measured microbial exposure levels may not 
reflect the level of exposure present when the reported episode of asthma severity actually 
happened. However, we feel that the microbial exposure levels reported in the current study may 
reflect similar exposure patterns that were occurring at the time of event for two reasons. First, 
studies have suggested that a single dust sampling for endotoxin analysis showed little variation 
over time56–58 and reflects longer-term exposure to microbial products for at least a 1 year 
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period.59 Second, while some studies might have reported seasonal variability in house dust 
levels and microbial components,21,60,61 we obtained similar results of associations between 
microbial exposures and asthma severity after additional adjustment for seasonality in our 
models. Finally, the dust extraction analysis procedure used in this study is specific in 
determining the water soluble (WS) fraction of beta-(1→3)-D-glucan62 which may not represent 
the most potent fraction of beta-(1→3)-D-glucan compared to alkaline soluble (AS) fraction.63 
This extraction procedure may be one of the reasons beta-(1→3)-D-glucan levels in the current 
study were overall lower (10 fold) than the amounts of beta-(1→3)-D-glucan detected in other 
studies.14,42,44,64 Furthermore, in addition to small sample size, the lower levels of the WS 
fraction of beta-(1→3)-D-glucan may also explain the lack of association seen in the case of 
strong estimates found for mattress beta-(1→3)-D-glucan levels and asthma severity in this 
study. However, while the AS fraction of beta-(1→3)-D-glucan may represent the most potent 
fraction of beta-(1→3)-D-glucan62 and has been the most commonly investigated,14,42,44,64 we 
have further demonstrated, in this study, that the WS soluble fraction of beta-(1→3)-D-glucan 
could also worsen respiratory symptoms in children with preexisting asthma conditions. 
Our study also has several strengths. We used objective measures for exposure and 
outcome assessments and recommended guidelines to define asthma severity,3 thus limiting the 
possibility of bias. Furthermore, clinical data and dust samples were collected by trained 
technicians using standardized protocols.26,65 Laboratory personnel were blinded to disease status 
of each child and to source of dust samples (play area or mattress dust). Finally, home dust 
collection was conducted concurrently with clinical data to eliminate possible bias in dust 
sampling which could have been influenced by the health status of the child.  
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In conclusion, we demonstrated that asthma severity in children is associated with indoor 
microbial exposure. Endotoxin increased the risk of moderate/severe asthma and worsened lung 
function in children with asthma while beta-(1→3)-D-glucan exposure was sufficient to 
exacerbate symptom severity but not enough to impair pulmonary function or induce 
moderate/severe asthma. These results are important as they help clarify the role of endotoxin 
and beta-(1→3)-D-glucan in childhood asthma morbidity, highlighting that endotoxin may have 
more detrimental effects on respiratory health outcome in children with asthma. This further 
supports the notion that asthma severity might not be associated with the same microbial 
exposures associated with asthma development. For examples, endotoxin13,14,66 and beta-(1→3)-
D-glucan44,57,67 exposures may prevent asthma development but may also increase severity of 
existing asthma conditions; warranting the need for indoor microbial exposure avoidance in the 
management of childhood asthma.   
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Table 6–1: Demographic characteristics of study population by asthma severity group 
 Mild Asthma 
(n = 88) 
Moderate/Severe Asthma 
(n = 28) 
p-value 
Mean age (±SD), years 11.0 (2.7) 10.9 (2.6) 0.78 
Body mass index (±SD), kg/m2 20.4 (4.7) 20.9 (5.8) 0.62 
% Overweight 14.8 16.0 0.89† 
% Male 61.4 75.0 0.19 
Ethnic background    
 % Caucasian 84.1 73.1 0.24† 
            % Others 15.9 26.9  
Physical activity    
   % Low 3.4 3.6 0.96† 
   % Moderate 35.2 32.1  
   % High 61.4 64.3  
Parental education level    
% > high school (maternal) 81.6 88.9 0.56† 
% > high school (paternal) 76.5 88.0 0.21 
Tobacco smoke exposure    
% Parental smoking 11.8 14.3 0.75† 
% Environmental tobacco smoke 
(ETS) 
10.2 3.7 0.45 
Home characteristics    
% Home with air filter 50.0 53.6 0.74 
% Home with humidifier 28.4 32.1 0.71 
% Pet ownership 59.1 57.1 0.86 
% Dampness in the home 33.3 21.8 0.26 
% Home with visible mold 22.2 8.4 0.08 
Atopic sensitization    
% Atopic‡ 72.4 69.6 0.79 
% Mold sensitization‡‡ 53.9 56.5 0.83 
Family history    
% Parental history of asthma 35.2 32.1 0.78 
% Parental history of allergy 59.1 64.3 0.63 
  
 
 
2
2
8
 
Location of residence    
Urban 88.6 82.1 0.35† 
Rural  11.4 17.9  
†Statistical difference assessed by the Fisher’s exact test due to small cell sizes (expected values < 5). 
‡Children were tested for atopic sensitization using a panel of standardized allergen extracts: cat, local grass, mold (Aspergillus, 
Alternaria, Cladosporium), and house dust mite. Subjects was considered atopic if a positive reaction to at least one of the applied 
allergens is raised ≥3 mm compared to the saline control. 
‡‡Sensitization (positive skin prick test) to any of the three tested mold allergens (Alternaria, Aspergillus, or Cladosporium). 
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Table 6–2: Profile of respiratory symptoms, asthma severity indicators, and healthcare accessibility among the study population 
 Mild Asthma 
(n = 88) 
Moderate/Severe Asthma 
(n = 28) 
p-value 
Respiratory symptoms    
% Wheeze past 12 months 39.3 88.5 <0.001 
% Night cough past 12 months 38.6 60.7 0.04 
% Wheeze during/after exercise 65.9 89.3 0.02 
% Sleep disturbance due to cough past 12 months 43.2 60.7 0.11 
Asthma severity indicators past 12 months    
% > 3 asthma episodes 27.3 48.1 0.04 
% > 3 wheeze episodes 29.5 42.3 0.28 
% Speech limit to 1–2 words 6.8 21.4 0.04 
School absenteeism    
% Missed school due to breathing problem past 12 
months 
28.9 38.5 0.01 
Mean (±SD) number of school missed days per child in 
the past 12 months 
1.0 (2.6) 3.3 (6.0) 0.07 
Median number of school missed days per child in the 
past 12 months 
0.0 2.0 0.002‡ 
Asthma medication    
% Prescribed breathing medication past 12 months 55.7 71.4 0.14 
% Taking asthma medication for at least 2 days per 
week 
23.9 35.7 0.22 
% Prescribed antibiotics for respiratory infections past 
12 months 
39.8 50.0 0.34 
Mean (±SD) number of time prescribed antibiotic per 
child per year 
1.6 (0.9) 2.2 (1.8) 0.11 
Median  number of time prescribed antibiotic per child 
in the past 12 months 
1.0 2.0 0.104‡ 
Healthcare accessibility    
Time travelled to access basic healthcare (±SD), 
minutes 
15.6 (19.9) 20.7 (21.3) 0.26 
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Time travelled to access emergency healthcare (±SD), 
minutes 
14.4 (14.7) 18.8 (16.7) 0.21 
SD: Standard deviation 
‡Test performed with Mann-Whitney U test. 
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Table 6–3: Comparison of lung function values between asthma severity groups  
 Mild Asthma 
(n = 81) 
Moderate/Severe Asthma 
(n = 25) 
 Absolute Value* 
Mean (SD) 
% Predicted of Normal 
Mean (SD) 
Absolute Value* 
Mean (SD) 
% Predicted of Normal 
Mean (SD) 
FVC (L) 3.15 (0.05) 102.8 (13.0) 2.83 (0.10)‡ 92.3 (13.0)† 
FEV1 (L)
  2.63 (0.05) 98.8 (12.9) 2.16 (0.09)‡‡ 74.0 (9.1)†† 
FEV1/FVC 0.84 (0.10) 95.8 (7.6) 0.77 (0.02)
‡‡ 87.6 (10.9)† 
FEF25%–75% (L) 2.82 (0.08) 89.8 (21.8) 2.01 (0.15)
‡‡ 64.2 (26.5)†† 
SD: Standard deviation; B: Baseline; L: Litre. 
*Adjusted for age, sex, and height. 
‡p<0.05, ‡‡p<0.001 (for absolute values); †p<0.001; ††p=0.001 (for percent predicted values).  
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Table 6–4: Geometric mean (GSD) of endotoxin and beta-(1→3)-D-glucan concentration and load in house dust from play area floor 
and mattresses by asthma severity status 
 Mild Asthma 
(n = 78) 
Moderate/Severe Asthma 
(n = 24) 
p-value 
Play area    
Endotoxin concentration (EU/mg) 58.7 (2.3) 49.2 (1.9) 0.64 
Endotoxin load (EU/m2) 23102.6 (2.4) 19559.2 (2.2) 0.41 
Beta-(1→3)-D-glucan concentration (µg/g) 9.7 (2.0) 7.1 (2.0) 0.05 
Beta-(1→3)-D-glucan load (µg/m2) 157.4 (5.4) 61.1 (9.3) 0.03 
Mattress    
Endotoxin concentration (EU/mg) 20.8 (2.4) 20.4 (2.3) 0.93 
Endotoxin load (EU/m2) 9610.4 (2.5) 9283.6 (2.8) 0.88 
Beta-(1→3)-D-glucan concentration (µg/g) 4.6 (2.0) 4.5 (1.7) 0.90 
Beta-(1→3)-D-glucan load (µg/m2) 46.7 (4.1) 40.3 (5.0) 0.67 
GSD: Geometric standard deviation. 
EU: Endotoxin units. 
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Table 6–5: Multiple logistic regression analyses describing the associations between endotoxin and beta-(1→3)-D-glucan levels† and 
moderate/severe asthma†† 
 Model I 
OR (95% CI) 
Model II* 
aOR (95% CI) 
Model III* 
aOR (95% CI) 
Model IV*§ 
aOR (95% CI) 
Play area     
Endotoxin concentration (EU/mg)     
Low 1.00 1.00 – 1.00 
Medium 1.61 (0.53–4.88) 2.88 (0.61–13.47) – 4.61 (0.77–27.82) 
High  1.00 (0.31–3.24) 1.11 (0.21–5.73) – 2.88 (0.44–19.07) 
Endotoxin Load (EU/m2)     
Low 1.00 1.00 – 1.00 
Medium 0.86 (0.29–2.57) 1.00 (0.24–4.14) – 3.23 (0.54–19.52) 
High 0.72 (0.23–2.22) 0.60 (0.11–3.53) – 1.96 (0.27–14.35) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
Low  1.00 – 1.00 1.00 
Medium  0.39 (0.13–1.21) – 0.15 (0.03–0.86)‡ 0.15 (0.03–0.89)‡ 
High  0.39 (0.13–1.21) – 0.17 (0.03–0.87)‡ 0.16 (0.03–0.89)‡ 
Beta-(1→3)-D-glucan load (µg/m2)     
Low 1.00 – 1.00 1.00 
Medium 0.45 (0.14–1.40) – 0.27 (0.06–1.29)‡ 0.23 (0.04–1.20) 
High 0.54 (0.18–1.63) – 0.13 (0.02–0.75)‡ 0.10 (0.02–0.72)‡ 
Mattress 
    
Endotoxin concentration (EU/mg)     
Low 1.00  1.00 – 1.00 
Medium 1.49 (0.46–4.86) 4.40 (0.82–23.55) – 7.05 (1.07–46.55)‡ 
High  2.10 (0.67–6.64) 5.36 (1.01–28.67)‡ – 11.40 (1.45–89.43)‡ 
Endotoxin Load (EU/m2)     
Low 1.00 1.00 – 1.00 
Medium 1.68 (0.52–5.39) 3.70 (0.76–17.90) – 4.08 (0.78–21.32) 
High 1.68 (0.52–5.39) 2.13 (0.44–10.36) – 2.41 (0.44–13.09) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
Low  1.00 – 1.00 1.00 
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Medium  1.94 (0.62–6.14) – 1.40 (0.31–6.34) 1.44 (0.30–6.94) 
High  1.44 (0.44–4.70) – 1.48 (0.36–6.11) 1.48 (0.30–7.22) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low 1.00 – 1.00 1.00 
Medium 0.74 (0.25–2.18) – 1.78 (0.44–7.24) 1.77 (0.43–7.23) 
High 0.51 (0.16–1.62) – 1.08 (0.25–4.67) 0.99 (0.22–4.42) 
EU: Endotoxin units. 
†Low, medium, and high levels for endotoxin and beta-(1→3)-D-glucan were determined based on their corresponding tertile values 
of the exposure distribution, separately, for play and mattress areas: Low (1st tertile), Medium (2nd tertile), and High (3rd tertile).  
††Severity category based on the NAEPP guidelines.3 Mild asthma used as reference category. 
*Statistical comparisons between moderate/severe asthma and mild asthma were completed using logistic regression with GEE to 
account for clustering within families. 
Model I: Model with no adjustments for moderate/severe asthma; Models II: Adjusted model for moderate/severe asthma with 
endotoxin as an independent variable; Model III: Adjusted model for moderate/severe asthma with beta-(1→3)-D-glucan as an 
independent variable. 
aOR: Adjusted odds ratio. Models II and III were adjusted for sex, age, parental smoke, home dampness, visible mold in home, 
asthma medication use, allergen sensitization, and location of residence. 
§In addition to adjusted variables in Models II and III, Model IV was mutually adjusted for endotoxin or beta-(1→3)-D-glucan as 
appropriate. That is, model with play area endotoxin concentration as an independent variable was adjusted for play area beta-(1→3)-
D-glucan concentration. Model with play area endotoxin load as an independent variable was adjusted for play area beta-(1→3)-D-
glucan load. Similar procedure was performed for mattress endotoxin and beta-(1→3)-D-glucan. 
‡p<0.05. 
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Table 6–6: Multivariate linear regression analyses* describing the associations between endotoxin and beta-(1→3)-D-glucan levels† 
and lung function among children with asthma 
 FVC 
β(SE) 
FEV1 
β(SE) 
FEV1/FVC 
β(SE) 
FEF25%–75% 
β(SE) 
Play area§     
Endotoxin concentration (EU/mg)     
Low Ref Ref Ref Ref 
Medium -0.19 (0.11) -0.17 (0.11) 0.01 (0.02) -0.22 (0.22) 
High  0.17 (0.12) 0.08 (0.13) -0.01 (0.03) 0.02 (0.25) 
Endotoxin Load (EU/m2)     
Low Ref Ref Ref Ref 
Medium -0.14 (0.12) -0.12 (0.12) 0.01 (0.02) -0.15 (0.24) 
High 0.20 (0.14) 0.19 (0.14) 0.02 (0.03) 0.20 (0.27) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
Low  Ref Ref Ref Ref 
Medium  0.16 (0.12) 0.19 (0.12) 0.02 (0.02) 0.28 (0.22) 
High  0.13 (0.12) 0.04 (0.12) -0.02 (0.02) -0.03 (0.23) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low Ref Ref Ref Ref 
Medium 0.05 (0.13) 0.13 (0.13) 0.03 (0.03) 0.33 (0.24) 
High 0.23 (0.14) 0.18 (0.13) 0.00 (0.03) 0.19 (0.24) 
Mattress§ 
    
Endotoxin concentration (EU/mg)     
Low Ref Ref Ref Ref 
Medium -0.40 (0.12)‡ -0.32 (0.12)‡ 0.00 (0.02) -0.29 (0.24) 
High  -0.32 (0.12)‡ -0.27 (0.12)‡ 0.00 (0.02) -0.25 (0.24) 
Endotoxin Load (EU/m2)     
Low Ref Ref Ref Ref 
Medium -0.18 (0.12) -0.22 (0.12) -0.02 (0.02) -0.26 (0.22) 
High -0.14 (0.13) -0.12 (0.12) 0.00 (0.02) -0.12 (0.24) 
Beta-(1→3)-D-glucan concentration (µg/mg)     
Low  Ref Ref Ref Ref 
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Medium  0.01 (0.13) -0.09 (0.12) -0.03 (0.02) -0.19 (0.23) 
High  0.04 (0.13) -0.06 (0.12) -0.02 (0.02) -0.12 (0.22) 
Beta-(1→3)-D-glucan load (µg/m2)     
Low Ref Ref Ref Ref 
Medium -0.00 (0.12) -0.06 (0.12) -0.02 (0.02) -0.06 (0.22) 
High -0.08 (0.12) -0.11 (0.12) -0.01 (0.02) -0.03 (0.22) 
EU: Endotoxin units. 
*Models adjusted for sex, age, height, parental smoking, home dampness, visible mold in home, allergen sensitization, asthma 
medication use, and location of residence.  
†Low, medium, and high levels for endotoxin and beta-(1→3)-D-glucan were determined based on their corresponding tertile values 
of the exposure distribution, separately, for play and mattress areas: Low (1st tertile), Medium (2nd tertile), and High (3rd tertile).  
§ In addition to adjusted variables, models were also mutually adjusted for endotoxin or beta-(1→3)-D-glucan as appropriate. That is, 
model with play area endotoxin concentration as an independent variable was adjusted for play area beta-(1→3)-D-glucan 
concentration. Model with play area endotoxin load as an independent variable was adjusted for play area beta-(1→3)-D-glucan load. 
Similar procedure was performed for mattress endotoxin and beta-(1→3)-D-glucan. 
β(SE): Beta coefficient and standard error for the difference in lung function per levels of endotoxin or beta-(1→3)-D-glucan 
exposure. 
‡p<0.05. 
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CHAPTER 7 
GENERAL DISCUSSION 
7.1 Summary of results and what the results add to the literature 
Childhood asthma is understood to differ in prevalence between urban compared to rural 
children1–6 despite reports of similar prevalence of asthma-related symptoms between the two 
locations.3,7,8 Environmental factors have mostly been implicated for the lower asthma 
prevalence in rural settings. Investigating urban-rural asthma diagnostic patterns may provide 
further explanation to the observed prevalence differences.  
With children spending most (approximately 90%) of their time indoors,9 the indoor 
environment has become an important factor in the management and risk of childhood asthma. 
Indoor microbial exposures, particularly endotoxin, have been observed to reduce the risk of 
childhood asthma,10,11 irrespective of location of dwelling.12 However, the evidence is 
inconsistent as other studies have reported increased risk13–15 as well as no association.16,17 
Similarly, protective18–20 and risk21,22 effects have also been observed for beta-(1→3)-D-glucan. 
An important question to address is whether these differential effects could be associated with 
asthma phenotypes in children with asthma.   
Furthermore, while indoor microbial exposures may protect against childhood asthma in 
general,18,23 there are indications that microbial exposure thought to protect against childhood 
asthma may result in worsened asthma symptoms or asthma severity in children with preexisting 
asthma but less is known about the specific indoor microbial agent aggravating the disease. 
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Identifying indoor microbial agents potentiating asthma exacerbation in children with the disease 
could aid attempts to reduce severity and associated asthma morbidity. 
This dissertation showed that the often reported geographical variation in childhood 
asthma could be, in part, related to diagnostic patterns. The dissertation also provided an 
alternative explanation to the environmental theory which has been considered in most previous 
studies24–26 as a reason for lower asthma prevalence in rural locations.  Because the proportion of 
children classified as having asthma increased by a much greater amount in rural children 
compared to children in large urban settings when objective clinical measures were considered, 
the results revealed evidence of asthma under-diagnosis in rural compared to urban settings. 
Symptoms consistent with asthma diagnosis can be higher in rural compared to urban 
children3,8,27 or similar in both groups,28 as also observed in this study. Therefore, it is possible 
that estimates of asthma prevalence in previous epidemiological studies using parent-report of 
physician-diagnosed asthma across geographic locations might be biased due to differences in 
diagnosing.  
Results from studies investigating the associations between microbial endotoxin 
exposures and childhood asthma have been inconsistent. Some of the inconsistency may be due 
to different presenting phenotypes. To bring some clarity to the inconsistencies in the 
associations, we assessed the relationships between endotoxin and beta-(1→3)-D-glucan with 
asthma phenotypes. Endotoxin exposure was inversely associated with atopic asthma but 
positively associated with bronchial hypperresponsiveness (BHR) assessed as exercised-induced 
bronchospasm (EIB). The results showed that indoor microbial exposures were related to asthma 
phenotypes in different ways and suggest that these differential relationships may help explain 
some of the inconsistency in previous reports of microbial exposure to asthma.  
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Allergen activation through the TH2-dependent pathway and IgE receptors is likely the 
most common occurrence in the pathophysiology of atopic asthma.29 While the mechanism for 
the paradoxical relationships between endotoxin exposure and atopic asthma and EIB was not 
investigated in the current study, the results further support the theory of imbalance between TH1 
and TH2 immune response (for atopic asthma)
30,31 and the release of histamine in the airways to 
induce bronchoconstriction (for EIB).32  The inverse association observed for endotoxin exposure 
and atopic asthma in this study correlates well with the suggestion that asthma is a TH2-cell-
dependent disease29 and further provides evidence that the association between endotoxin and 
asthma may be potentially mediated by an effect of endotoxin on atopy. Also, sensitized mast 
cells may activate cytokines to induce airway bronchoconstriction.33 Therefore, the increased 
risk of EIB as observed in the current study further supports the theory that allergic mechanisms 
may not be the only and/or most important underlying mechanism in the pathophysiology of 
asthma.34  
The above results are consistent with our hypothesis that the discrepancies in the 
associations between endotoxin and childhood asthma, as reported in previous studies, could be 
linked to different presentations of the disease in children with asthma. While there is evidence 
that inhaled endotoxin exposure can induce BHR, these effects have only been found in 
adults35,36 and an animal studies37 using endotoxin inhalation challenge test methods. Results 
from the current study complement these earlier results35,36,37 by showing similar findings in 
children with EIB and home based indoor endotoxin exposures from house dust. 
Central to the pathophysiology of asthma is underlying airway inflammation which 
reflects different aspects of the disease severity from mild intermittent to severe persistent.33 The 
indoor environment has been reported as a possible source of triggers that could worsen asthma 
  
240 
 
severity in individuals with asthma.38 While indoor exposures to dust mite,39,40 furred pets,41,42 
tobacco smoke,43,44 and report of visible mold45,46 have been shown to be associated with asthma 
symptoms severity, the role of indoor microbial exposure from house dust on clinically assessed 
degree of asthma severity remains less studied.  
Results from the current study further confirm and extends the existing literature on 
respiratory outcomes in children with asthma following exposure to indoor microbial endotoxin 
and beta-(1→3)-D-glucan. Asthma severity was associated with indoor endotoxin and beta-
(1→3)-D-glucan exposures. However, while beta-(1→3)-D-glucan exposure could only be 
sufficient to exacerbate asthma symptom frequency it was not enough to impair pulmonary 
function. Contrary to the results for beta-(1→3)-D-glucan, endotoxin was consistently associated 
with adverse lung health outcomes.  
One of the fundamental components of asthma guidelines has been the assessment of 
disease severity and associated risk factors to guide treatment recommendations and 
management of asthma conditions such as avoidance of factors that could trigger and worsen 
asthma.47 In line with these guidelines, results from this study highlight that exposure to 
microbial inflammatory agents, such as endotoxin and beta-(1→3)-D-glucan can increase asthma 
severity in children with asthma.   
To summarize, while differences in the environment may explain some of the observed 
differences in asthma prevalence between urban and rural areas, presenting and diagnosing 
patterns should also be considered. Also, while studies have shown protective associations 
between childhood asthma and microbial exposures (e.g. endotoxin),10,11 and used this 
information to help explain the differences in asthma prevalence between urban and rural 
locations, this study further showed that some of the inconsistencies with these associations with 
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microbial exposures may be due to differences in phenotypes; and that asthma severity might be 
associated with the same microbial exposures thought to protect against asthma development, 
particularly endotoxin.  
7.2 Validity of the study 
The overall validity of this dissertation and the results are further discussed below. 
7.2.1 Internal validity 
In epidemiological studies, there is need to determine if observed differences in outcomes or 
effects of certain exposure on an outcome variable are likely to be due to alternative 
explanations. The process of ruling out such alternative explanation is referred to as assessing or 
establishing internal validity and shows the extent to which the findings of the study reflect the 
actual situation of the study population.48 Establishing internal validity for this study is based on 
assessment of research design and/or operational procedures for the study. 
7.2.1.1 Research design  
7.2.1.1.1 Selection bias 
A major selection issue that could impact this study is response bias which occurs when 
participants differ from non-participants or there is a systematic difference between responders 
and non-responders. The sampling frame for this study was based on a 2013 cross-sectional 
survey of schoolchildren as previously described.27 Of the 3,509 participants who completed the 
survey in 2013, 1,348 (38.4%) agreed to participate in further survey and clinical testing (clinical 
testing phase) and were re-approached in 2015. However, only 335 children (24.8%) participated 
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and formed the study population for this dissertation (Appendix 13). Reasons for the low 
participation rate were relocation (packages were returned stamped “Moved”, n = 154), refusal 
(subjects were no longer interested in the study, n = 257), and non-response (packages not 
returned to study center, n = 602).  There were significant differences in age (mean age: 9.03 vs. 
9.52 years), parental education (maternal: 86.1% vs. 73.7%; paternal: 78.3% vs. 67.2%), parental 
smoking (14.7% vs. 31.3%), and parental history of allergy (50.1% vs. 37.3%) between those 
who completed the clinical testing phase (in 2015) and those who did not (only completed the 
cross-sectional survey in 2013), respectively. Participation of study subjects in 2015 was also 
driven by the presence of respiratory symptoms (wheeze) and report of physician diagnosis of 
asthma in the 2013 survey, which may indicate the possibility of response bias and a tendency 
towards a less healthy population for this study (Appendix 14).  
The potential presence of a biased sample is not a major problem for this study because 
of the study objectives and the outcomes assessed. Manuscript I assessed asthma diagnostic 
patterns within each location of dwelling as opposed to comparing asthma prevalence across the 
urban-rural gradient. This allowed each location of dwelling to serve as its own comparison 
when estimating the changes in proportions of survey-based asthma classification and algorithm-
based asthma classification. However, we acknowledge that if the full population (n = 1,348) had 
participated, the proportion of survey report of physician-diagnosed asthma is likely to be lower 
than the estimates reported in this study and likely to represent the population prevalence 
estimates more closely. Also, since only children identified as positive for asthma from 
Manuscript I formed the study population for results reported in Manuscripts II and III, the 
associations reported in Manuscripts II and III will be valid given the well-defined study 
population and objective measures used in selecting these participants.   
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Finally, while the participants in the current study differed in some characteristics 
compared to those that participated in the 2013 cross-sectional survey (Appendix 14), the 
presence of biased sample in this study is expected to have occurred non-differentially between 
locations of dwelling. For example, the proportion of subjects that did not participate in the 2015 
study was equally distributed across locations of dwelling (Large Urban = 90.1%, Small Urban = 
92.8%, and Rural = 92.4%). Furthermore, the proportions of parental history of asthma and 
allergy, parental education levels, child reporting ever being diagnosed for asthma by physician, 
or ever wheeze were not significantly different across locations of dwelling. This allowed the 
interpretation of the results to still remain valid.       
7.2.1.1.2 Information bias  
This study was conducted in a way to attempt minimizing information bias, both for exposures of 
interest [endotoxin and beta-(1→3)-D-glucan] and outcomes (asthma phenotypes and severity).  
In Manuscript I, asthma was initially assessed based on survey report to classify subjects 
into three distinct groups: physician-diagnosed asthma (if they reported ever being diagnosed for 
asthma by a physician), at-risk-for-asthma (if they reported asthma-related symptoms but no 
physician-diagnosed asthma), and no asthma (no physician-diagnosed asthma and no asthma-
related symptoms). However, to further validate these responses for the presence or absence of 
asthma, all consenting subjects further performed spirometry and ECT. Subjects positive for 
asthma were then identified using a validated asthma case-detection algorithm that combined 
survey responses and the clinical measures.49 This procedure improved the asthma diagnostic 
classification and minimized possible information bias that might have occurred from survey 
responses.  
  
244 
 
This study further employed objective clinical assessments to reduce information bias 
greatly when classifying outcome variables for Manuscript II (atopic asthma and EIB) and 
Manuscript III (mild asthma vs. moderate/severe asthma). Subjects were classified as atopic vs. 
non-atopic based on objective SPT or as EIB vs. no EIB based on the results of ECT. The use of 
asthma severity classification guidelines50 which combined night- and day-time symptom history 
with lung function (determined by FEV1) further enabled us to move beyond the common 
questionnaire reports of frequency of symptom history as indicators of asthma severity in this 
study to evidence-based severity classification guided by expert panel recommendations.50  
The exposure variables for Manuscript II and III were endotoxin and beta-(1→3)-D-
glucan. In the current study, endotoxin and water soluble fraction of beta-(1→3)-D-glucan, as 
markers of microbial exposures, were objectively measured using recommended protocols51 and 
appropriate analytical procedures based on the quantitative kinetic chromogenic LAL assay 
(endotoxin) and the Kinetic Onset Time Glucatell assay [beta-(1→3)-D-glucan], thus eliminating 
the possibility of exposure misclassification. Finally, all samples were analyzed after 
questionnaire data collection was completed and in the same batch in the laboratory. 
7.2.1.1.3 Dust sample measurement 
Handling and measurement of dust samples in the current study were done in accordance to 
recommended protocol51 to increase internal validity. In order to correct for any modifying 
factors during the dust sampling process, a blank sample was collected for every sixth house 
visited according to recommended protocol.51 Following dust sample collection, filter socks were 
placed back in the Ziploc bag and transported to the Canadian Center for Health and Safety in 
Agriculture’s National Agricultural and Industrial Hygiene Laboratory (CCHSA’s–NAIHL) for 
further processing. The filter socks containing the dust samples were weighed after dust sample 
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collection by the same person that weighed them prior to data collection, using the same scale. 
To minimize errors and ensure repeatability in dust weight, all pre- (filter socks only) and post-
data collection (filters socks with dust sample) weights were completed in triplicate and the 
average weight recorded. Microbial endotoxin and beta-(1→3)-D-glucan were measured from 
the aliquots extracted from 10 mg (0.010 g) of sieved dust samples (also weighed three times to 
ensure repeatability and accuracy of dust weight).    
7.2.1.2 Operational procedures  
7.2.1.2.1 Confounding factors 
Manuscripts II and III for this dissertation used risk factor modeling based upon a priori 
etiological hypothesis rather than exploratory modelling. The models were focal in nature in that 
they related exposures to endotoxin and beta-(1→3)-D-glucan to specific respiratory outcome 
assessed as asthma phenotypes and asthma severity. When results are not likely attributable to 
chance as depicted by p≤0.05 for the main results of this dissertation, then it is important to 
assess whether the results could be explained by other factors.  
This study observed adverse as well as protective effects of indoor exposure to microbial 
agents in relation to asthma phenotype and asthma severity. However, there are a number of 
factors which have to be accounted for in order for the observed associations to be valid. 
Controlling for potentially confounding variables in this dissertation minimizes the potential for 
an alternative explanation for the results observed and provides more confidence that the effects 
of endotoxin and beta-(1→3)-D-glucan on asthma phenotypes and asthma severity are due to the 
appropriate independent variable. The confounding variables were controlled for using 
multivariate analyses. We considered and included in our models the common and important 
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known risk factors and confounders for asthma phenotypes and severity based on literature, 
biological/clinical importance and statistical significance. However, it is possible that there may 
be some other unmeasured potential confounders (residual confounders) in this study such as 
information on household income, age at which asthma was diagnosed, and levels of control. 
Also, it is possible that other unmeasured constituents in dust samples, such as particulate matter, 
metals, ergosterol, and/or peptidoglycan were involved in mediating the associations between 
endotoxin and beta-(1→3)-D-glucan and asthma outcomes observed in the current study. Finally, 
to avoid reporting spurious associations between studied health outcomes and endotoxin levels, 
all analyses were adjusted for beta-(1→3)-D-glucan levels and vice versa. 
7.2.2 External validity 
The participants in this study were school-age children from both urban and rural settings in the 
province of Saskatchewan, Canada. The definition of urban-rural gradient for this study parallels 
the Statistics Canada definitions based on modified Beale codes which considers population size, 
density, and distance to metropolitan areas and is applicable across locations in Canada.52 For 
this reason, findings from Manuscript I might also reflect a similar urban-rural pattern in asthma 
burden in other provinces if children of a similar age range were screened for asthma using 
similar asthma case-detection procedures.  
Similarly, we used a validated asthma case-detection method to identify the study 
population for Manuscripts II and III. Since healthcare and asthma management are standardized 
across locations in Canada,53 we expect that results of Manuscripts II and III will also reflect 
similar effect patterns among children with asthma in other location if similar procedures are 
used. However, caution should be taken when comparing these results with populations from 
other countries where environmental exposures and healthcare management practices may differ 
  
247 
 
significantly from that obtained in Canada. Also findings from this study, especially results of 
asthma diagnosis using lung function assessments in Manuscript I, may not be applicable to 
populations outside of the age range studied (7–17 years old).  
7.3 Evaluation of evidence of cause-effect relationships in this study 
Showing that endotoxin and beta-(1→3)-D-glucan are associated with asthma phenotypes and 
asthma severity in this study does not necessarily imply that there is a cause-effect relationship. 
While the design and analytical procedures for this study might have greatly reduced the 
potential for systematic and random errors as well as controlled for important confounding 
variables, the results of this study should be evaluated based on the “Bradford Hill (Hill’s) 
criteria” for assessing evidence of cause-effect relationship.  
7.3.1 Temporality 
The studies in this dissertation used a cross-sectional design and presents challenges in drawing 
causal associations due to temporality of events between exposures and respiratory health 
outcomes. Hill’s criteria necessitate an exposure to precede the occurrence of outcomes.54 In 
Manuscript II and III for this dissertation, exposures and respiratory health outcomes were 
determined at the same time preventing from drawing a causal relationship as we were unable to 
determine which come first: the microbial exposures or the respiratory outcomes. While settled 
house dust sample may have little variation over time and reflects longer-term exposure to 
microbial agents,55 the associations observed in the current study would need to be confirmed in 
longitudinal cohort studies investigating early indoor microbial exposures and later respiratory 
disease development.  
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7.3.2 Strength of association  
Manuscript II showed statistically significant decreased risk of atopic asthma and increased risk 
of EIB for endotoxin exposures. Similarly Manuscript III demonstrated statistically significant 
decreased risk of moderate/severe asthma for beta-(1→3)-D-glucan but increased risk of 
moderate/severe asthma for endotoxin exposure. Hill’s criteria suggests that strong associations 
are more likely to be causal than weak associations if confounding factors have been adequately 
adjusted for in the analyses.54 The results reported in this study attempted to remove confounding 
effects and were moderate to strong associations. However, while some of the associations 
observed in this study were strong, they were not statistically significant, likely due to the small 
sample size.   
7.3.3 Biological gradient (dose-response relationship)  
This study also showed a dose-response pattern for endotoxin exposure and decreased risk of 
atopic asthma (Medium level: OR = 0.42; High level: OR = 0.15) compared to low levels. 
Similarly, a dose-response pattern was also observed for endotoxin exposure and increased risk 
of EIB (Medium level: OR = 2.46; High level: OR = 7.80) and asthma severity (Medium level: 
OR = 7.05; High level: OR = 11.40) compared to low levels. These results are also consistent 
with other studies that have demonstrated dose-response curves in the relationship between 
microbial exposure and asthma exacerbation56 and atopic asthma.30    
7.3.4 Consistency of associations 
The results for endotoxin exposures and asthma phenotypes as well as asthma severity are mostly 
consistent with what has been previously reported. The ALEX study in Austria, Germany, and 
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Switzerland provides some of the strongest evidence suggestive of inverse associations between 
endotoxin exposure in house dust and atopic asthma.12 The Prevention of Allergy Risk Factors 
for Sensitization in Children Related to Farming and Anthroposophic Lifestyle (PARSIFAL) 
study in Austria, Germany, the Netherlands, Sweden, and Switzerland also demonstrated a 
decreased risk of atopic wheeze associated with mattress dust endotoxin exposure.57 With 
regards to asthma severity, previous studies have also shown that asthma severity is positively 
associated with exposure to microbial contaminants. A study in the Netherlands showed a 
significantly positive association between endotoxin exposure and increased PEF variability as 
indicator of asthma severity in children with asthma symptoms.58 Other studies have also shown 
an association between endotoxin exposure and increased frequency of wheezing and asthma 
medication use as severity indicators.15,50  
Few studies have investigated the relationship between beta-(1→3)-D-glucan and asthma 
severity. However, the available evidence also suggests positive associations with severity 
indicators such as frequency of ED visits56 and PEF variability.58 In contrast to results from these 
studies, we observed inverse associations between beta-(1→3)-D-glucan and moderate/severe 
asthma. The reasons are not clear in this study but it has been shown that acute exposure to beta-
(1→3)-D-glucan may not elicit an inflammatory response that had occurred after exposure to 
endotoxin.59,60 It is difficult to ascertain if a similar situation occurred in this study. 
Alternatively, beta-(1→3)-D-glucan might be an inadequate surrogate of house dust microbial 
exposure in Canada because of the relatively colder and drier environment with lower RH 
compared to European countries where some of the studies have reported positive association 
with beta-(1→3)-D-glucan.58 
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Some of the associations observed were not consistent by location of microbial exposure 
within the indoor environment (play area and mattresses) of the current study. For example, the 
decreased risk of atopic asthma with endotoxin exposure was only significant for play area and 
not mattress endotoxin levels. The increased risk of EIB and asthma severity with endotoxin 
exposure was significant in mattress and not play area endotoxin levels. Reasons for the varied 
associations are unclear in this study but may be related to differences in the determinants of 
endotoxin in different locations in the homes,10,61 proximity to microbial agents in mattress 
compared to play areas, or differences in endotoxin’s structures and potency in the specific home 
location62 rather than location itself. For example, mattress dust contains longer-chain 3-OHFA 
while play area endotoxin contain shorter-chain 3-OHFA62  and it is suggested that longer-chain 
3-OHFAs (C12:0–C14:0) may elicit stronger and significant potent immunological effects 
compared to shorter-chain 3-OHFAs.63 
7.3.5 Biological plausibility and coherence 
A number of studies have demonstrated the inflammatory and allergic mechanism of microbial 
exposures and this is consistent with the multicellular processes involved in the pathophysiology 
of asthma.29,33 Endotoxin exposure inhibits the TH2 and promotes TH1 immune responses, 
preventing atopic immune development and associated diseases in humans30,31,32 as well as in 
animals.37 Furthermore, agricultural and domestic house dust extracts induced significant TNF-α 
inflammatory cytokine in human monocytes.64 Removal of endotoxin from all dust samples 
significantly reduced TNF-α responsiveness, suggesting a preferential role for endotoxin in 
inducing inflammatory responses from airway inflammatory cells. The mechanism for beta-
(1→3)-D-glucan is less clear but is believed to also induce increases in airway eosinophil and 
neutrophils counts.60 Therefore, findings from this study have some basic biological plausibility 
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relating microbial exposures to asthma-related outcomes as demonstrated in both humans and 
animals studies based on the natural history of the disease. 
7.4 Other limitations and strengths of the study 
Limitations and strengths of the specific objectives for this study have been mentioned in their 
respective chapters: Chapter 4 (asthma diagnosis along an urban-rural gradient, Manuscript I), 
Chapter 5 [the association between endotoxin and beta-(1→3)-D-glucan with asthma 
phenotypes, Manuscript II], and Chapter 6 [the association between endotoxin and beta-(1→3)-
D-glucan with asthma severity, Manuscript III]. However, there are some other limitations and 
strengths regarding the dissertation in general that should be mentioned.  
7.4.1 Other limitations  
One major limitation of the study is that all data (survey, clinical assessments, and home dust 
collection) was obtained using a cross-sectional study design. This study design can only identify 
associations and not necessarily establish causation since exposures and outcomes were 
measured at the same time point. However, due to practical considerations, cross-sectional 
studies are common and important and this limitation is considered typical of all cross-sectional 
studies.10,14,61  
ECT was used to induce bronchoconstriction in this study. However, there are other 
challenge tests that have been completed in epidemiological studies to identify children positive 
for asthma. These include hypertonic saline65 and methacholine challenge test (MCT)66 and have 
been found to show similar validity when assessed against actual physician assessment of asthma 
as gold standard (Saline test: sensitivity = 54%, specificity = 94%; MCT: sensitivity = 50%, 
specificity = 84%). These results correspond to the validity obtained for ECT in another study 
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(sensitivity = 57% and specificity = 90%).67 This suggests that ECT as used in the current study 
has similar validity indicators as other asthma challenge methods and should be suitable for the 
purposes of the current study.  
A case-detection protocol may not be as valid as using physician assessment. However, 
we used a validated asthma case-detection algorithm49 to identify children positive for asthma in 
this study. The asthma case-detection algorithm used to identify children for asthma in this study 
has been validated against clinical physician assessment of asthma and has shown high 
sensitivity (82%) and specificity (93%).49 These children formed the study population for 
investigating the objectives reported in Manuscripts II and III. While we acknowledge that the 
use of algorithm-based asthma classification may not be as accurate as physician assessment of 
asthma, due to practical considerations, convenience and cost, physician assessment was not 
possible in the current study.   
The outcome for Manuscript II was asthma phenotypes based on skin prick testing (SPT) 
and ECT to determine atopic asthma and EIB, respectively. We determined atopy based on a 
positive skin reaction to at least one of the tested allergens (cat, house dust mite, local grass 
Alternaria, Cladosporium, and Aspergillus). These allergens–though believed to be common in 
the areas under study– may not necessarily identify all cases of atopy in our study population. 
Some children may be allergic to other allergens not tested in this study (e.g. dog, horse, and 
other food allergens) and thus misclassified as non-atopic in this study. Therefore, it is important 
to also consider atopy defined in terms of total serum IgE to provide an overall estimate of 
allergic sensitization in our study population of children with asthma.  
In the current study, asthma phenotypes were not entirely distinct as there was some 
overlap between atopic asthma and EIB. For example, 17/116 (17.2%) children with asthma in 
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this study had both atopic asthma and EIB (Appendix 15). While the study protocol used 
objective measures to minimize misclassification of asthma phenotypes, analyses for atopic 
asthma and EIB, separately, comprised of subjects with both phenotype subclass and were not 
mutually exclusive of each. However, this is not unusual and it should be noted that asthma is an 
heterogeneous disease with multiple presenting phenotypes47,68 and no single asthma phenotype 
class achieves all the requirements for a distinct or discrete asthma phenotype class.68 Even in 
latent cluster analyses (LCA) studies which attempt to eliminate bias in categorizing asthma 
phenotypes by avoiding definition of the asthma conditions before analysis, there were clear 
overlaps in phenotypes despite differences in study designs, variables that were analyzed, and 
studied populations.69–71,72  
Seasonal variation in asthma severity is another inherent limitation in this study. Asthma 
severity were assessed based on a combination of day- and night-time symptoms as well as 
objective lung function assessment. While asthma severity is not a stable feature but may change 
with time, classification by disease severity typically suggests a static feature.73 It is suggested 
that asthma severity be assessed over a sufficient period of 6–12 months for accurate prognosis 
of severity.73 Therefore, in the assessment of asthma severity based on symptoms and lung 
function, a single point-in-time classification may be less reliable. To help guide initial disease 
management and assessment of individuals at risk of asthma exacerbation in a population, 
planning and results of epidemiological research (especially cross-sectional studies) are currently 
based on such limited information.73 In addition, to accurately assess asthma severity in patients 
with asthma, determination of severity status should be made before the start of treatment 
therapy.74 This is to enable practitioners to develop a stepwise management protocol according to 
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the degree of disease severity.75 To minimize the effect of this limitation on the estimates 
reported in this study, we adjusted for asthma medication use in all models for asthma severity.   
Although assessment of endotoxin and beta-(1→3)-D-glucan in settled dust is considered 
to be an objective method, both microbial agents may only represent part of the indoor total 
microbial exposure comprising other agents such as muramic acid, ergosterol, and 
peptidoglycan.76 An index of combined quantity of indoor microbial exposure is suggested to 
predict asthma better than single microbial marker independently of microbial diversity.76 
Therefore, causal conclusions may be hindered by the variability of the microbial components in 
the indoor environment. Also while beta-(1→3)-D-glucan represents the major component of 
cell wall of most fungi,77 it is also found in certain plant materials as well as some bacteria.77,78 
For this reason, indoor fungal exposure based on beta-(1→3)-D-glucan as a marker of exposure 
might therefore be overestimated. Furthermore, the dust extraction analysis procedure used in the 
current study is specific in determining the water soluble fraction of beta-(1→3)-D-glucan79 
which may not represent the most potent fraction of beta-(1→3)-D-glucan compared to alkaline 
soluble fraction.77 This may be one of the reasons, in addition to small sample size, that beta-
(1→3)-D-glucan levels were not associated with some relatively strong strengths of association 
observed in the analyses for Objective 3.  
All assessments of house dust endotoxin and beta-(1→3)-D-glucan, as markers of 
microbial exposures, in the current study assume that the endotoxin and beta-(1→3)-D-glucan 
concentrations measured are a proxy for inhaled endotoxin and beta-(1→3)-D-glucan levels. 
Endotoxin and beta-(1→3)-D-glucan were assayed from settled house dust samples in this study. 
This was done by vacuuming predefined areas from mattress and play area floors following 
standardized protocol.51 One major criticism of this method is that certain particles found in 
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settled house dust may be too large or heavy to become airborne and might not be inhalable. It is 
suggested that air sampling methods, particularly personal exposure monitoring of personal 
cloud,80 could be considered to more represent the risk of relevant exposure to inhalable 
microbial components in the indoor environment.81 However, air sampling requires large 
numbers of samples to be collected as temporal variation in airborne concentration is very high.82 
Since these methods are also very costly, work intensive, time consuming and mostly impractical 
in large epidemiological studies, assessment of microbial exposures in settled house dust by 
vacuuming currently represents the most convenient, less expensive objective indicator that the 
indoor environment is out of balance. Another advantage of settled dust sampling over personal 
exposure monitoring is the presumed integration over time that occurs in deposition of dust on 
surfaces.82 Since dust samples were collected on surfaces such as carpets, microbial agents can 
proliferate sufficiently whereas air sampling may allow only crude measure of dust sampling for 
airborne microbial concentrations.82      
7.4.2 Other strengths  
Establishing an accurate diagnosis of asthma is important for patient care as it helps guide 
treatment protocols.50 This study expanded on previous work by using a validated algorithm, 
which included symptoms report and clinical measurements to classify asthma status then 
included those children identified using the algorithm in the subsequent studies (Objectives 2 and 
3) allowing for a strong definition of asthma cases.  
 Separating the independent effects of indoor microbial agents has been one of the major 
difficulties of earlier studies, this study measured and considered both fungal and bacterial 
exposures in all models to try and tease out the independent effects of endotoxin and beta-
(1→3)-D-glucan on asthma phenotypes and severity.    
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While few studies have also been conducted to assess relationships between microbial 
exposures (particularly endotoxin exposures) and BHR, this has only been done in adults35,36 and 
animal model37 studies using inhalation challenge tests. This dissertation expands the findings to 
child populations for the first time using EIB as indicator of BHR and microbial exposure in 
house dust. Due to the manuscript-based nature of this dissertation and the involvement of inter-
disciplinary teams, the manuscripts presented in Chapters 4, 5, and 6 also benefitted immensely 
from a variety of feedback and perspectives from several review comments. This may have 
enhanced the interpretation and presentation of findings reported in this work. 
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CHAPTER 8 
RECOMMENDATIONS AND CONCLUSIONS 
8.1 Recommendations 
The results from this dissertation lead to some recommendations.  
Establishing an accurate diagnosis of asthma is important in order to guide therapy and 
improve patient care.1 One factor that seems to contribute to asthma misdiagnosis is that 
objective measures are not often utilized in combination with symptom history, especially in 
community-based epidemiological studies. The use of objective measures in combination with 
symptom history in diagnosing childhood asthma is necessary in order to comply with 
recommended guidelines2 and for accurate assessment of asthma burden for public health 
planning.  
Studies comparing urban-rural asthma prevalence have, to date, implicated environmental 
factors as a possible explanation to the lower asthma prevalence in rural areas. However, based 
on the results from this study, the prevalence of asthma should also consider under-diagnosis 
issues in order not to further underestimate asthma in rural areas. In addition, it is important to 
use objective measures in rural areas to assess patients and reduce misclassification, which was 
seen in this study and possibly occurred through lack of access to basic equipment such as 
spirometers. Overall, because we found that the algorithm-based asthma classification identified 
more children with asthma compared to survey-based report of physician-diagnosed asthma 
(34.6% vs. 28.4%, p<0.001), Manuscript I has a central message for asthma diagnosis and 
management: “if a child is wheezing, coughing, or experiencing shortness of breath, parents 
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should insist on having objective clinical assessments completed (spirometry and/or BHR test) 
for accurate assessment of their child’s respiratory condition when they see their physician.” 
Inadequate treatment and control of asthma as defined by Canadian Asthma Consensus 
Guidelines,2 is still present in 26%–45% Canadian children.3,4 This may be due to lack of 
diagnosis and appropriate therapy in children with asthma. More accurate diagnosis of asthma 
should better determine clinical management of the disease and improve quality of life, 
especially in rural settings. Since rural children have limited access to healthcare compared to 
urban children as seen in this study and may also have a shortage of healthcare professionals, 
findings from this study call for a need for school-based screening programs for childhood 
asthma. This is likely to eliminate the barriers to symptoms reporting and asthma diagnosis; and 
improve public health planning for childhood asthma across urban-rural locations. This may 
have direct implications for asthma management in terms of treatment, medication prescription, 
and asthma education. While school-based asthma screening program will be very helpful in 
identifying children with asthma in rural areas, it will only be cost effective in locations where 
there is a high prevalence of children with unrecognized asthma. 
Since group and/or location comparisons facilitate our understanding of asthma burden, 
this study has implications for epidemiological research of asthma prevalence and risk factors. 
For example, epidemiological research of childhood asthma in Canada has been largely based on 
parental report of physician-diagnosed asthma.5–8 Findings from this dissertation suggest that this 
method of asthma prevalence assessment may result in underestimation of the true prevalence 
and burden of asthma across locations. Measures that could improve accurate diagnosis of 
asthma such as supplementing existing healthcare services, especially in rural settings, to include 
pulmonary specialists and improved healthcare accessibility are needed. These measures could 
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improve public health planning for disease prevention, intervention or management that are 
location-specific.       
Results from this study also provide understanding of indoor microbial agents associated 
with asthma phenotype and severity. Given the important role indoor microbial exposures, 
particularly endotoxin, play in asthma exacerbation and bronchoconstriction as observed in the 
current study and other studies,9,10,11 avoidance or elimination of microbial agents in the indoor 
environment–once a child has been diagnosed with asthma–, could improve clinical asthma 
outcomes and related asthma morbidity in children and doing so improve patient care. While no 
intervention studies specifically evaluating the effectiveness of reducing endotoxin or beta-
(1→3)-D-glucan concentrations on asthma morbidity have been performed, a randomized trial in 
the USA showed that reduction of microbial contaminants through moisture remediation 
strategies (reduction in water infiltration, heating, ventilation/air conditioning alterations) 
significantly reduced asthma exacerbations in the remediation group compared to the control 
group.12 The population attributable fraction of childhood asthma among Canadian children is 
high for indoor microbial exposures (13%).13 Also, the average direct cost from asthma 
exacerbations among children in Canada is estimated to be around $883.48 per patient per year.14 
Current recommendations by the Canadian Asthma Consensus guidelines for asthma control in 
children acknowledge the use of environmental control measures.15 Thus, remediation strategies 
aimed at reducing indoor endotoxin levels and other indoor microbial contaminants are 
warranted and could form part of the Canadian Asthma Consensus guidelines to assist in 
controlling childhood asthma, reduce asthma morbidity, and decrease associated healthcare cost.  
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8.2 Future research directions 
 The strong associations between microbial exposures [endotoxin and beta-(1→3)-D-glucan] and 
asthma phenotypes and severity observed in the current study are interesting. However, the study 
used a cross-sectional design which can only identify associations and not necessarily establish 
causation. Cohort or longitudinal studies of asthma severity and phenotypes in relation to indoor 
endotoxin and beta-(1→3)-D-glucan exposures are needed for establishing causation. While 
early life exposures to microbial agents may protect against asthma development later in life,16 it 
is also possible that such early life exposure to endotoxin and beta-(1→3)-D-glucan in children 
with asthma may have greater effects on asthma severity and morbidity later in life compared to 
current exposures.   
Furthermore, measurements of endotoxin and beta-(1→3)-D-glucan as markers of indoor 
microbial exposures represent only crude markers of the total microbial exposure in the indoor 
environment.17 Exposure to microbial derived components may not be confined to a specific 
agent but rather the composition and diversity of indoor microbial exposure might play a crucial 
role than the quantity of specific microbial exposure levels17 and result in different respiratory 
outcomes from different microbial profiles. Therefore, studies of microbial exposures 
characterizations involving molecular techniques quantitative polymerase chain reaction (qPCR) 
or microbial DNA profiling analyses are needed to improve evidence about the diversity of 
indoor microbial exposure and associated respiratory health outcomes.  
Different species of bacteria can release different types of endotoxin18 and beta-(1→3)-
D-glucan reactivity also appears to be related to specific fungal specie.19 This might be the 
reason beta-(1→3)-D-glucan was also inversely associated with moderate/severe asthma in this 
study. This hypothesis should be evaluated in future studies by identifying specific bacterial and 
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fungal species in house dust and their associations with asthma respiratory morbidity, including 
asthma severity.  Different markers of endotoxin could have varied health effects.20,21 Studies 
that characterize endotoxin based on the length of fatty acid chain and investigate their 
associations with asthma respiratory outcomes is warranted to further explain some of the results 
in this study. In addition to speciation and structural components, it is possible that endotoxin 
exposure levels from different sources could elicit different patterns of inflammation as observed 
in the current study. Mattresses endotoxin was strongly associated with asthma phenotype (EIB) 
and asthma severity (moderate/severe asthma) in this study compared to play area endotoxin 
levels. Assessment of determinants of microbial exposures levels in different indoor 
environments will allow more specific control measures to be developed and help improve 
asthma management in children with the disease. 
Asthma is a complex multifactorial disease with both the involvement of environment 
and genetic component. A recent study from the Danish Twins Registry identified that while 
76% of the variations in overall asthma symptoms and severity were associated with 
environmental factors, 24% of the variations were due to genetic factors after adjusting for 
confounders,22 suggesting possible effects of gene-by-environment interactions in the 
development of asthma. Future research should also consider the role of genetic component 
when investigating the relationships between indoor microbial exposures and respiratory 
outcomes in children. The tendency of genetic component to influence the impact of microbial 
exposures might identify reason for the paradoxical relationship between microbial exposure and 
asthma-related outcomes.   
Finally, this was a cross-sectional study with adequate but relatively small sample size. 
This might have resulted in low statistical power for one of the objectives and explains the 
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absence of statistical significance for some of the strong estimates observed in this study. Future 
population-based studies with larger sample size are warranted to further validate the results 
reported in this study as well as to extend the investigation to potential interactions such as the 
gene-environment interactions described above. A larger sample, population-based study may 
also help in assessing the proportion of respiratory outcomes attributable to exposure of interests 
in this study. The population attributable fraction will be an efficient and powerful tool for 
planning and setting priorities for prevention and interventions strategies that may help reduce 
the burden of asthma in the population.   
8.3 Conclusions 
Several studies have showed evidence suggesting that asthma prevalence is lower in rural 
compared to urban settings. This study revealed that undiagnosed asthma may be a more 
common phenomenon in rural compared to urban settings and may explain some of the 
previously reported lower prevalence of asthma in rural children. This is further evidenced from 
results of studies which have revealed childhood asthma prevalence in rural locations to be 
similar with urban setting23,24 with the rural asthma distribution associated with socioeconomic 
status and certain environmental factors (such as indoor smoking, pest in home, etc.) rather than 
geographical location.25,26 Findings from this dissertation support the use of objective measures 
in combination with symptom history when evaluating asthma prevalence across geographical 
locations.   
 Furthermore, asthma is a heterogeneous disease with multiple presenting phenotypes.27 A 
broad review of literature suggests inconsistencies in associations between indoor microbial 
exposure and childhood asthma and morbidity. This study identified a contrasting effect in the 
association between endotoxin exposure, as a marker of indoor bacterial exposure, and asthma 
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phenotypes. Two subtypes of asthma, atopic asthma and EIB, are affected differently by indoor 
endotoxin exposure; suggesting that the inconsistencies in associations in previous studies could 
be related to different asthma phenotypes.   
With regards to asthma severity and microbial exposure, this study further supports the 
notion that severity might be associated with the same microbial exposures though to prevent 
asthma development. For example, with microbial exposure being higher in the indoor 
environments, such exposure may keep allergic asthma from developing but continuous inhalation 
may increase the risk of asthma severity and induce both immediate and sustained airway 
obstruction in individuals with preexisting asthma conditions.  
 Overall, the results of this study highlight the importance for improving understanding of the 
urban-rural asthma burden and identifying indoor microbial factors associated with asthma morbidity 
for planning and developing programs aimed at reducing asthma morbidity among children.   
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Appendix 3 
The Saskatchewan Children’s Lung Health Study Questionnaire 
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Appendix 4 
Saskatchewan Children’s Lung Health Study Dust Extraction and Analysis Standard 
Operating Procedures  
Weighing and Sieving Samples 
Required Equipment, Supplies, and Solutions: 
Top Loading Adventurer Balance from OHAUS Corp. 
 Item Number: AR1530 
Polypropylene Low-profile Snap-seal Sample Container, 120 mL (4 oz) from VWR 
 Catalogue Number: 16126-022 
Fisherbrand sieve 50 mesh size sieve (300 µm) from Fisher  
 Catalogue Number: 361014743 
Kimberly-Clark Kimtech Science Kimwipes Delicate Task Wipes (4.4 x 8.4 inches) from Fisher 
(Health Sciences Supply Centre)  
 Catalogue Number: 06666-2 
70% Ethanol made from 100% Ethanol (purchase at Health Science Supply Centre, 4L) 
Dish Soap  
Distilled Water  
100ml beaker 
Weighing Protocol 
Wear gloves, mask and lab coat when weighing settled dust samples! 
1. Place 100ml beaker into scale and zero the scale 
2. Place the Ziplock bag with filter in a 100ml plastic beaker 
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3. Place this beaker into the scale 
4. Wait for the scale to equalize 
5. Record weight 
6. Repeat Steps 4 and 5 two more times for a total of three trials to consider repeatability  
7. Record average dust weight from the three trials  
8. Remove the filter 
Note: The above procedures were performed exactly the same way for pre- (empty filters) and 
post-data collection (filters containing dust sample) weights 
Sieving Protocol 
Wear gloves and mask when dealing with settled dust!  
Sieve will need to be cleaned after each sample with soap and water, then rinsed with water 
and Sprayed with 70% ethanol. Make sure that the sieve is dry before proceeding with the next 
sample. 
9. Label polypropylene containers on the top and the side with Sample ID.  
10. Obtain a sterile polypropylene container and zero the balance.  
11. Remove the container from the balance and place the Fisherbrand sieve 50 mesh size 
sieve (300 µm) on top of it.  
12. Empty the contents of the sock onto the sieve. 
13. Weigh the contents of the polypropylene container to obtain a sieved mass for the 
sample.  
14. Record the weight of the dust in the container in your logbook as post sieved weight.  
15. Discard the contents that were larger than the sieve.  
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16. Clean the sieve between each sample with dish soap and water, rinse with water, and 
spray with 70% ethanol. Wait until the sieve is dry before proceeding to the next sample. 
To aid in the drying of the sieve faster, one can use a Kimwipe and gently pat the sieve 
and also place the sieve in the fumehood. 
17. Repeat Steps 1-5 for each sample.  
Settled Dust Extraction 
Required Equipment, Supplies, and Solutions: 
Mettler Toledo MX5 microbalance, (max 5.1 g) from Mettler Toledo  
 Item Number:  
OHAUS Top Loading balance 
Falcon 50mL conical Polypropylene tubes from Fisher (Health Science Supply Centre) 
 Catalogue Number: 352070 
Hyclone HyPure Cell Culture Grade Water (Pyrogen-free water, 500mL) from Fisher 
 Catalogue Number: SH30529.02 
Tween 20 from Fisher (500mL) 
 Catalogue Number: BP337-500 
Thermo Scientific MaxQ 2000 Bench Top Shaker  
 Model 4310 
Sorvall ST 16R Bench Top Centrifuge from Fisher  
0.05% Tween 20 solution (Pyrogen-free) made from 100% Tween 20 and Hyclone Hypure Cell 
Culture grade water.  
Sterile Serological Pipettes from Fisher (Health Science Supply Centre) 
Sterile Graduated cylinders 
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Sterile Nalgene bottles 
1.5 mL microcentrifuge tubes (RNase, DNase, and Pyrogen-free) from Fisher (Health Science 
Supply Centre)  
Weighing of dust samples 
1. Label 50mL conical tubes with Sample ID before beginning.  
2. Weigh out 10 mg (0.010 g) of the sieved settled dust into a 50 mL conical tube. Record 
the weight of the dust in your logbook.  
3. If one is not using the dust immediately after weighing, store the samples at 4°C until 
ready for extraction. 
Preparing Pyrogen-free 0.05% Tween 20  
i.  Make this solution in the biosafety cabinet, to limit any possible contamination of the 
solution.  
ii.  Tween 20 is a very viscous solution, pipette slowly when aspirating and dispensing 
from the pipette.   
iii. This solution should be made fresh before each set of extractions.  
1. Turn on the biosafety cabinet, and clean with 70% ethanol. Allow a contact time of 5 
minutes before wiping down the hood.  
2. Prepare 0.05% Tween 20 (Pyrogen-free) using Tween 20 (Fisher, Cat# BP337-500) and 
Hyclone HyPure Cell Culture Grade Water (Fisher, Cat# SH30529.02) in a Sterile 
Nalgene Bottle.  
3. Put the lid on the bottle and mix thoroughly.  
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Extraction of Sieved Settled Dust Samples. 
1. If samples have been stored at 4°C, take the appropriate number of samples out of the 
fridge and allow them to come to room temperature for 15-30 minutes.  
2. Add 20mL of 0.05% Tween 20 (Pyrogen-free) to each sample.  
3. Label 1.5mL microcentrifuge tubes for the aliquots of dust extracts.  
4. Shake the samples at room temperature at 325 RPM for 2 hours on the Thermo Scientific 
MaxQ 2000 Bench Top Shaker.  
5. Centrifuge the samples at 1000 x g for 15 minutes in the Sorvall ST 16R centrifuge.  
6. Aliquot the supernatant in ~1.0 mL volumes into 1.5mL microcentrifuge tubes for 
Endotoxin and water-soluble β-(13)-D-glucan analysis.  
7. Store the aliquots in -80°C until endotoxin and β-(13)-D-glucan analysis is ready to be 
done.  
Endotoxin and Water-soluble β-(13)-D-glucan Analysis 
Required Equipment, Supplies, and Solutions: 
Limulus Amebocyte Lysate Kinetic-QCL kit from Lonza 
 Catalogue Number: 50-650U 
Glucatell Kit made by Associates of Cape Cod, from MJS Biolynx 
 Catalogue Number: GT002 
BioTek ELx808 plate reader from Fisher 
 Item Number: 
Gen5 2.06 Software from Fisher  
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Endotoxin 
1. Dilute samples at least 1:10 with Pyrogen-free water.  
2. Perform assay as per the procedure provided with the kit.  
Beta-(13)-D-glucan  
1. Dilute samples at least 1:100 with Pyrogen-free water.  
2. Perform assay as per the Kinetic – Time of Onset Assay procedure provided with the kit.  
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Appendix 5 
Template of the 96-well plate used for endotoxin and beta-(1→3)-D-glucan analysis 
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Appendix 6 
Sample size and power calculation summary 
Sample size for Objective 1 
 
Proportions of survey-based and algorithm-based asthma classification were compared. Based on 
expected difference of ≥20% if asthma is under-diagnosed in the rural areas, a sample of 180 
children was calculated per location of dwelling for a total of 540 children in order to detect 
significant differences in proportion between survey-based and algorithm-based asthma 
classification. Power (1-β) was set at 80% and α level was 0.05.  
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Sample size for Objective 2 
 
Results from the 2002 childhood asthma and endotoxin study by Braun-Fahrlander et al. was 
used to calculate sample size for Objective 2. The study reported that current mattress endotoxin 
exposures (endotoxin loads in units/mg of dust) in home of 812 children (6–13 years old) 
showed an inverse association with atopic asthma. Based on the reported OR of 0.52 (95%CI: 
0.30–0.90) for atopic asthma in exposed children, a total sample size of 125 children was 
calculated and found to be sufficient to detect differences in the association between endotoxin 
exposures and atopic asthma. Power (1-β) was set at 80% and α level was 0.05. 
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Sample size for Objective 3 
 
Results from the 2011 study by Lawson et al. investigating the association between endotoxin 
and lung function among children and adolescents living in a rural area was used to calculate 
sample size for Objective 3. During a 2-week monitoring period of DV-PEF among children and 
adolescent, Lawson et al. reported positive association between endotoxin and greater DV-PEF 
(OR = 2.42; 95%CI: 1.03–5.67).  Based on the Cohen’s medium effect size of 0.3, a total of 85 
sample was found to be sufficient to detect moderate associations in the relationship between 
endotoxin and lung function. Power (1-β) was set at 80% and α level was 0.05. 
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Appendix 7 
Ethical approval certificates 
(Original, amendments, and re-approval certificates) 
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Appendix 8 
Parental consent and child assent form 
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Appendix 9 
The 3-Stage asthma-case detection algorithm* used in the study  
 
*Algorithm was developed by the Lung Health Center study team at the University of 
Alabama at Birmingham  
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Appendix 10 
Mean endotoxin and beta-(1→3)-D-glucan exposure levels in house dust with ranges 
Sampling location 
(no. of detectable 
samples/total samples) 
Mean Standard 
Deviation 
Minimum Maximum Interquartile Range 
(IQR) 
 Ln Geometric Ln Geometric Ln Geometric Ln Geometric Ln Geometric 
Play area (102/102)           
Endotoxin, EU/mg 3.96 52.46 0.79 2.20 2.20 9.03 6.55 699.24 0.98 2.66 
Endotoxin, EU/m2 10.01 22247.84 0.87 2.39 8.19 3604.72 12.76 348014.70 0.96 2.61 
Beta-(1→3)-D-glucan, µg/g 2.20 9.03 0.70 2.01 0.31 1.36 5.03 152.93 0.89 2.44 
Beta-(1→3)-D-glucan, µg/m2 4.84 126.47 1.86 6.42 0.69 1.99 8.47 4769.51 2.72 15.18 
Mattress (102/102)           
Endotoxin, EU/mg 3.04 20.91 0.82 2.27 0.69 1.99 6.21 497.70 1.01 2.74 
Endotoxin, EU/m2 9.16 9506.06 0.94 2.56 6.02 411.58 12.18 194852.86 1.22 3.39 
Beta-(1→3)-D-glucan, µg/g 1.52 4.57 0.65 1.91 0.15 1.16 4.41 82.27 0.84 2.32 
Beta-(1→3)-D-glucan, µg/m2 3.81 45.15 1.46 4.31 0.44 1.55 7.43 1685.81 2.39 10.91 
Ln: Natural log transformed. 
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Appendix 11 
Correlation between play area and mattress endotoxin and beta-(1→3)-D-glucan levels 
 Play area Mattress 
Play area Endotoxin Beta-(1→3)-D-glucan Endotoxin Beta-(1→3)-D-glucan 
Endotoxin (EU/mg) 1; 0.94** 0.23*, 0.30* 0.10, 0.11 -0.03, -0.01 
Endotoxin (EU/m2) 0.94**, 1 0.22*, 0.43** 0.08, 0.11 -0.06, 0.00 
Beta-(1→3)-D-glucan (µg/mg) 0.23*, 0.22* 1, 0.65* -0.04, -0.01 0.01, 0.00 
Beta-(1→3)-D-glucan (µg/m2) 0.30*, 0.43** 0.65*, 1 0.05, 0.09 -0.00, 0.09 
Mattress     
Endotoxin (EU/mg) 0.10, 0.08 -0.04, 0.05 1, 0.93** 0.44**, 0.14 
Endotoxin (EU/m2) 0.11, 0.11 -0.01, 0.09 0.93**, 1 0.39**, 0.22* 
Beta-(1→3)-D-glucan (µg/mg) -0.03, -0.06 0.01, -0.00 0.44**, 0.39** 1, 0.53** 
Beta-(1→3)-D-glucan (µg/m2) -0.01, 0.00 0.00, 0.09 0.14, 0.22* 0.53**, 1  
Values in bold and italic represent indoor load levels for endotoxin and beta-(1→3)-D-glucan as appropriate. 
*p<0.05; **p<0.001 
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Appendix 12 
Determinants of indoor endotoxin and beta-(1→3)-D-glucan levels by location within home 
 Play area Mattress 
 Endotoxin  
(EU/mg) 
β (SE) 
Endotoxin 
(EU/m2) 
β (SE) 
BDG 
(µg/mg) 
β (SE) 
BDG 
(µg/m2) 
β (SE) 
Endotoxin  
(EU/mg) 
β (SE) 
Endotoxin 
(EU/m2) 
β (SE) 
BDG 
(µg/mg) 
β (SE) 
BDG 
(µg/m2) 
β (SE) 
Parental smoking  
(ref: none) 
0.19 (0.22) 0.26 (0.24) 0.01 (0.27) 0.19 (0.70) -0.17 (0.31) -0.05 (0.34) -0.04 (0.24) 0.79 (0.53) 
Parental education 
 (ref: ≤high school) 
0.09 (0.23) 0.06 (0.25) -0.24 (0.30) -0.83 (0.74) 0.06 (0.33) 0.09 (0.36) -0.16 (0.26) -0.30 (0.57) 
Age of home (ref: 
before 1980) 
0.25 (0.15) 0.23 (0.17) 0.20 (0.19) 0.15 (0.50) 0.22 (0.22) 0.18 (0.24) 0.13 (0.17) 0.17 (0.38) 
Pet ownership  
(ref: none) 
0.13 (0.15) 0.09 (0.16) -0.25 (0.19) -0.76 (0.48) 0.02 (0.21) 0.08 (0.23) 0.08 (0.17) 0.44 (0.36) 
Parental history of 
allergy (ref: none) 
0.03 (0.16) 0.07 (0.17) -0.13 (0.20) 0.23 (0.50) 0.22 (0.23) 0.08 (0.24) 0.46 (0.17)‡ 0.57 (0.39) 
Humidifier  
(ref: none) 
-0.12 (0.18) -0.04 (0.20) -0.24 (0.23) -0.08 (0.58) 0.23 (0.26) 0.16 (0.28) -0.29 (0.20) -0.15 (0.45) 
Home dampness  
(ref: none) 
0.20 (0.16) 0.18 (0.18) -0.15 (0.21) 0.10 (0.53) 0.21 (0.24) 0.30 (0.26) -0.09 (0.18) -0.11 (0.40) 
Visible mold  
(ref: none) 
-0.22 (0.20) -0.07 (0.22) -0.01 (0.26) 0.54 (0.66) 0.03 (0.30) -0.15 (0.32) 0.39 (0.23) 0.15 (0.50) 
Rural home  
(ref: urban) 
-0.84 (0.27)‡ -0.99 (0.29)‡ -0.16 (0.34) -1.64 (0.86) -0.47 (0.39) -0.54 (0.42) -0.46 (0.30) -0.82 (0.66) 
Season  
(ref: fall/winter) 
-0.71 (0.20)‡ -0.63 (0.21)‡ -0.29 (0.20) -0.90 (0.63) 0.11 (0.28) 0.31 (0.30) -0.02 (0.22) 0.44 (0.48) 
EU: Endotoxin unit, BDG: Beta-(1→3)-D-glucan, β: beta coefficient, SE: standard error. 
Model adjusted for each variable in the table as well as sex, age, dehumidifier, fireplace, environmental tobacco smoke, presence of 
mice in home, and farm living status. Endotoxin and beta-(1→3)-D-glucan are log transformed. 
‡p<0.05. 
  
319 
 
Appendix 13 
Flow chart of study respondents depicting numbers of participants for each phase of the 
study 
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No asthma 
(n = 119) 
Participated in cross-sectional survey in 2013 
(n=3338) 
Asthma 
(n = 95) 
At-risk-for-asthma 
(n = 121) 
Agreed to participate in further survey and clinical testing and were approached in 
2015 
(n=1348) 
Completed survey in 2015 
(n = 335) 
Completed clinical assessment (spirometry and exercise challenge test)  
(n = 288) 
 100 103 85 
Diagnosed with asthma based on survey responses and/or clinical assessments 
 (n = 116) 
9 12 95 
Completed home dust collection  
(n = 102) 
85 11 6 
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Appendix 14 
Comparison of characteristics between participants in the 2013 baseline survey and those in the 2015 follow-up study 
 Did not complete the clinical 
testing phase 
(2013)  
(n = 3338) 
Completed the clinical 
testing phase 
(2015) 
(n = 335) 
p-value 
Personal characteristics    
Mean age (±SD), years 9.52 (2.76) 9.03 (2.52) 0.001 
% Female 50.6 48.5 0.456 
% > high school (maternal) 73.7 86.1 <0.001 
% > high school (paternal) 67.2 78.3 <0.001 
Ethnic background    
 % Caucasian 62.6 79.8 <0.001 
 % Other ethnic background 37.4 20.2  
Tobacco smoke exposure    
% Maternal smoking 18.7 4.6 <0.001 
% Paternal smoking 24.3 12.9 <0.001 
% Either parent smoking 31.3 14.7 <0.001 
Indoor characteristics    
% Pet ownership 52.2 53.2 0.731 
% Dampness in home 16.3 19.2 0.182 
% Home mold 12.2 11.0 0.546 
% Air conditioner 71.2 76.7 0.041 
% Air filter 63.2 64.9 0.569 
% Humidifier 38.3 41.5 0.292 
Parental history of asthma and allergies    
% Parental history of asthma 16.9 20.9 0.07 
% Parental history of allergy 37.3 50.1 <0.001 
Child’s previous history of wheeze and asthma    
% Ever wheeze 7.8 12.2 <0.001 
% Ever asthma 8.2 12.6 <0.001 
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Appendix 15 
Venn diagram of asthma phenotypes among children with asthma in the study population showing proportions with overlap in 
atopic asthma and EIB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Proportion with no atopic asthma and no EIB. 
§17/116 of the children identified to have asthma did not consent to skin prick test. 
Atopic asthma 
54 (54.5%) 
Exercise-induced 
bronchospasm 
6 (6.1%)  17 (17.2%) 
22 (22.2%)* 
N = 99§ 
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Supplementary I 
Specific variables determined during the study 
 
Variable 
 
Procedure 
Phase of 
assessment 
Specific 
Objective 
1. Subject descriptors 
Demographics SQ I  
Age, gender, ethnicity SQ I  
Health information SQ I  
Location of residence 
(Large Urban, Small Urban, and Rural) 
SQ I 1 
2. Asthma diagnostic pattern    
Physician-diagnosed asthma SQ, CA, ACDA I, II 1 
At-risk-for asthma SQ, CA, ACDA I, II 1 
No asthma SQ, CA, ACDA I, II 1 
3. Asthma phenotype categories     
Atopic asthma and non-atopic asthma SQ, SPT I 2 
EIB and no EIB LFT, ECT, CA I 2 
4. Asthma severity categories 
Mild intermittent asthma SQ, LFT, CA I 3 
Mild persistent asthma SQ, LFT, CA I 3 
Moderate persistent asthma SQ, LFT, CA I 3 
Severe persistent asthma SQ, LFT, CA I 3 
5. Pulmonary Function test 
FEV1 (Liters) % predicted LFT I 3 
FVC (Liters) % predicted LFT I 3 
FEV1/FVC (%) LFT I 3 
FEF25-75% (Liters) % predicted LFT I 3 
PEFR (Liters) % predicted LFT I 3 
6. Allergy skin test  
Alternaria  SPT I 2 
Cladosporium SPT I 2 
Aspergillus SPT I 2 
House dust mite SPT I 2 
Local grasses SPT I 2 
Cat dander SPT I 2 
7. Biological and environmental assessment 
Endotoxin concentration and load LMA II 2, 3 
Beta-(1→3)-D-Glucan concentration and load LMA II 2, 3 
Abbreviations: SQ– Survey questionnaire; CA– Clinical assessment; ACDA– Asthma case-detection 
algorithm; EIB– Exercise-induced bronchospasm; LFT– Lung function testing; ECT– Exercise 
challenge test; FEV1– Forced expiratory volume in 1 second; FVC– Forced vital capacity; FEF– 
Forced expiratory flow; LMA: Laboratory microbiology analysis. 
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Supplementary II 
Relationship between other risk factors examined in the literature review and asthma 
phenotypes and severity 
 Atopic asthma  
OR (95%CI) 
EIB  
OR (95%CI) 
Asthma severity* 
OR (95%CI) 
Sex    
   Male 1.00 1.00 1.00 
   Female 1.01 (0.40–2.58) 0.61 (0.23–1.59) 0.53 (0.21–1.38) 
Age    
   < 12 years 1.00 1.00 1.00 
   ≥ 12 years 0.87 (0.36–2.11) 0.51 (0.20–1.29) 0.99 (0.42–2.33) 
Ethnicity    
   Caucasian 1.00 1.00 1.00 
   Others 0.71 (0.24–2.04) 1.21 (0.39–3.76) 1.96 (0.68–5.59) 
Obesity     
   Not overweight 1.00 1.00 1.00 
   Overweight 0.75 (0.23–2.44) 0.71 (0.62–0.81) 1.10 (0.32–3.76) 
Parental history of asthma    
   No 1.00 1.00 1.00 
   Yes 0.89 (0.36) 0.64 (0.24–1.67) 0.87 (0.35–2.16) 
Parental history of allergy    
   No 1.00 1.00 1.00 
   Yes 1.15 (0.47–2.80) 0.39 (0.16–0.94) 1.25 (0.52–3.01) 
Pet ownership (Cat)    
   No 1.00 1.00 1.00 
   Yes 2.07 (0.69–6.14) 1.09 (0.42–2.84) 0.44 (0.15–1.28) 
Pet ownership (Dog)    
   No 1.00 1.00 1.00 
   Yes 0.58 (0.24–1.41) 1.14 (0.48–2.74) 1.15 (0.49–2.67) 
Pet ownership (Cat and Dog)    
   No 1.00 1.00 1.00 
   Yes 0.94 (0.30–2.95) 1.50 (0.52–4.36) 0.47 (0.13–1.72) 
Pet ownership (Cat or Dog)    
   No 1.00 1.00 1.00 
   Yes 1.03 (0.42–2.48) 0.85 (0.39–2.31) 0.92 (0.39–2.18) 
Paternal smoking    
   No 1.00 1.00 1.00 
   Yes 0.81 (0.22–2.96) 1.65 (0.46–5.89) 0.89 (0.23–3.49) 
Maternal smoking    
   No 1.00 1.00 1.00 
   Yes 3.00 (0.35–25.58) 0.45 (0.06–3.99) 0.42 (0.05–3.60) 
Father and mother smoking    
   No 1.00 1.00 1.00 
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   Yes 1.25 (0.12–12.52) 1.12 (0.11–11.25) 0.74 (0.67–0.83) 
Either father or mother smoking    
   No 1.00 1.00 1.00 
   Yes 0.92 (0.26–3.26) 1.40 (0.40–4.90) 1.25 (0.36–4.35) 
Dampness in home past  year    
   No 1.00 1.00 1.00 
   Yes 1.21 (0.42–3.48) 0.49 (0.15–1.55) 1.79 (0.69–4.62) 
Visible mold/mildew in home    
   No 1.00 1.00 1.00 
   Yes 1.4 (0.27–7.23) 1.09 (0.27–4.31) 3.10 (0.94–10.22) 
EIB: Exercised-induced bronchospasm. 
*Outcome is moderate/severe asthma. 
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Supplementary IIIA 
Histogram for log endotoxin values (n = 102) 
 
Histogram for: (A) log play area endotoxin concentration (EU/mg); (B) log play area endotoxin 
load (EU/m2); (C) log mattress endotoxin concentration (EU/mg); (D) log mattress endotoxin 
load (EU/m2).
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Supplementary IIIB 
Histogram for log beta-(1→3)-D-Glucan values (n = 102)
 
Histogram for: (A) log play area beta-(1→3)-D-Glucan concentration (µg/g); (B) log play area 
beta-(1→3)-D-Glucan load (µg/m2); (C) log mattress beta-(1→3)-D-Glucan concentration 
(µg/g); (D) log mattress beta-(1→3)-D-Glucan load (µg/m2). 
